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 The first two sections of this dissertation describe the development of a regioselective 
palladium-catalyzed cross-coupling strategy to access highly functionalized heterocycles. This 
method was successfully applied to 2,4,7-trichloroquinazoline, allowing for the efficient 
synthesis of quinazolines bearing functionality in specific positions of the heterocyclic ring.  The 
strategy was also extended to 1,3,6-trichloroquinoline for the synthesis and scale-up of a 
promising 3-aminoisoquinolin-1(2H)-one inhibitor of the dual-specificity phosphatase Cdc25B.   
The third section of this dissertation describes the design and synthesis of novel 
thieno[3,2-d]pyrimidine- and thieno[3,2-c]pyridine-based analogs for the inhibition of protein 
kinase D.  A small library of analogs was prepared to assess the structure-activity relationship, 
and one analog was tested in vivo. 
 The fourth section of this dissertation discusses the investigation of an unusual alkene 
isomerization process, which occurred during the ring-closing metathesis for the preparation of a 
tricylic isoindolinone scaffold.  The final section of this thesis details our work towards the 
synthesis of Stemona alkaloids.  In particular, a second-generation approach to sessilifoliamide 
was achieved. 
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 1 
1.0  REGIOSELECTIVE PALLADIUM-CATALYZED CROSS-COUPLING OF 2,4,7-
TRICHLOROQUINAZOLINE 
1.1 INTRODUCTION 
Palladium-catalyzed cross-coupling reactions represent a powerful and popular method for the 
formation of highly substituted heterocycles.1 The regioselective activation of polyhalogenated 
heteroaromatics in cross-coupling reactions has been extensively studied1 and provides a 
versatile method for incorporating substituents in specific positions of the heterocyclic scaffold. 
One heterocyclic scaffold in particular, quinazoline, is a component of a variety of biologically 
active compounds, including potent tyrosine kinase inhibitors,2 antibacterial,3 and anticancer 
agents.4  Tri-substituted quinazoline derivatives 1-1 and 1-2 (Figure 1) have been prepared as 
part of a series of liver X receptor (LXR) modulators for the treatment of atherosclerosois.5  
Several approved drugs also contain the quinazoline moiety6 including Erlotinib (1-3),7 used to 
treat several types of tumors, Gefitinib (1-4),8 an epidermal growth factor receptor inhibitor 
approved for the treatment of non-small cell lung cancer, and Prazosin (1-5),9 an -adrenergic 
receptor blocker (Figure 2).   
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Figure 1.  Quinazoline derivatives designed as LXR modulators. 
 
 
Figure 2.  Quinazoline-based drugs approved for clinical use. 
 
The regioselectivity for palladium-catalyzed alkylation10, alkynylation,11 and arylation12 
of 2,4-dichloroquinazolines 1-6 and 1-10 have been explored.  Selective Stille coupling13 of the 
C-4 position using trimethyl- or triisobutylalanes in the presence of catalytic amounts of 
Pd(PPh)4 was reported to proceed in good yields, with only a small amount (<10%) of the 2,4-
dialkylated quinazoline being detected (Scheme 1).10  Subjecting C-4 alkylated products 1-7a 
and 1-7b to a second equivalent of either alane worked equally well and provided the 
corresponding bis-coupled products 1-8a–d (Scheme 1).10  Analogously, the palladium-catalyzed 
Sonagashira cross-coupling reaction of 1-6 gave excellent selectivity for the C-4 coupled product 
1-9 (Scheme 2).11  Although the Stille coupling of 2,4-dichloroquinazoline 1-10 with 
arylstannane 1-11 has been reported to provide C-2 coupled product 1-12, the yields and 
selectivity are not disclosed (Scheme 3).12     
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Scheme 1.  Regioselective palladium-catalyzed alkylations of 2,4-dichloroquinazoline (1-6) with trialkylalanes.10 
 
 
Scheme 2.  Regioselective Sonagashira cross-coupling reactions of 2,4-dichloroquinazoline (1-6).11 
 
 
Scheme 3.  Stille coupling of 2,4-dichloroquinazoline 1-10 with arylstannane 1-12.12 
 
In addition to selective couplings involving 2,4-dichloroquinazolines (1-6 and 1-10), 
attempts to achieve monosubstitution of more highly halogenated quinazolines under palladium-
catalyzed conditions have also been explored.  Alkylation of 6-bromo-2,4-dichloroquinazoline 
(1-13) using trimethylalane, in a similar manner to that reported in Scheme 1, provided a 3:1 
mixture of 1-14a and 1-15a, with the major product resulting from substitution at the C-4 
position (Scheme 4).10b  An improved selectivity of 6:1 in favor of monoalkylated product 1-14b 
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was observed when triisobutyl alane was employed.  The Sonagashira cross-coupling reactions 
of 6-bromo-2,4-dichloroquinazoline (1-13) was also plagued by a lack of regioselectively 
(Scheme 5), yielding a 3:1 mixture of C-4 and C-6 monosubstituted products 1-16 and 1-17, 
respectively.11  Prior to the disclosure of our work discussed in this thesis, the sequential Suzuki-
Miyaura cross-coupling14 of polyhalogenated quinazolines had not been disclosed. 
 
 
Scheme 4.  Regioselective palladium-catalyzed alkylation of 6-bromo-2,4-dichloroquinazoline (1-13) with 
alkylalanes.10b 
 
 
Scheme 5.  Sonagashira cross-coupling reaction of 6-bromo-2,4-dichloroquinazoline (1-13).11 
 
 Since the 2010 publication of our work detailed in this thesis,15 the regioselective Suzuki-
Miyaura reaction of 4,7-dichloroquinazoline 1-18 was reported (Scheme 6).16  Vanelle and co-
workers achieved selective cross-coupling of the C-4 position by using 1.5 equivalents of 
boronic acid in the presence of Pd(PPh3)4.  The reactions were carried out at 80 °C under 
microwave irradiation with DME/EtOH (9:1) as a solvent to furnish monocoupled products 1-19.  
The solubility properties of 1-19 under their original conditions prevented efficient coupling at 
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C-7.  The solvent mixture was changed to DMF/EtOH (9:1) resulting in the successful coupling 
1-19 to provide 4,7-diarylquinazolines 1-20 in modest to good yields (Scheme 6).  
 
 
Scheme 6.  Regioselective Suzuki-Miyaura cross-coupling reactions of 4,7-dichloro-2-(2-methylprop-1-enyl)-6-
nitroquinazoline (1-18).16 
 
The regioselectivity of the abovementioned palladium-catalyzed cross-coupling reactions 
of polyhalogenated quinazoline is well supported by computational studies by Houk and co-
workers.17  In general, the oxidative insertion step is considered to be the selectivity determining 
step in the overall cross-coupling process.  The factors controlling the regioselectivity during the 
oxidative addition include both the energy to distort reactants to the transition state geometry, a 
factor related to the bond dissociation energy (BDE), and the interaction between these distorted 
reactants, which is governed by the frontier molecular orbital (FMO) interactions.17-18  In order to 
develop a predictive model for determining the reactivity in sequential cross-coupling reactions, 
the C-Cl BDEs of quinazoline were explored using B3LYP19 and G3B320 calculations (Figure 
3).17   
 It was determined that the lowest carbon-chlorine BDE exists at the C-4 position with a 
value of 92 kcal/mol, followed by the C-2 position at 95 kcal/mol (Figure 3).  All of the positions 
on the phenyl ring were reported to have similar BDEs and were 5-6 kcal/mol higher in energy 
than the BDE of the C-2 position.  Based on these calculated BDEs, the trend for reactivity, and 
hence regioselectivity, was shown to be in good agreement with the abovementioned 
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experimental data (Scheme 1–Scheme 6), supporting the utility of BDE calculations as a useful 
tool for predicting the relative reactivity of polyhalogenated quinazolines.  The exception to this 
trend is the Sonagashira coupling of 6-bromo-2,4-dichloroquinazoline 1-13 (Scheme 5) where 
the BDE of the carbon-chlorine bond at the C-4 position (85 kcal/mol) is actually larger than that 
of the carbon-bromine bond at the C-6 position (83 kcal/mol).  The selectivity of this coupling 
reaction is thought to be governed by the FMO interactions between the distorted reactants, 
which evidently favors coupling with the stronger carbon-chlorine bond at position C-4.17   
 
 
Figure 3.  Carbon-chlorine BDE's of quinazoline using G3B3 (bold) and B3LYP (parentheses); energies in 
kcal/mol.17 
1.2 RESULTS AND DISCUSSION 
Our initial goal for this project was to achieve regioselective cross-coupling of 2,4,7-
trichloroquinazoline 1-2121 by consecutive Suzuki-Miyaura reactions (Scheme 7).  At the outset 
of this project, the regioselective Suzuki-Miyaura cross-coupling reactions of polyhalogenated 
quinazolines had not been reported, although the analogous reactions of the polyhalogenated 
parent heterocycle, pyrimidine, had been extensively studied.1  Based upon the calculated 
carbon-chlorine BDEs of quinazoline (Figure 3),17 we envisioned the first coupling reaction to 
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take place at the most electrophilic C-4 position, followed by substitutions at the C-2 and C-7 
positions, respectively.  Initial coupling reactions at the C-4 position under standard Suzuki-
Miyaura coupling conditions provided the desired products 1-22a–c in good yields (Table 1, 
entries 1-3).  However, the reactions alkyl-substituted boronic acids in the C-4 coupling reactions 
proved to be low-yielding due to competitive hydrolysis at that site (Table 1, entries 4 and 5).  
Nonetheless, subsequent coupling at the C-2 position under both conventional heating and 
microwave heating provided the desired bis-coupled products 1-23a–e in good to modest yields 
(Table 2).  It was evident from these data that attenuation of the reactivity of position C-4 was 
required to achieve selective coupling of C-4 with optimal yields while avoiding hydrolysis. 
 
 
Scheme 7.  Selective cross-coupling strategy to minimize synthetic steps and maximize diversity in quinazolines 1-
24. 
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Table 1.  Selective Suzuki coupling at the C-4 position. 
 
 
Table 2.  Selective Suzuki coupling at the C-2 position. 
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To circumvent the problem with competitive C-4 hydrolysis, the reactions were carried 
out under anhydrous conditions.  Unfortunately, the reaction was either sluggish or did not 
progress under these conditions.  At this stage a new route was designed in which the C-4 
position would be temporarily deactivated by a thioether, followed by a regioselective cross-
coupling at the C-2 position (Scheme 8).  The C-4 position would then be functionalized via 
sulfur oxidation and either substitution or cross-coupling of the resulting sulfone to provide 
compounds of type 1-23.  A final Suzuki reaction at the remaining C-7 position would provide 
tri-functionalized quinazoline target compounds 1-24.  
 
 
Scheme 8.  Alternative strategy to selective cross-couplings reactions. 
 
Thioether 1-25 was accessed by treatment of 1-2121 with 1.05 equiv of thiophenol and 
NaH (Scheme 9).  Substitution occurred exclusively at the more electrophilic C-4 position.  
Subsequent regioselective C-2 cross-coupling of 1-25 with thiophene-2-boronic acid proceeded 
in good yield in the presence of 5 mol% Pd(OAc)2 and 15 mol% PPh3 in refluxing DME to 
furnish product 1-26a.  Attempts to oxidize 1-26a to the corresponding sulfone using Oxone 
gave no reaction, while treatment with m-CPBA or Na2WO4 and H2O2 led to hydrolysis at 
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position C-4.  Hydrolysis at the C-4 position is likely a result of initial formation of the sulfone, 
which activates the C-4 position allowing for hydrolysis during the basic aqueous workup. 
 
 
Scheme 9.  Synthesis of thioether 1-26a. 
 
At this point, hydrolysis at position C-4 was still a major problem and an alternative route 
was designed.  This route would also feature the deactivation of the C-4 position by a thioether 
followed by regioselective coupling at C-2 (Scheme 10).  This strategy would rely on the 
palladium-catalyzed, copper(I)-mediated cross-coupling method developed by Liebeskind and 
co-workers22 to functionalize the C-4 position.  This approach would avoid activation and 
subsequent hydrolysis of the C-4 position, and provide compounds of type 1-23. The 2,4-
disubstituted quinazolines (1-23) would then undergo a Suzuki-Miyaura reaction to provide 
trifunctionalized quinazoline targets 1-24.  
 
 
Scheme 10. Alternative route to selective cross-coupling reactions.  
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The key step in this approach employs on the palladium-catalyzed, copper (I)-thiophene-
2-carboxylate (CuTC) mediated, base-free coupling method developed by Liebeskind.22  This 
group reported the efficient coupling of a range of thioether heteroaromatics to a variety of 
boronic acids within 18 h at 50 °C in THF in the presence of stoichiometric CuTC.  The 
proposed mechanism of this transformation relies on CuTC to facilitate the baseless 
transmetallation of ArB(OH)2 by simultaneously polarizing the Pd–S bond while activating the 
trivalent boron (Scheme 11, intermediate I).  This desulfitative coupling method has been 
successfully employed by Guillaumet and co-workers to achieve the regioselective cross-
coupling of 2,4-dichloropyrido[3,2-d]pyrimidine and other heterocycles.23 
 
 
Scheme 11.  Mechanism of palladium-catalyzed, copper-mediated cross-coupling of heteroaryl thioethers with 
boronic acids.22 
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Thioether 1-28 was accessed by treatment of 1-2121 with 1.05 equiv of isopropyl 
mercaptan and NaH.  Substitution occurred exclusively at the more electrophilic C-4 position. 
Subsequent regioselective C-2 arylation of 1-28 proceeded in excellent yields with most 
arylboronic acids in the presence of 5 mol% Pd(OAc)2 and 15 mol% PPh3 at 75 °C, furnishing 
products 1-29a–g (Table 3, entries 1-7).  In the case of oxygen- and nitrogen-containing 
heterocyclic nucleophiles, slightly lower yields were obtained (Table 3, entries 8-10).  This is 
presumably due to the electron-poor nature of heteroarylboronic acids, which undergo 
transmetalation at a slower rate.  Additionally, electron-poor boronic acids are susceptible to 
homocoupling and metal-catalyzed protodeboronation.24  The lower reactivity of these reagents 
is further supported by the need for prolonged reaction times and excess boronic acid (1.5 equiv) 
to ensure complete consumption of starting material.  
 13 
Table 3.  Selective Suzuki reaction at the C-2 position.15 
 
 
Stage 2 functionalization at the C-4 position was performed using the palladium-
catalyzed, copper(I)-mediated desulfitative coupling conditions reported by Liebeskind and co-
workers.22  These reactions were carried out in the presence of excess CuTC and boronic acid.  
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All desulfitative arylations were achieved with complete selectivity for the C-4 position and in 
excellent yields (Table 4).  Notably, unprotected 5-indoleboronic acid provided 1-23o in good 
yield despite the lower reactivity of unprotected N-heteroarylboronic acids in cross-coupling 
reactions (Table 4, entry 8).24 
 
Table 4.  Palladium-catalyzed, copper(I)-mediated coupling at the C-4 position.15 
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The third and final cross-coupling reaction was initially carried out using the conditions 
reported in Table 3 (Table 5, entry 1).  Incomplete consumption of starting material resulted, and 
attempts to facilitate complete conversion of starting material using elevated temperatures and 
increasing the equivalents of boronic acid gave a 1:1 mixture of starting material and product 
(Table 5, entry 2).  In order to ensure the complete consumption of starting material, 10 mol% 
Pd(OAc)2, 30 mol% PPh3, and 4.0 equiv of boronic acid were used.  These conditions resulted in 
successful cross-coupling at the C-7 position in good yields for both aryl- and heteroarylboronic 
acids (Table 5, entries 3-5).  The regioselectivity of these cross-coupling reactions was 
confirmed by X-ray analysis of 1-24b (Figure 4) and is in agreement with the predicted order of 
coupling as calculated by Houk.18 
Table 5.  Suzuki reaction at the C-7 position.15 
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Figure 4.  X-Ray crystal structure of 1-24b (Appendix A.1). 
1.3 BIOLOGICAL ACTIVITY 
A selection of fourteen substituted quinazolines was deposited in the PubChem database.  Five of 
these compounds were tested against 88 protein targets in 92 primary assays and 24 confirmatory 
assays, yielding one active compound (1-23a).  Compound 1-23a was identified as a weak 
agonist of mouse 5-hydroxytryptamine (serotonin) receptor 2A (HTR2A) and showed 17.4% 
activation at 7.6 μM.  Due to the structurally similarity of these substituted quinazolines to 
known liver X receptor (LXR) modulators 1-1 and 1-2 (Figure 1), we submitted these 
compounds to our collaborators25 to evaluate their effect on the activation of LXRs.  Human H4 
neuroglioma cells were treated with each compound at 10 μM.  Three of the compounds (1-24b–
d) resulted in upregulation of gene expression relative to the vehicle (DMSO); however, they 
were significantly less effective than the positive control.25  
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1.4 CONCLUSION 
We have demonstrated that temporary deactivation of the C-4 position of 2,4,7-
trichloroquinazoline by substitution of the chlorine atom with isopropyl mercaptan allowed for 
the regioselective palladium-catalyzed cross-coupling at the C-2 position in 2,7-
dichloroquinazoline (1-28).  Subsequent palladium-catalyzed, copper(I)-mediated desulfitative 
coupling at the C-4 position, followed by the final palladium-catalyzed cross-coupling at the C-7 
position, allowed for convenient access to the desired tricarbosubstituted quinazolines.15  This 
simple and efficient sequential coupling route to highly substituted quinazolines showcases the 
utility of regioselective palladium-catalyzed cross-coupling reactions for the preparation of 
focused libraries of kinase inhibitors.26   
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2.0  REGIOSELECTIVE CROSS-COUPLING REACTIONS OF 1,3,6-
TRICHLOROISOQUINOLINE:  SYNTHESIS OF A DUAL-SPECIFICITY 
PHOSPHATASE CDC25B INHIBITOR 
2.1 INTRODUCTION 
2.1.1 Biological Significance of Cdc25 
The cell division cycle 25 (Cdc25) dual specificity phosphatases, a subclass of protein tyrosine 
phosphatases, play an essential role in the regulation of the mammalian cell cycle.  Cdc25s 
dephosphorylate and subsequently activate cyclin-dependent kinase (CDK) complexes, making 
their regulation of critical importance in controlling cell proliferation.  These protein kinases 
serve as key activators of the CDK complexes and are also crucial components in cell cycle 
checkpoints that prevent CDK activation following DNA damage (Figure 5).27  There are three 
human Cdc25 isoforms, Cdc25A, Cdc25B, and Cdc25C.  The over-expression of one isoform in 
particular, Cdc25B, enables the bypass of normal cell cycle checkpoints and has been linked to a 
variety of human cancers.27a,28  As a result, Cdc25B has become an attractive target for the 
development of anticancer therapeutics.27b,29 
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Figure 5.  CDC25 phosphatases control mammalian cell-cycle progression.30 
 
The structures of the catalytic domains of the Cdc25 isoforms have been solved by X-ray 
crystallography31 and contain the signature active site sequence, HCX5R, common to all protein 
tyrosine kinases.32  The catalytic sequence forms a loop that is positioned above a long α-helix.  
This positioning creates a unique dipole environment in which the catalytic cysteine exists as a 
thiolate with a pKa of 5.6-6.3 (ca. 8.0 for free cysteine).
33  This unusually low pKa of the active 
site cysteine renders it highly susceptible to covalent modifications and oxidation by reactive 
oxygen species (ROS).34  Additionally, the active site pocket is surprisingly shallow with no 
apparent groove for binding proteins or small molecules.32      
The inherent features of the Cdc25 active site pose a formidable challenge for inhibitor 
development.  Numerous promising advancements have been made, but a clinically active 
candidate in this field has yet to emerge.27b,29  The majority of Cdc25 inhibitors fall into six 
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distinct classes, which were previously designated and reviewed by Wipf and Lazo.29b  These 
classes include, but are not limited to: (1) natural products dysidolides and dnacins; (2) 
hydrophobic acids SC-ααδ9; (3) quinones and vitamin K analogs menadione and DA3003-1; (4) 
electrophiles such as fascaplysin; (5) phosphate surrogates such as the xenicane diterpenoids; and 
(6) peptides and peptide analogs (Figure 6). 
 
 
Figure 6.  Known inhibitors of Cdc25 phosphatases. 
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2.1.2 Synthesis and Biological Evaluation of 3-Aminoisoquinolin-1(2H)-one Inhibitors of 
Cdc25B:  Previous Work in the Wipf Group 
Although non-quinoid compounds have attracted attention as inhibitors of Cdc25, quinone-type 
compounds still represent the majority of the known inhibitors of Cdc25.  As part of a high-
throughput screening (HTS) effort, Wipf and co-workers identified the 3-amino-1,2-dihydro-1-
isoquinolinone (2-2) scaffold as a promising non-quinoid pharmacophore for Cdc25B inhibition 
(Figure 7).35 These heterocycles were not extensively characterized chemically and 
biologically;36 therefore, a medicinal chemistry program to investigate structure-activity 
relationships (SARs) in this series was initiated by our group.  
 
 
Figure 7.  HTS hit for Cdc25B inhibition. 
 
The synthesis of the initial HTS hit 2-2 began with the preparation of 2-
cyanomethylbenzoic acid 2-4, which was readily available from the nucleophilic opening of 
phthalide 2-3 with sodium cyanide at 185 C (Table 6).37  Subsequent treatment of the acid with 
aniline in chlorobenzene at reflux afforded target compound 2-2 in 58% yield (Table 6, entry 
1).36  The rapid construction of the isoquinolinone core enabled the synthesis of a variety of 
derivatives (2-5a–s) by modification of the amine used in the condensation reaction (Table 6, 
entries 2-19).  The wide range of yields (25-82%) was attributed to the low solubility of some of 
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the products in 2-propanol and methanol, which were used in the streamlined purification 
process. 
 
Table 6.  Synthesis of 3-amino-1,2-dihydro-1-isoquinolinone with various amines and the in vitro inhibitory activity 
against Cdc25B.38 
 
entry R1 yield (%) 
In vitro Cdc25B 
IC50 (μM)a 
compound 
1 aniline 58 0.74 ± 0.10 2-2 
2 2-chloroaniline 55 4.19 ± 0.49 2-5a 
3 4-methylaniline 69 0.77 ± 0.17 2-5b 
4 2-fluoroaniline 48 1.85 ± 0.07 2-5c 
5 4-fluoroaniline 81 0.83 ± 0.11 2-5d 
6 p-anisidine 45 13.63 ± 2.79 2-5e 
7 2,5-dimethoxyaniline 59 5.25 ± 0.62 2-5f 
8 2-aminophenol 35 1.21 ± 0.20 2-5g 
9 4-aminoethylbenzene 62 10.75 ± 0.75 2-5h 
10 2-phenylaniline 45 2.57 ± 0.32 2-5i 
11 benzyl amine 60 0.85 ± 0.17 2-5k 
12 4-methoxybenzylamine 70 0.77 ± 0.11 2-5l 
13 N-methylbenzylamine 76 1.55 ± 0.32 2-5m 
14 2-bromo-N-methylbenzylamine 82 3.80 ± 0.68 2-5n 
15 1,2,4-triazole-3-amino 74 4.48 ± 1.37 2-5o 
16 2-aminopyridine 53 3.31 ± 0.55 2-5p 
17 piperidine 60 2.31 ± 0.39 2-5q 
18 morpholine 75 3.37 ± 0.30 2-5r 
19 6-amino-1-hexanol 25 0.64 ± 0.16 2-5s 
a Histidine6-tagged recombinant Cdc25B was assayed in vitro with 7-10 concentrations of each 
compound and with the artificial substrate O-methylfluorescein phosphate as previously described.35,39  
Each IC50 was calculated as the mean ± standard deviation, n = 3. 
 
 
Initial insight into the substituent effects of these compounds was determined base on the 
biological evaluation of 2-5a–s by Johnston and co-workers.38  The parent hit 2-2 showed good 
activity with an IC50 value of 740 nM (Table 6, entry 1).  Substitution on the aniline ring gave 
analogs with comparable or diminished IC50 values (Table 6, entries 2-10).  Specifically, ortho-
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substituted anilines gave analogs with reduced inhibitory activity, while the para-methyl and 
para-fluoro anilines were well tolerated.  The aniline moiety was also replaced by benzyl amine 
to afford 2-5k and the methoxy substituted 2-5l, which possessed comparable inhibitory 
activities to the parent hit (Table 6, entries 1, 11, and 12).  The corresponding N-alkylated 
derivatives were less active (Table 6, entries 13 and 14). 
Heterocyclic amines as R1 groups in the 3-position were also explored (Table 6, entries 
15-18).  However, both the triazole (2-5o) and the pyridine (2-5p) showed only modest activity 
with IC50 values of 4.48 µM and 3.31 µM, respectively.  The fully saturated piperidine (2-5q) 
and morpholine (2-5r) derivatives were also less active than the parent compound 2-2, although 
the hexanol analog 2-5s showed slightly improved activity with an IC50 of 640 nM (Table 6, 
entry 19). 
To further evaluate the structural requirements for Cdc25B inhibition, and to restrict the 
rotational flexibility of the R1 amino substituent in the 3-position of the isoquinolinone 2-2, the 
fused tetracyclic analog was synthesized (Scheme 12).  The synthesis of 2-8 was accomplished 
in 71% yield by heating homophthalic anhydride 2-6 at reflux with ortho-phenylenediamine 2-7 
in acetic acid.40  The loss in inhibitory activity of 2-8 (IC50 = 5.25 M) suggested that a planar 
orientation of the tetracycle was detrimental for target inhibition, and the hydrogen-bond donor 
at the 2-position of the isoquinolinone may be required for activity. 
 
 
Scheme 12.  Synthesis of fused tetracyclic analog 2-8.38 
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     A unique chemical characteristic of the isoquinolinone core structure is its high 
nucleophilicity at the 4-position.  This “enamine-like” position can react with suitable 
electrophiles,36,41 which provides an opportunity for further structural diversification.  Although 
substitution at this position was not exploited extensively, the acylated analog 2-10 was 
synthesized in 45% yield by treatment of isoquinolinone 2-5c with benzoyl chloride in dioxane 
(Scheme 13). Substitution at this position proved to be detrimental to the inhibitory activity (IC50 
> 50 M).  
 
 
Scheme 13.  Synthesis of 4-substituted isoquinolinone 2-10.38 
 
After exploring variations of the 3-amino side chain, the next focus was on the 
functionalization of the 6-position of the arene ring of the isoquinolinone (Scheme 14).  Opening 
of lactone 2-11 with neat NaCN according to the protocol used in the conversion of 2-3 to 2-4 
resulted in the decomposition of the starting material.  Employing DMSO as a solvent provided a 
good yield of the desired 5-bromo-2-cyanomethylbenzoic acid 2-12, which was then exposed to 
Suzuki coupling conditions.  This approach was not an effective method for library construction 
due to the difficulty in monitoring the reaction progress and purifying the product mixtures.  The 
use of 2-14a and 2-14b as coupling components was explored, and although the Suzuki reaction 
was successful in the case of 2-14a to provide 2-15, this strategy was not employed for library 
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synthesis due to the potential contamination of the products with trace amounts of palladium in 
the last step of the synthesis. 
 
 
Scheme 14.  Initial synthetic strategies to functionalize the 6-position of isoquinolinone.38 
 
Wipf and co-workers developed a modified protocol to introduce various substituents at 
the 5-position of 5-bromophthalide 2-11 prior to lactone opening (Scheme 15).   Suzuki coupling 
of 2-11 with commercially available electron-rich and -poor boronic acids proved to be a 
successful strategy to afford the substituted phthalides 2-16a–f in high yields (Scheme 15).  
Subsequent exposure of 2-16a–f to NaCN in DMSO resulted in the desired benzoic acids 2-17a–
f.  These benzoic acid derivatives were then treated with aniline or o-anisidine and heated to 
reflux in chlorobenzene to afford isoquinolinones 2-18a–g. 
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Scheme 15.  Synthetic strategy to obtain functionalized isoquinolines 2-18a–g (n.d.= not determined).38 
 
The biological activity of analogs 2-18a–g was carried out by our collaborators38 and is 
summarized in Table 7. Interestingly, isoquinolinones with R1 being a meta-substituted arene 
showed the best activity (Table 7, entries 4-8).  Their IC50 values ranged from 0.22–2.7 M and 
were comparable or higher than the activity found for the initial hit 2-2 (IC50 = 0.74 M).  The 
most potent compound was the 3-acetamidobenzene substituted analog 2-18e, which was three-
fold more potent than 2-2.  Other substituted arenes, such as 3-acetylbenzene 2-18f and 3-
methoxybenzene 2-18g, showed comparable activity to 2-2.  The 4-trifluoromethoxybenzene 
analog 2-18a, as well as the 2-fluorobenzene (2-18c), thiophene (2-18d), 3-aminobenzene (2-15), 
and bromide (2-14a) analogs also possessed significant, low micromolar inhibitory activities.  
We only briefly explored the SAR of the R2 group in analogs 2-18a–g, and found that the 
addition of a methoxy group in the 2-position of the aniline (i.e. 2-18a) decreased the IC50 ca. 
five-fold over the R2-unsubstituted 2-18b. 
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Table 7.  In vitro Cdc25B inhibitory activity of C-6 functionalized isoquinolinone analogs.38 
 
entry R1 R2 
In vitro Cdc25B 
IC50 (μM)a 
compound 
1 4-trifluoromethylbenzene OMe 2.48 ± 0.33 2-18a 
2 4-trifluoromethylbenzene H 12.19 (1) 2-18b 
3 2-fluorobenzene H 1.77 ± 0.41 2-18c 
4 3-thiophene H 1.20 (1) 2-18d 
5 3-acetamidobenzene H 0.22 ± 0.04 2-18e 
6 3-acetylbenzene H 0.87 ± 0.12 2-18f 
7 3-methoxybenzene H 0.75 (1) 2-18g 
8 3-aminobenzene H 2.70 ± 1.70 2-15 
9 Br H 1.16 ± 0.44 2-14a 
a Histidine6-tagged recombinant Cdc25B was assayed in vitro with 7-10 concentrations of each 
compound and with the artificial substrate O-methylfluorescein phosphate as previously described.35,39  
Each IC50 was calculated as the mean ± standard deviation, n = 3 unless noted with parenthesis, which 
indicates an n = 1. 
 
2.2 RESULTS AND DISCUSSION 
2.2.1 Application of a Regioselective Cross-Coupling Strategy for the Synthesis and Scale-
up of Lead Structure 2-15 
As a representative example for the 6-(3-aminophenyl)isoquinolin-1(2H)-one series, analog 2-
15, which was computationally predicted to have a favorable aqueous solubility of 2.5 mg/mL, 
was further investigated.  This lead molecule was found to lack the ability to generate reactive 
oxygen species (ROS), a common issue leading to artifacts in phosphatase assays.42  Compound 
2-15 was also 6-fold less active in vitro against human PTP1B (IC50 = 15.3 M), demonstrating 
modest selectivity for Cdc25B.  This promising data led us to explore an alternative synthetic 
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route to access 2-15 in larger quantities for in vivo studies.  This new route would allow for the 
application and expansion of the aforementioned regioselective cross-coupling method 
developed in our lab and others.15,23a  
Beginning with 1,3,6-trichloroisoquinoline (2-19), we envisioned deactivation of the 
most active C-1 position with the introduction of isopropyl mercaptan, followed by a 
regioselective amination reaction at the C-3 position (Scheme 16).  At this point, hydrolysis at 
the C-1 position would allow for the removal of the thioether moiety and generation of the 
desired isoquinolinone core.  A final Suzuki cross-coupling reaction at the remaining C-6 
position with 3-aminophenylboronic acid would provide the desired compound, 2-15.   
 
 
Scheme 16.  Initial synthetic route for the synthesis of inhibitor 2-15. 
 
 Thioether 2-20 was accessed by treatment of 2-19 with 1.1 equiv of isopropyl mercaptan 
and NaH (Scheme 17).  Subsequent regioselective nucleophilic substitution at the C-3 position 
with aniline in refluxing EtOH or diglyme gave no reaction.  Efforts to facilitate the substitution 
by treatment of aniline with NaH prior to addition to 2-20 did not provide the desired product.  
Instead, analysis of the crude reaction mixture indicated that substitution of the isopropyl 
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thioether moiety with aniline had occurred in preference of chloride displacement at position  
C-3.  In order to circumvent this problem, palladium-catalyzed Buchwald-Hartwig coupling 
reactions were explored.  Reactions employing either Pd2(dba)3 or Pd(OAc)2, in combination 
with phosphine ligands DavePhos, PPh3, or ()-BINAP (Figure 8), resulted in no reaction and 
starting material was recovered.  
 
 
Scheme 17.  Attempted synthesis of thioether 2-21. 
 
 
Figure 8.  Chemical structures of phosphine ligands used for the Buchwald-Hartwig amination reactions of 2-20. 
 
At this point we revised our synthetic approach to begin with hydrolysis at position C-1, 
followed by selective amination at the C-3 position, and final Suzuki coupling at the C-6 position 
(Scheme 18).  With the reactivity of the C-1 site attenuated by formation of the isoquinolinone 
moiety, chloride displacement at position C-3 should proceed without competitive substitution at 
C-1. 
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Scheme 18.  Alternative route to 2-15. 
 
Hydrolysis at the C-1 position using excess KOSiMe3 furnished the desired product 2-23 
in quantitative yield (Scheme 19).  Regioselective amination of the C-3 position via nucleophilic 
substitution with aniline, both in the presence and absence of NaH, resulted in complete recovery 
of starting material.  Buchwald-Hartwig coupling reactions were also explored, but as with the 
thioether derivative 2-20, attempts to use either Pd2(dba)3 or Pd(OAc)2, in combination with 
phosphine ligands DavePhos, PPh3, or ()-BINAP resulted in no reaction.  It was suspected that 
both substrates 2-20 and 2-23 were incompatible with the Buchwald-Hartwig amination 
conditions due to the formation of palladium metal (Pd0) after prolonged exposure to the reaction 
conditions. 
 
 
Scheme 19.  Attempted synthesis of isoquinolinone 2-22. 
 
In order to avoid this problem, the most electrophilic C-1 position of 1,3,6-
trichloroisoquinoline (2-19) was protected as methyl ether 2-24 (Scheme 20).  As with 2-20 and 
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2-23, introduction of aniline via nucleophilic substitution in the presence of NaH resulted in 
displacement of the C-1 methyl ether, rather than the chloride at the C-3 position.  In contrast to 
2-20 and 2-23, subjection of 2-24 to Buchwald-Hartwig amination reactions furnished the 
desired product 2-25; however, optimization of the reaction conditions required the screening of 
several catalyst systems.  The best ratio of the desired to isomeric coupled products was achieved 
using Pd(OAc)2 and Xantphos.  Under these conditions, the desired compound 2-25 was isolated 
in 49% yield (57% BRSM), and only 23% (27% BRSM) of the undesired C-6 coupled product 
was observed.  The Suzuki cross-coupling reaction at position C-6 was successful in a sealed 
tube at 120 C in the presence of Pd2(dba)3 and P(t-Bu)3.  With 2-27 in hand, the final 
demethylation proceeded smoothly in 4 M HCl in 1,4-dioxane at 80 C to afford 0.450 g of 
target compound 2-15 (Scheme 20).  The TFA salt 2-16 was prepared by treatment of a 
suspension of 2-15 in CH2Cl2 with TFA at room temperature.  The identity of 2-16 was 
confirmed based on the downfield shifts of the ortho and meta carbons of the aniline ring in the 
13C NMR spectra from from 112.6, 114.0, and 114.9 to 116.4, 117.7, and 119.9, respectively.  
Additionally, an upfield shift from 148.7 to 143.7 ppm was observed for carbon directly attached 
to the amine.  The TFA salt was prepared 2-16 to enhance the solubility of 2-15 for in vivo 
studies, and was soluble up to 4.4 mg/mL when formulated with 20% (w/v) Solutol® HS 15 in 
H2O. 
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Scheme 20.  Regioselective palladium-catalyzed cross-coupling strategy to synthesize 2-15. 
2.2.2 Biological Activity 
Prior to in vivo studies, a confirmative in vitro assay was performed by Prof. Lazo and co-
workers38 using the material from our revised route.  The average IC50 over 4 days was 2.7 μM, 
which is in good agreement with the inhibitor obtained from the previous route.38  With the 
inhibitory activity confirmed, in vivo studies were carried out by Prof. Eiseman et al.43 on mice 
bearing MDA-MB-231 xenografts with 45 mg/kg (iv) 2-16.  Unfortunately, 2-16 has no effect on 
tumor size over 15 days of administration and peak tumor concentrations were reached at ca. 10 
min.43  The pharmacokinetic data indicated a maximum plasma concentration of 2-16 observed 
at ca. 15 min.43  Plasma disappearance of 2-16 was rapid and accompanied by the appearance of 
a metabolite; and neither 2-16, nor the metabolite, was detectable beyond 24 h.43  Additionally, 
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the highest tissue concentration in the kidney and liver was observed at the earliest time point 
sampled (ca. 5 min).43   
2.3 CONCLUSION 
3-Aminoisoquinolines were identified as attractive new scaffolds for the discovery of non-
quinoid dual-specificity phosphatase inhibitors devoid of ROS-generating side effects.  We 
successfully applied a regioselective cross-coupling method15 in the scale-up of the 
representative 2.7 M Cdc25B inhibitor 2-15.  Our preliminary biological studies indicate that 2-
15 inhibits the in vitro dephosphorylation of Cdk1 by Cdc25B in the absence of ROS production 
and prevents cell proliferation during mitosis.  Unfortunately, 2-15 was rapidly metabolized in 
vivo, limiting the therapeutic potential of this compound.  
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3.0  INHIBITORS OF PROTEIN KINASE D:  SYNTHESIS AND STRUCTURE-
ACTIVITY RELATIONSHIP 
3.1 INTRODUCTION 
3.1.1 Protein Kinase D as a Potential New Target for Cancer Therapy 
Protein Kinase D (PKD) constitutes a novel family of serine/threonine kinases and diacylglycerol 
(DAG) receptors that have emerged as key regulators of multiple cancer-promoting pathways 
(Figure 9).44 PKD is classified as a subfamily of the Ca2+/calmodulin-dependent kinase 
superfamily and three PKD isoforms have been identified to date: PKD1 (formerly PKCµ),45 
PKD2,46 and PKD3 (formerly PKCν).47  All three PKD isoforms possess a highly homologous 
sequence and share a distinct structure that includes a catalytic domain, a pleckstrin homology 
(PH) domain that mediates protein-protein interactions and PKD autoinhibition, and an N-
terminal cysteine-rich DAG/phorbol ester binding domain (C1 domain).   
The activation of PKD and the regulatory mechanisms that control PKD activity have 
been well documented.44,48  Interaction of DAG-responsive protein kinase C (PKC) with the PH 
domain of PKD results in transphosphorylation of the conserved Ser744 and Ser748 within the 
activation loop,49 and subsequent autophosphorylation at multiple sites, including Ser916, results 
in full activation PKD.50  PKD is also capable of shuttling between different subcellular 
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compartments as a result of spatial regulation by DAG or phorbol esters.48a,b,51  The fundamental 
PKD function in cells is therefore reliant upon this canonical DAG/PKC/PKD pathway. 
PKD has been implicated in a variety of cellular processes, including cell proliferation, 
cell survival through oxidative stress-induced activation of nuclear factor-kappaB (NF-κB) 
signaling,52 gene expression by regulation of class IIa histone deacetylases (HDAC),53 protein 
trafficking,54 cell motility,55 and immune responses56 due to its central position in the signal 
transduction pathway (Figure 9).  Studies assessing the expression levels of all three isoforms of 
PKD have shown that PKD is dysregulated in several cancer types, including breast, prostate, 
and gastric cancer.57  PKD also plays an active role in pathological processes such as cardiac 
hypertrophy,58 angiogenesis,59 and tumor cell proliferation and metastasis.60  This ubiquitous role 
of PKD renders this class of kinases an attractive therapeutic target for drug development.44a 
 
 
Figure 9.  Major PKD signaling pathways.61 
 36 
3.1.2 Chemical Inhibitors of PKD:  Old and New 
Extensive analysis of the role of PKD in biological processes has been hampered by the 
lack of a three-dimensional (3D) structure of PKD, which prohibits the use of structure-based 
drug design. Additionally, early inhibitors of PKD were not selective.  Among the early 
inhibitors of PKD were the ATP competitive pan-kinase inhibitor staurosporine and 
staurosporine related analogs such as K252a (Figure 10).  These analogs showed IC50 values in 
the low nanomolar range but lacked the requisite kinase specificity necessary to interrogate PKD 
in cells.62  Indolocarbazole Gö697 also inhibits PKD with an IC50 ca. 20 nM; and, although it is 
foremost a classical PKC inhibitor, it is commonly used to inhibit PKD in various cellular 
contexts.62-63   
Resveratrol, a common antioxidant and chemopreventive agent, has also been reported to 
inhibit PKD (Figure 10).64  Resveratrol is not selective for PKD and high micromolar 
concentrations of resveratrol are necessary for inhibition of PKD.  Nonetheless, resveratrol has 
shown potent antitumor activity in multiple animal models and it is possible that part of its 
effectiveness is due to PKD inhibition. 64c  In contrast to the aforementioned inhibitors, the 
hexasulfonated naphthylurea, suramin, has been shown to be a novel and effective activator of 
PKD.  Suramin has proved to be a valuable tool for dissecting the activities of different PKC 
isozymes, but it is also plagued by promiscuous kinase inhibition thereby limiting its 
effectiveness to probe PKD function in relevant biological environments.65  
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Figure 10.  PKD inhibitors staurosporine, Gö6976, K252a, and resveratrol; and PKD activator suramin. 
 
A major advance in this area was the identification and characterization of CID755673 
by Wipf and co-workers (Figure 11).66  CID755673 inhibited all PKD isoforms with an IC50 of 
200-300 nM and showed specificity toward PKD over several related kinases.  Notably, 
CID755673 was not competitive with ATP for enzyme inhibition, suggesting an alternate 
binding site on the enzyme.  Due to the highly conserved nature of ATP-binding domains among 
kinases, this alternative binding mode may account for the selectivity of CID755673 for PKD 
compared to other protein kinases.  Additionally, CID755673 effectively blocked PKD-mediated 
cell functions and inhibited novel tumor-promoting functions of PKD in prostate cancer  
cells.66-67   
Since the disclosure of CID755673, promising ATP-competitive inhibitors continue to 
emerge in the literature.58b,68 The novel 2,6-naphthyridine 3-1 was identified by a high 
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throughput screen (HTS) as a dual PKC/PKD inhibitor (Figure 11).68e  Modification of this hit in 
an effort to reduce the off-target effects and improve PKD selectivity led to a series of 
amidobipyridyl-based analogs.68f  BPKDi (Figure 11) was identified from this series as a potent 
and selective pan-PKD inhibitor with single-digit nanomolar IC50 values and caused substantial 
inhibition of PKD1 signal-dependent phosphorylation and increased nuclear retention of class 
HDAC4 and HDAC5 in cardiomyocytes.58b  
The ATP-competitive, pan-PKD inhibitor CRT0066101 was also reported to inhibit all 
isoforms of PKD with single-digit nanomolar IC50 values (Figure 11).
68a,68c  While CRT0066101 
was shown to block cell proliferation, induce apoptosis, and reduce the viability of pancreatic 
cancer cells both in vitro and in vivo, the most attractive features of CRT0066101 are its 
reported orally availability and efficacy in vivo.68a,68c  Pyrazine benzamide CRT5 inhibited PKD 
with an IC50 value of 1.5 nM and suppressed VEGF-induced endothelial cell migration, 
proliferation, and tubulogenesis.69  Lastly, a novel 3,5-diarylazole 3-2 (Figure 11) that was 
identified in a HTS showed moderate kinase inhibition and led to a series of promising 
benzamide analogs.68d  One analog in particular, 3-3 (Figure 11), inhibited all PKD isoforms 
with low nanomolar IC50 values and had modest preference for PKD1 inhibition versus PKD2 
and PKD3, respectively.  Furthermore, 3-3 possessed high selectivity for PKD against a panel of 
other kinases and pharmacokinetic studies in rats.68d 
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Figure 11.  Recent PKD inhibitors from the research and patent literature. 
3.1.3 Structure-Activity Relationship of  CID755673:   Previous Work in the Wipf Group 
Despite the high specificity of CID755673 and its potent in vitro inhibition of PKD, its 
cellular activity was relatively weak (EC50 = 11.8 μM).66-67 Recent evidence also suggests 
additional targets of CID755673,70 but since this structure is not competitive with ATP for PKD 
inhibition, it represents an orthogonal approach to gain further understanding of the structure and 
function of PKD.  In an effort to enhance the selectivity and potency for potential in vivo 
applications, Wipf and co-workers probed the SAR for CID755673 by modification of the core 
structure as well as the side chains.  To guide the design of these structural analogs and elucidate 
SAR, the parent compound CID755673 was dissected into four major structural zones (Figure 
12).67,71 
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Figure 12.  Major structural zones dissected for SAR analysis. 
 
Zone I was modified to include functionalization of the aryl moiety and substitutions on 
the phenolic hydroxyl group (Table 8). Most of the zone I derivatives were less active than 
CID755673.  Specifically, carbon substituents ortho to the phenol and O-acylations and 
silylations were detrimental to in vitro activity (Table 8, entries 4, 5, and 9), however ortho-
halogenation and O-methylation and allylation were well tolerated (Table 8, entries 2, 3, and 6-
8).   
 
Table 8.  PKD inhibitory activity of CID755673 and zone I analogs.71b  
 
Entry Compound 
Structure IC50 
R1 R2 R3 IMAP-FP PKD1 (μM)a Radiometric PKD1 (μM)b 
1 CID755673 H OH H 0.64 ± 0.03 0.182 ± 0.02 (n = 5) 
2 kb-NB77-56 H OMe H 2.4 ± 0.14 2.39 (n = 1) 
3 kb-NB77-84 H OAllyl H 2.6 ± 0.2 1.23 (n = 1) 
4 kb-NB123-36 H OAc H 84.89 ±3.21 n.d. 
5 kb-NB77-77 H OTBS H not inhibitory n.d. 
6 kb-NB77-88 Cl OH H 1.4 ± 0.1 0.892 (n = 1) 
7 kb-NB96-21 F OH H 1.3 ± 0.05 0.238 (n = 1) 
8 kb-NB96-43 Cl OH Cl not inhibitory n.d. 
9 kb-NB96-02 Allyl OH H 2.4 ± 0.3 1.58 (n = 1) 
a PKD1 IC50 was determined using an automated, HTS formatted IMAP-based PKD Fluorescence Polarization (FP) 
assay as previously described.66  Each IC50 was calculated as the mean ± SEM of at least three independent 
experiments with triplicate determinations at each concentration in each experiment; n = number of independent 
experiments.  b PKD1 IC50 was determined using a radiometric kinase activity assay as previously described.66  Each 
IC50 was calculated as the mean ± SEM with triplicate determinations at each concentration in each experiment; n = 
number of independent experiments.   
 
I II 
III 
IV 
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In zone II, the replacement of the oxygen in the parent compound CID755673 with sulfur 
resulted in enhanced activity, but replacement with nitrogen was associated with a loss of 
activity (Table 9, entries 2 and 3).  In zone III, the ring size was altered by addition or removal of 
methylene groups and substitution at the benzylic position.  Decreasing or increasing the 
azepinone ring size, although tolerated, resulted in reduced inhibitory activity relative to 
CID755673 (Table 9, entries 7 and 8).  All modifications of the azepinone moiety at the 5-
position (Z), with the exception of thioether insertion, yielded analogs with reduced inhibitory 
activity (Table 9, entries 3-6).  All modifications to zone IV, which included functional group 
interconversions and replacement of the amide moiety, did not enhance the inhibitory activity 
(Table 9, entries 9 and 10).  
 
Table 9.  PKD inhibitory activity of CID755673 and zone II-IV analogs.71b   
 
Entry Compound 
Structure IC50 
R5 n Y Z 
IMAP-FP 
PKD1 (μM)a 
Radiometric PKD1 (μM)b 
1 CID755673 H 1 O CH2 0.64 ± 0.03 0.182 ± 0.02 (n = 5) 
2 kb-NB123-57 H 1 N CH2 2.14 ± 0.12 0.130 ± 0.01 (n = 3) 
3 kb-NB142-70 H 1 S S 0.71 ± 0.02 0.0283 ± 0.002 (n = 3) 
4 kb-NB123-63 H 1 O C=O 14.93 ± 1.17 0.850 ± 0.11 (n = 2) 
5 kb-NB123-89 H 1 O CHOH 24.09 ± 0.71 1.23 ± 0.21  (n = 2) 
6 kb-NB142-05 H 1 O C=NNHPh 21.70 ± 0.52 1.13 (n = 1) 
7 kb-NB123-23A H 0 O CH2 12.6 ± 1.3 1.4 (n = 1) 
8 kb-NB96-53 H 2 O CH2 8.3 ± 0.6 1.03 (n = 1) 
9 kb-NB142-25 Me 1 O CH2 n.d. 4.02 ± 1.09 (n = 2) 
10 kb-NB165-15 
 
n.d. not inhibitory 
a PKD1 IC50 was determined using an automated, HTS formatted IMAP-based PKD Fluorescence Polarization (FP) 
assay as previously described.66  Each IC50 was calculated as the mean ± SEM of at least three independent 
experiments with triplicate determinations at each concentration in each experiment; n = number of independent 
experiments.  b PKD1 IC50 was determined using a radiometric kinase activity assay as previously described.66  Each 
IC50 was calculated as the mean ± SEM with triplicate determinations at each concentration in each experiment; n = 
number of independent experiments.   
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At this stage, benzothienothiazepinone kb-NB142-70 emerged as the lead compound 
with ca. 7-fold increase in potency toward PKD1 with IC50 values of 28.3 nM.  This increased 
potency was further confirmed in cell-base assays for which the IC50 was 2.2 μM, a 5-fold  
improvement over CID755673 (IC50 = 11.8 μM).  At this point, further modifications to this lead 
compound according to the pharmacophore zones in Figure 12 were explored to elucidate 
essential SAR (Table 10).   
Masking the hydroxyl group as methoxy analog kb-NB165-09 was only slightly 
detrimental to PKD inhibition, while the benzyl derivative kb-NB123-66 resulted in complete 
loss of inhibitory activity (Table 10, entries 3 and 4).  Replacement of the hydroxyl moiety with 
the corresponding azide resulted in comparable in vitro and cellular activities (Table 10, entry 5).  
Iodination at R1 was also well tolerated with an in vitro IC50 of 114 nM (Table 10, entry 6). 
These data suggest that while the zone 1 binding pocket may be sterically restricting, the 
hydrogen-bond donor capability of the lead structure is not necessary for inhibitory activity. 
Zone II and III modifications explored sulfur oxidations, thiazepinone ring enlargement, 
and opening of the thiazepinone ring.  While sulfur oxidations provided analogs with 
significantly reduced inhibitory activity, increasing the azepinone ring size had only minor 
effects (Table 10, entries 7-9).  The open chain analog did not show any PKD1 inhibition and 
implies that the zone III binding pocket may require the rigidity of the ring for optimal binding 
interactions (Table 10, entry 12).  Finally, functional group interconversions and replacement of 
the amide moiety in zone IV did not enhance the inhibitory activity (Table 10, entries 10 and 11). 
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Table 10.  PKD inhibitory activity of kb-NB142-70 and zone I-IV analogs.71b   
 
Entry Compound 
Structure IC50 
R1 R2 R5 n W Y Z 
Radiometric  
PKD1 (μM)a 
Cellular  
PKD1 (μM)b 
1 CID755673 H OH H 1 O O CH2 0.182 ± 0.02 (n = 5) 11.8 ± 4.0 (n = 3) 
2 kb-NB142-70 H OH H 1 O S S 0.0283 ± 0.002 (n = 3) 2.2 ± 0.6 (n = 3) 
3 kb-NB165-09 H OMe H 1 O S S 0.0825 ± 0.005 (n = 4) 3.1 ± 0.5 (n = 3) 
4 kb-NB123-66 H OBn H 1 O S S not inhibitory n.d. 
5 mcf-292-08 H N3 H 1 O S S 0.0749 ± 0.01 (n = 5) 2.2 ± 0.2 (n = 3) 
6 kb-NB165-31 I OH H 1 O S S 0.114 ± 0.02 (n = 5) 8.6 ± 2.0 (n = 3) 
7 kb-NB184-25 H OMe H 1 O S=O S 1.08 (n = 1) n.d. 
8 kb-NB184-45 H OMe H 1 O S S=O not inhibitory n.d. 
9 kb-NB165-92 H OH H 2 O S S 0.111 ± 0.006 (n = 3) 2.6 ± 0.7 (n = 2) 
10 kb-NB165-17 H OH Me 1 O S S 0.450 ± 0.05 (n = 2) n.d. 
11 kb-NB165-83 H OH H 1 H2 S S 16.4 (n = 1) n.d. 
12 kb-NB184-80 
 
not inhibitory n.d. 
a PKD1 IC50 was determined using a radiometric kinase activity assay as previously described.66  Each IC50 was calculated as 
the mean ± SEM with triplicate determinations at each concentration in each experiment; n = number of independent 
experiments.  b Cellular IC50 was determined by densitometry analysis of Western blotting data for PKD1 
autophosphorylation at S916 in LNCaP cells as previously described.67  Each IC50 was calculated as the mean ± SEM of at 
least three independent experiments; n = number of independent experiments. 
 
After initial activity screening of all of the derivatives (ca. 50), Wipf and co-workers 
identified five analogs that were of equal or greater potency compared to the parent compound 
CID755678 (Figure 13).  These five analogs were subjected to further analysis and each of the 
analogs demonstrated increased inhibition of PMA-induced autophosphorylation of PKD1, 
caused a dramatic arrest in cell proliferation, and inhibited cell migration and invasion.67  From 
these experiments, kb-NB142-70 and kb-NB165-09 were identified to be the most potent and 
specific analogs both in vitro and in cells.       
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Figure 13.  Chemical structure lead compound kb-NB142-70 and four analogs. 
  
The in vivo efficacy and pharmacokinetics of kb-NB142-70 and kb-NB165-09 were 
examined.72 The phenolic derivative, kb-NB142-70, was rapidly metabolized, with peak tumor 
concentrations of 11.8 nmol/g obtained at 5 min, and a plasma half-life of 6 min.  The major 
metabolite of kb-NB142-70 was identified by LC/MS-MS to be an O-glucuronide.  The methoxy 
analog, kb-NB165-09, which featured protection of the major site of metabolism, showed a 
maximum tumor concentration of 8.0 nmol and a 2.3-fold increase in the plasma half-life from 6 
to 14 min.  Metabolite studies of kb-NB165-09 did not reveal kb-NB142-70 as a metabolite, 
suggesting that the methoxy group diverts metabolism from glucoronidation to primarily 
oxidation.  Based on these data, the therapeutic potential of kb-NB142-70 and kb-169-05 is 
limited. 
3.2 RESULTS AND DISCUSSION 
With rapid metabolism being a major roadblock in tuning the efficacy of kb-NB142-70 and kb-
NB165-09 in vivo, we envisioned a zone I modification to install a heteroaryl moiety in place of 
the aryl group (Figure 14).  The replacement of an aryl group with a heteroaryl group is a 
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classical bioisosteric replacement used to enhance the physical properties and metabolic stability 
of a drug.73  The incorporation of heterocyclic moieties serves to replace the site of metabolism, 
decrease the basicity of the ring, and lower the LogD.   
 
 
Figure 14.  Zone I modification of the lead compounds to install a pyrimidine moiety. 
 
This strategy has been successfully implemented to improve the metabolic profiles in the 
development of several clinical candidates.73  An example of this was reported by Kadow and 
co-workers for a series of HIV-1 inhibitors.74  Indole 3-4 was a potent antiviral agent, but 
suffered from rapid metabolism via O-demethylation (Scheme 21).  Systematic replacement of 
the aromatic CH sites with N yielded analog 3-5, which possessed improved aqueous solubility 
and eliminated the potential for quinone formation in the event of demethylation (Scheme 21).74  
Analog 3-5 was advanced to clinical trials for the inhibition of HIV-1 in human subjects.74 
 
 
Scheme 21.  Bioisosteric replacement of aromatic CH with N to yield clinical candidate 3-5. 
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3.2.1 Synthesis of Thieno[3,2-d]pyrimidine-Based Analogs 
Our synthetic approach to the thieno-[3,2-d]pyrimidine-containing analogs 3-6 would 
feature formation of the thiazepinone moiety via one-pot nucleophilic displacement-
condensation reaction of 3-7 with cysteamine hydrochloride (Scheme 22). We envisioned a 
directed metalation of 3-8 at the C-6 position and trapping with a suitable electrophile would 
install the requisite ester.  Regioselective halogenation at position C-7 would provide access to 3-
7.  Precursor 3-8 would be readily prepared by pyridimine formation of commercially available 
3-aminothiophene-2-carboxylate (3-9). 
 
 
Scheme 22.  Retrosynthetic approach to thieno[3,2-d]pyrimidine analogs 3-6. 
 
Synthesis of the requisite cyclization precursor 3-7 began with thiophene 3-9 (Scheme 
23).  Formation of the pyrimidine moiety using potassium cyanate, followed by chlorination with 
POCl3 gave dichloride 3-11.
75 Palladium-catalyzed regioselective dechlorination of 3-11 in the 
presence of Na2CO3 occurred exclusively at the C-4 position,
76 and substitution of the remaining 
C-2 chloride with methoxide provided 3-13 in 79% yield over the two steps.  At this point we 
envisioned elaboration of the thiophene C-6 position to be achieved via directed lithiation using 
n-butyllithium, followed by quenching with methylchloroformate (3-14).  Unfortunately, 
subjection of 3-13 to these conditions did not give the desired C-6 functionalized product 3-16.  
Rather, analysis of the crude reaction mixture by 1H NMR indicated nucleophilic addition of the 
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base at the C-4 position (3-15).  This result is well documented in the literature, and is due to the 
electrophilic nature of the ring, which can readily undergo addition at position C-4.77  Direct 
functionalization of these pyrimidine-containing systems by lithiation is indeed difficult and 
often requires low temperature or the use of less nucleophilic bases.77a,b  
 
 
Scheme 23.  Attempted synthesis of 3-16. 
 
In light of this result, we sought to avoid the use of strong nucleophilic bases, such as n-
BuLi, and instead use the mixed lithium and magnesium base, TMPMgCl·LiCl (3-17), reported 
by Knochel and co-workers.78  Treatment of 3-13 with freshly prepared TMPMgCl·LiCl78d and 
subsequent quenching with Mander’s reagent (3-18), resulted in exclusive regioselective 
metalation at the C-6 position to provide target compound 3-16 in 53% yield (Scheme 24).  With 
the desired methyl ester in hand, the selective halogenation at position C-7 was explored.  
Attempts to introduce a halogen atom using directed metalation at position C-7 and quenching 
with I2 or I(CH2)2I  resulted in no reaction in cases where s-butyllithium was used and both C-4 
and C-7 halogenated products were observed in the case of TMPMgCl·LiCl.  Electrophilic 
halogenation of 3-16 using N-bromosuccinimide, N-chlorosuccinimide, or bromine under a 
variety of different solvent and temperature conditions gave no reaction; and, in all cases starting 
 48 
material was recovered.  The lack of reactivity at the C-7 position is presumably a result of the 
presence of the methyl ester at position C-6, which deactivates the C-7 position towards 
electrophilic attack. 
 
 
Scheme 24.  Regioselective metalation at positions C-6 and C-7.   
  
In order to circumvent this problem, we explored the halogenation of 3-13 prior to the 
installation of the methyl ester (Scheme 25).  Electrophilic bromination of 3-13 using Br2 in 
AcOH79 gave the desired C-7 brominated compound 3-20 in modest yield.  Functionalization of 
position C-6 under Knochel’s conditions,78a-c as in Scheme 24, gave the required cyclization 
precursor 3-21 in excellent yield. Formation of the thiazepinone moiety was achieved by a one-
pot nucleophilic displacement-condensation reaction of 3-21 with cysteamine hydrochloride and 
provided the desired methoxy analog kmg-NB4-23 in good yields.  A crystal structure of kmg-
NB4-23 was obtained and confirms the regioselectivites of the synthetic sequence (Scheme 25, 
Appendix A.2).  This structure has been deposited at the Cambridge Crystallographic Data 
Centre and allocated the deposition number CCDC 822403.   
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Scheme 25.  Synthesis of thieno[3,2-d]pyrimidine analog kmg-NB4-23. 
 
At this point, all that remained was O-demethylation of kmg-NB4-23 to arrive at kmg-
NB4-69A.  This seemingly trivial transformation could not be affected under a variety of 
demethylation conditions.  Treatment of kmg-NB4-23 with BBr3 or NaI in AcOH at elevated 
temperatures resulted in quantitative recovery of starting material.  In contrast, both concentrated 
aqueous HCl and HI provided complete consumption of starting material; however, the desired 
product was not detected.  Treatment of kmg-NB4-23 with 33% HBr in AcOH under reflux 
conditions did provide the desired product kmg-NB4-69A, however the reaction was low-
yielding and irreproducible.  From these data, it was clear that reactivity could only be affected 
under strongly acidic conditions, but that aqueous reaction and workup conditions must be 
avoided.  Therefore, kmg-NB4-23 was subjected to 4 M HCl in 1,4-dioxane.  Gratifyingly, we 
observed complete conversion of the starting material to the desired product kmg-NB4-69A after 
6 days (Scheme 26).  The product from this reaction was isolated as the hydrochloride salt and 
could be readily converted to the free base upon treatment with poly(4-vinyl)pyridine (Scheme 
26).  As in the case of kmg-NB4-69A, it was imperative that aqueous reaction and workup 
conditions be avoided for the formation of the free base.  
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Scheme 26.  Synthesis of thieno[3,2-d]pyrimidine analogs kmg-NB4-69A and kmg-NB4-77A3. 
 
An interesting observation was noted regarding the stability of compounds kmg-NB4-
69A and -77A3. After treatment with methanol, a ca. 2:1 ratio of kmg-NB4-69A/77A3 and 3-22 
was observed by 1H NMR (Scheme 27).  The structure of 3-22 was proposed based on the 
diagnostic –OCH3 peak at 3.10 ppm, a pair of doublets at 8.20 and 5.74 ppm (HB’ and HA’, 
respectively).  This structure was further supported by observing that 3-22 is converted to kmg-
NB4-69A/77A3 upon removal of methanol.  To confirm this hypothesis, kmg-NB4-69A/77A3 
was dissolved in DMSO-d6 and MeOD-d4 was added.  The 
1H NMR revealed a ca. 2:1 mixture 
of kmg-NB4-69A/77A3 and 3-22, which supports our hypothesis that kmg-NB4-69A/77A3 can 
be converted to 3-22 in the presence of methanol.  Similarly, it has been reported that the 
recrystallization of 2-pyrimidinones from methanol results in the formation of the corresponding 
methanol adducts, which readily lose methanol upon warming.80  
 
 
Scheme 27. Conversion of kmg-NB4-69A/77A3 to 3-22 in the presence of MeOH. 
 
Since the C-4 position was susceptible to nucleophilic attack, we decided to synthesize 
analogs that featured protection at this site.  To this end, we utilized dichloropyrimidine 3-11 as 
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the common intermediate.  Similarly to the above synthetic sequence, 3-11 was treated with 
NaOMe at reflux to provide dimethoxypyrimidine 3-23, followed by regioselective 
functionalization to provide 3-25 (Scheme 28).  Treatment of 3-25 with cysteamine 
hydrochloride provided the desired C-4 protected analog kmg-NB5-13C.  Selective methyl 
deprotection of the C-4 position provided kmg-NB5-15A.  Attempts to obtain the corresponding 
dihydroxypyrimidine were unsuccessful. 
 
 
Scheme 28.  Synthesis of C-4 protected thieno[3,2-d]pyrimidine analogs kmg-NB5-13C and kmg-NB5-15A. 
3.2.2 Synthesis of Thieno[3,2-b]pyridine-Based Analogs 
In an attempt to gain further insight into the SAR and metabolic stability, we sought an 
additional modification to zone I by introducing the pyridine moiety (Scheme 29).  Our synthetic 
strategy to access the thieno[3,2-b]pyrindine-based analogs was analogous to the route employed 
for the thieno[3,2-d]pyrimidine series.  We envisioned the last step to be thiazepinone ring 
formation via intermediate ester 3-27.  Ester 3-27 would arise from regioselective 
functionalization of the thieno[3,2-b]pyridine core (3-28).  The core would be synthesized from 
commercially available 3-acetylthiophene 3-29 according to literature protocol (Scheme 29).81 
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Scheme 29.  Retrosynthetic strategy to access thieno[3,2-b]pyridine analogs 3-23. 
 
Beginning with 3-acetylthiophene 3-29, oxime 3-30 was obtained using standard 
conditions using hydroxylamine hydrochloride.82 Beckmann rearrangement83 of 3-30 furnished 
3-acetamidothiophene 3-31, which was subjected to Vilsmeier reagent84 in order to generate the 
desired thieno[3,2-b]pyridine core (3-32).81  Chloride displacement using refluxing NaOMe 
provided the desired precursor for regioselective functionalization.  We envisioned regioselective 
bromination to occur under the same conditions as in the case of the thieno[3,2-d]pyrimidine 
series.  Treatment of 3-33 with Br2 and AcOH at room temperature resulted in complete 
consumption of starting material after 1 h.  Unfortunately, the undesired tribrominated product 3-
34 was isolated in 73% yield.  It was apparent that the 2-methoxypyridine 3-33 was much more 
activated toward electrophilic additions than the corresponding 2-methoxypyrimidine 3-13. 
 
 
Scheme 30.  Attempted synthesis of thieno[3,2-b]pyridine analogs. 
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To circumvent this issue, we subjected chloropyridine 3-32 to the bromination conditions 
prior to treatment with NaOMe (Scheme 31).  This strategy provided the desired mono-
brominated product 3-36 in good yield.  Regioselective metalation of 3-36 at position C-6 and 
subsequent trapping with Mander’s reagent85 afforded the cyclization precursor 3-37 in 76% 
yield with exclusive selectivity.  Thiazepinone formation under the previously reported 
conditions (Scheme 25) using excess cysteamine hydrochloride gave the unexpected thioether 
kmg-NB6-19B. 
 
 
Scheme 31.  Revised synthetic approach to thieno[3,2-b]pyridine analogs. 
 
To avoid the displacement of both halogens during thiazepinone formation, the reaction 
was performed in a step-wise manner (Scheme 32).  Serendipitously, treatment of 3-37 with 1.5 
equivalents of cysteamine hydrochloride at room temperature did not provide the expected 
product 3-38, but rather the thiazepinone kmg-NB6-22A in excellent yield.  Methoxide 
displacement and subsequent methyl deprotection provided target analogs kmg-NB6-38 and 
kmg-NB6-41, respectively (Scheme 32).  
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Scheme 32.  Revised synthesis of thieno[3,2-b]pyridine analogs. 
3.2.3 Biological Activity of Analogs 
The in vitro and cellular PKD inhibitory activities of these novel thieno[3,2-d]pyrimidine- and 
thieno[3,2-b]pyridine-based analogs were determined and the results are summarized in Table 
11.71,86  Methoxy analog kmg-NB4-23 was a potent pan-PKD inhibitor with nanomolar IC50 
values, which is only a slight decrease in activity compared to the parent compound kb-NB165-
09 (Table 11, entry 1).  In contrast, kmg-NB4-69A had only weak inhibitory activity against 
PKD1 and the corresponding free base kmg-NB4-77A3 was inactive towards inhibition of PKD1 
(Table 11, entries 2 and 3).  The lack of activity of the hydroxy analogs is presumably due to the 
instability of this compound towards nucleophilic addition at the C-4 position, as noted in section 
3.2.1.  Unfortunately, all but two compounds in the thieno[3,2-b]pyridine series lacked PKD 
inhibitory activity.  Analogs kmg-NB6-19B and kmg-NB6-38 showed good activities in the 
radiometric kinase assay; however, both compounds were inactive in the corresponding cellular 
assays. 
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Table 11.  Chemical structures and PKD1 inhibitory activities of the thieno[3,2-d]pyrimidine and thieno[3,2-b] 
analogs.71b,86 
 
Entry Compound 
Structure IC50 
R1 R2 Y 
% PKD 
activity at 
(1 μM) 
Radiometric 
PKD1 (μM)a 
Cellular 
PKD1 (μM)b 
1 kmg-NB4-23 OMe H N n.d. 0.124 ± 0.031 (n = 4) 6.8 ± 1.3 (n = 3) 
2 c kmg-NB4-69A OH H N n.d. 25.3 (n = 1) n.d. 
3 kmg-NB4-77A3 OH H N n.d. not inhibitory n.d. 
4 kmg-NB5-13C OMe OMe N n.d. >30  (n = 2) n.d. 
5 kmg-NB5-15A OMe OH N n.d. >30 (n = 2) n.d. 
6 kmg-NB6-19B -S(CH2)2NH2 H CH 46.3 ± 0.7 0.453 ± 0.013 (n = 3) >50 
7 kmg-NB6-22A Cl H CH 70.7 ± 8.8 n.d. n.d. 
8 kmg-NB6-38 OMe H CH 33.2 ± 2.5 0.234 ± 0.015 (n = 3) > 50 
9 kmg-NB6-41 OH H CH 97.1 ± 1.7 n.d. n.d. 
a PKD1 IC50 was determined using a radiometric kinase activity assay as previously described.66  Each IC50 was calculated as 
the mean ± SEM with triplicate determinations at each concentration in each experiment; n = number of independent 
experiments.  b Cellular IC50 was determined by densitometry analysis of Western blotting data for PKD1 
autophosphorylation at S916 in LNCaP cells as previously described.67  Each IC50 was calculated as the mean ± SEM of at 
least three independent experiments; n = number of independent experiments. c HCl salt.  
 
From these studies, kmg-NB4-23 emerged as the most potent compound.  This analog 
not only validates our design, but also suggests that the zone I binding pocket is tolerant to a 
decrease in electron density in the aryl region.  Despite the decrease in activity on going from in 
vitro to cellular assays, the cellular activity was promising for further biological testing.  The low 
aqueous solubility posed a significant challenge and led us to explore injectable formulations of 
kmg-NB4-23.  The concentration of the formulations was determined by UV-Vis using a 
standard curve.  We first tried the mixed organic/aqueous formulations such as Solutol® HS 15, 
Cremaphor® EL, Povidone®, DMSO, NMP, and MMS-350.  The solubility in each of these 
formulations was <0.2 mg/mL.  We also tried to solubilize kmg-NB4-23 via cyclodextrin 
complexation using β-cyclodextrin and hydroxypropyl-β-cyclodextrin. The highest concentration 
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obtained was <0.4 mg/mL, which prevented the evaluation of the pharmacokinetics, efficacy, 
and metabolism of this compound.   
Although this compound could not be formulated for intravenous administration, it was 
administered to nude mice bearing s.c. prostate cancer (PC3) xenografts via oral gavage to 
determine in vivo efficacy.86  Preliminary data demonstrate that when mice are treated with kmg-
NB4-23 alone there is a decrease in the mean tumor weight and volume; although, the 
differences were not statistically relavent (Figure 15).86  In contrast, when mice were treated with 
a combination of kmg-NB4-23 and PX-866,26c a known pan-PI3K tumor growth inhibitor, an 
apparent additive effect is observed.86  These data are preliminary and must be confirmed prior to 
moving forward with this class of inhibitors. 
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Figure 15.  Effect of kmg-NB4-23 (KMG) on PC3 s.c. tumor xenografts in nude mice and the structure of PX-
866.86 
3.3 CONCLUSION 
A series of thieno[3,2-d]pyrimidine- and thieno[3,2-b]pyridine-based inhibitors were 
successfully synthesized to probe the effects of the incorporation of heteroaryl moieties.71  One 
promising analog, kmg-NB4-23, was a potent pan-PKD inhibitor with an IC50 of 124 nM.  This 
result validates our inhibitor design and shows that a decrease in the electron density of the 
heterocyclic scaffold is well tolerated in the zone 1 binding pocket.  Although the limited 
aqueous solubility prevented the evaluation of the pharmacokinetic and metabolism data, the 
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compound was administered to nude mice bearing s.c. prostate cancer (PC3) xenografts via oral 
gavage to determine in vivo efficacy.86  These data are preliminary, but do indicate that kmg-
NB4-23 may be capable of reducing tumor growth when used alone or in combination with the 
known inhibitor PX-866.   
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4.0  INVESTIGATION OF AN ALKENE ISOMERIZATION REACTION DURING 
THE PREPARATION OF TRICYCLIC ISOINDOLINONES 
4.1 INTRODUCTION 
Isoindolinones have demonstrated a variety of pharmacological activities including anti-
inflammatory,87 antihypertensive,88 vasodilatory,89 antipsychotic,90 and anticancer effects.91  
These heterocycles also represent a common scaffold seen in many natural products such as 
magallanesine,92 lennoxamine,93 and clitocybin A,94 as well as drug candidates such as 
pagoclone (Figure 16).95  A variety of approaches for the preparation of these biologically 
relevant heterocycles have been explored.96  The Wipf group has reported a synthetic approach 
to isoindolinones via the addition of functionalized alkenylalanes to phthalimide and 
succinamide derived N-acyliminium ions (Scheme 33).97  This method is highly amenable to 
chemical library synthesis due to the commercial availability or ease of preparation of the 
starting materials, as well as the opportunities for further functionalization of the scaffold.  Of 
particular interest to the Wipf group was the ring closing metathesis of the alkene addition 
product (4-3) which affords structurally novel tricyclic isoindolinones containing a newly formed 
seven-membered ring (4-4) (Scheme 33).97 This concept was further developed toward a library 
synthesis of novel tricyclic isoindolinone amino alcohols 4-5 (Scheme 33).  During the 
preparation of this library, a unique alkene isomerization was observed by our group.   
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Figure 16.  Isoindolinone natural products and pharmaceuticals.98 
 
 
Scheme 33.  Wipf group approach to isoindolinones97 and strategy for the preparation of a library of tricyclic 
isoindolinone amino alcohols (4-5).98  
 
Preparation of the library began with N-alkylation of phthalimide (4-6) with 4-penten-1-
ol under Mitsunobu conditions.  Subsequent NaBH4 reduction and protection of the intermediate 
hemiaminal as the pivaloate provided alkene 4-7 in 59% overall yield (Scheme 34).  
Hydrozirconation-transmetalation of 1-hexyne generated the alkenylalane in situ, which reacted 
with the N-acyliminium ion of 4-7 to afford diene 4-8.97,99  Ring-closing metathesis of 4-8 using 
Grubbs 2nd generation catalyst 4-1290b was carried out in the presence of 1 equiv of Ti(Oi-Pr)4 at 
room temperature.100   Surprisingly, the alkene-isomerized homoallylic amide 4-10 was isolated 
rather than the expected allylic amide 4-9 (Scheme 34). To explore the reproducibility of this 
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result, the RCM was carried out using Zhan catalyst-1B (4-13).101  The alkene-isomerized 
product 4-10 was isolated in 50% yield.  Epoxidation of 4-10 using NaHCO3-buffered meta-
chloroperbenzoic acid (m-CPBA) afforded epoxide 4-11 in 57% yield.  X-ray analysis of 4-11 
confirmed the formation of the alkene-isomerized product 4-10 (Scheme 34). 
 
 
Scheme 34.  Synthesis of isomerized azepinoisoindolinone 4-10 and epoxide 4-11.98 
 
The unexpected formation of isomerization product 4-10 under the aforementioned 
metathesis conditions could be explained by a ruthenium-catalyzed double bond 
isomerization.102  The release of ring strain can only be partially responsible for this 
isomerization process since the analysis of the 5 possible alkene isomers of 4-9 using DFT 
calculations indicated a decrease in relative energy from 4-9 to 4-10, while other isomers were 
even lower in energy (4-14–16) (Figure 17).   
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Figure 17.  Relative energies of alkene isomers based on RB3LYP/6-311G* calculations with MacSpartan ’06.98 
 
To further investigate the factors influencing the alkene isomerization process, Wipf and 
co-workers conducted the ring-closing metathesis in the absence of Ti(Oi-Pr)4 (Scheme 2). The 
resulting product was quite unstable and was therefore immediately subjected to m-CPBA 
epoxidation conditions to provide 4-17 in modest yields.  The structure of 4-17 was assigned by 
X-ray analysis (Scheme 35) and implies the intermediate presence of the expected RCM product 
4-9. The isolation of 4-17, and the absence of significant quantities of 4-11, suggests the 
chelating additive Ti(Oi-Pr)4 is the primary factor responsible for the isomerization of 4-9 to 4-
10 in Scheme 34. The ability of Ti(Oi-Pr)4 to induce alkene isomerization during the RCM 
reaction is noteworthy.  Although there are a number of additives known to decrease the rate of 
isomerization in RCM,103 we are unaware of a previous report on an alkene isomerization-
promoting effect of an additive in this reaction. 
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Scheme 35.  Ring-closing metathesis of diene 4-8 in the absence of Ti(Oi-Pr)4 and hydroxyepoxide 4-17.98 
4.2 RESULTS AND DISCUSSION 
To further investigate the factors influencing the alkene isomerization process, we studied the 
influence of the diene substitution pattern on the rate of isomerization from 4-9 to 4-10 (Scheme 
36).  Addition of in situ prepared vinyl alane to pivaloate 4-7 provided 4-18 in 80% yield.  RCM 
of 4-18 using Grubbs 2nd generation catalyst in the presence of Ti(Oi-Pr)4 gave 4-9 exclusively.  
No alkene isomerization was observed and homoallylic amide 4-10 was not detected in the 
reaction mixture.   
 
 
Scheme 36.  Preparation and RCM reaction in the presence of Ti(Oi-Pr)4 of bis-terminal diene 4-18.98 
 
Next, we performed the RCM in the absence of Ti(Oi-Pr)4 (Scheme 37).  Crude 4-9 was 
obtained in 77% yield.  Product 4-9 was difficult to purify due to its chemical instability.  
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Therefore, the RCM reaction of 4-9 was conducted on larger scale in the absence of Ti(Oi-Pr)4, 
and the crude intermediate was subjected to m-CPBA oxidation.  Epoxide 4-17 was isolated in 
11% overall yield and LCMS and NMR analysis suggested a 5:1 ratio of epimers at the 
hemiacetal carbon.  The spectral data of epoxide 4-17 matched the spectra isolated from the route 
in Scheme 35.  This result provides further support for the exclusive formation of alkene 4-9 
from the RCM of bis-terminal alkene 4-18.  Unlike 4-8, the presence or absence of Ti(Oi-Pr)4 
does not appear to have an effect on alkene isomerization for the RCM reaction of 4-18. 
 
 
Scheme 37.  RCM reaction in the absence of Ti(Oi-Pr)4 of bis-terminal diene 4-18 and epoxide formation.98 
 
Our initial results suggested that the isomerization of 4-8 was primarily due to the 
chelating additive Ti(Oi-Pr)4; however, the results of the RCM of 4-18 indicate that additional 
factors may be operational.  While several reports have indicated that the decomposition 
products of the ruthenium catalysts are responsible for alkene isomerization, the isomerized 
alkene is only a minor byproduct and much less than in the case of 4-8 (Scheme 34).104  
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Therefore, we proposed that the alkene isomerization process could also be attributed to the 
stability of the intermediate alkylidine complexes for each substrate.  In the case of 4-8, the 
resulting alkylidene complex could form a ruthenium hydride species, which would mediate 
alkene isomerization. In contrast, the metathesis of 4-18 results in a more reactive methylidene 
complex that is likely to react more quickly and is therefore unable to facilitate isomerization of 
product 4-9.   
To test this hypothesis, diene 4-8 was subjected to RCM in the presence of Ti(Oi-Pr)4 
under an atmosphere of ethylene.  We envisioned that ethylene would react with the intermediate 
alkylidene complex to regenerate a catalytically active alkylidene, and thus mitigate alkene 
isomerization.  Although a significant amount of starting material was recovered from this 
reaction, 4-9 was the only product observed (Scheme 38).  This result supports our hypothesis 
that the alkene isomerization process is dependent on both the presence of Ti(Oi-Pr)4 and the 
identity of the intermediate alkylidene species. 
 
 
Scheme 38.  RCM reaction of 4-8 in the presence of Ti(Oi-Pr)4 under an atmosphere of ethylene. 
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4.3 CONCLUSION 
The Wipf group has successfully developed a synthetic method to prepare libraries of 
functionalized isoindolinones.  While preparing these novel tricyclic isoindolinones, an 
interesting alkene isomerization was observed during the RCM reaction.  Further investigation of 
this isomerization process suggested that the alkene isomerization from allylic to homoallylic 
amides under RCM conditions is dependent on the presence of the Lewis acidic additive Ti(Oi-
Pr)4 as well as the substitution pattern of the -diene precursor.  
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5.0  PROGRESS TOWARD THE SYNTHESIS OF SESSILIFOLIAMIDE C 
5.1 INTRODUCTION 
5.1.1 Introduction to Stemona Alkaloids 
The Stemona alkaloids represent a structurally diverse set of natural products with relatively 
complex structures.  The extracts from several plants of the Stemonaceae family have been used 
in both China and Japan as insecticides and as a traditional medicine for the treatment of 
respiratory diseases.105  To date, more than 139 Stemona alkaloids have been reported and most 
are characterized by either an exposed or hidden pyrrolo[1,2-a]azepine core (5-1).105b,106  Pilli 
and co-workers106b have recently classified the Stemona alkaloids into eight groups based on 
their structural features:  stenine (I), stemoamide (II), tuberostemospironine (III), stemonamine 
(IV), parvistemoline (V), stemofoline (VI), stemocurtisine (VII), and a miscellaneous group 
(VIII) (Figure 18).  The miscellaneous group contains alkaloids that do not display the structural 
motifs contained in the other seven groups, or are the lone representative of a novel group. 
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Figure 18.  Classification of Stemona alkaloids into eight groups.106b 
 
The first total synthesis of a member of this class of natural products was that of 
croomine reported in 1989 by Williams and co-workers.107  Since this seminal synthesis, a 
number of synthetic strategies and methodologies have been developed in an effort to synthesize 
Stemona alkaloids.106a,b,108  The Wipf group has remained active participants in the total 
synthesis of Stemona alkaloids since the 1990’s.109  In particular, Wipf and co-workers 
accomplished the total synthesis of stenine (5-3) and tuberostemonine (5-4) using an elegant 
scaffold-driven approach (Scheme 39).109a,b,109f,110  This strategy was based on the stereoselective 
oxidative cyclization of tyrosine to access hydroindolines (5-2) discovered and developed in their 
group.109a  More recently, Wipf and Hoye reported the first total synthesis of sessilifoliamide C 
using a convergent route featuring a [3,3]-sigmatropic rearrangement (See 5.1.2, Scheme 41). 
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Scheme 39.  Oxidative cyclization of Cbz-L-tyrosine and the conserved hydroindole core found in stenine and 
tuberostemonine.109a 
5.1.2 Total Synthesis of (–)-Sessilifoliamide C in the Wipf Group 
Sessilifoliamides A–D were isolated from the roots of Stemona sessilifolia in 2003 by Takeya 
and co-workers (Scheme 40).111  Since 2003, the isolation of sessiliofoliamides E–J has been 
reported by the same group.112 Each of the sessiliofoliamides A–D possess the characteristic 
pyrrolo[1,2-a]azepine core bearing a butenolide substituent at C-9. The structure and absolute 
configuration of sessilifoliamide C (5-7) was determined by chemical derivitization and 
comparison to a known analog of 5-5, whose absolute confirmation was determined by X-ray 
analysis.111  The structures of sessiliofoliamides A–D bear striking resemblance to the previously 
identified alkaloid parvistemoline (5-9).113 A possible biosynthetic relationship between 
parvistemoline and sessilifoliamides A–D through oxidation and cyclization events was proposed 
by Wipf and Hoye (Scheme 40).109g  Accordingly, Wipf and Hoye investigated a unified and 
possibly biomimetic strategy toward sessifoliamide A–D.  They chose to synthesize (–)-
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sessilifoliamide C first, due to its structural similarity to the more complex ring system present in 
parvistemoline. 
      
 
Scheme 40.  Biosynthetic hypothesis based on the structural similarities between parvistemoline and 
sessilifoliamides.109g 
 
The Wipf group retrosynthetic strategy for the preparation of 5-7 relied upon the 
installation of the requisite stereocenters at C-9 and C-10 prior to construction of the butenolide 
(Scheme 41).  Wipf and Hoye envisioned that these stereocenters would be constructed in a 
single step via a [3,3]-sigmatropic Claisen rearrangement.114  The key rearrangement precursor 
would be accessed by RCM of 5-12, which would arise from the alkylation of known 
vinylpyrrolidinone 5-14115 with iodide 5-15116 (Scheme 41).   
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Scheme 41.  Retrosynthetic approach for sessilifoliamide C.109g 
 
Methods for constructing the vinylpyrrolidine fragment 5-14 have been reported, but 
were found to suffer from laborious purifications, redox processes, or low-yielding 
eliminations.115  Therefore, Wipf and Hoye pursued an alternative strategy beginning with 
conversion of (S)-pyroglutamic acid 5-16 to the corresponding thioester followed by N-Boc 
protection to obtained 5-17 (Scheme 42).  Fukuyama reduction117 of the thioester and Wittig 
olefination of the resulting aldehyde provided the desired vinylpyrrolidine 5-19 with 72% ee 
(Scheme 42).  Next, Wipf and Hoye prepared the requisite iodide fragment by a two-step 
reduction and iodination of known t-butyl ester 5-20.116  Ester 5-20 was synthesized on large 
scale using a previously reported enzymatic resolution strategy (Scheme 43).116    
 
 
Scheme 42.  Preparation of vinylpyrrolidinone 5-19. 
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Scheme 43.  Preparation of iodide fragment 5-15. 
 
With the coupling partners in hand, the N-alkylation was explored after cleavage of the 
N-Boc group with TFA.  Alkylation of amide 5-14 required optimization due to reproducibility 
and scalability issues.  Phase-transfer conditions were found to be superior to other methods 
explored and provided RCM precursor 5-13 in good yield.  RCM of diene 5-13 using Grubbs II 
generated the characteristic pyrrolo[1,2-a]azepine core in 91% yield as a 6:1 mixture of 
diastereomers at C-9a.  Removal of the TBS protecting group under acidic conditions furnished 
alcohol 5-12. 
 
 
Scheme 44.  Synthesis of key intermediate 5-12. 
 
At this stage, esterification of 5-23 using butyric acid produced the key [3,3]-sigmatropic 
Claisen rearrangement precursor (Scheme 45).  Enolization of 5-23 with LiHMDS in the 
presence of TIPSCl generated TIPS-silyl ketene acetal, which was subjected to thermal 
rearrangement conditions to provided the desired silyl ester 5-11a.   Conversion of 5-11a to the 
methylester 5-11b to simplify analysis proceeded smoothly and provided the desired product in 
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51% yield over 4 steps as a 6:1 mixture of diastereomers at C-10 (Scheme 45).  Hydrogenation 
of the double bond and conversion of the methyl ester to the aldehyde by a reduction/oxidation 
sequence allowed for chromatographic separation of the minor diastereomer to afford pure 5-10.  
Construction of the butenolide by employing a known RCM strategy118 and subsequent MPLC 
separation of the reaction mixture revealed (–)-sessilifoliamide C (5-7) as the major isomer 
(Scheme 45).  This represents the first synthesis of (–)-sessilifoliamide C, which was achieved in 
18 steps from (S)-pyroglutamic acid in a 5.6% overall yield. 
 
 
Scheme 45.  Synthesis of sessilifoliamide C via a novel [3,3]-sigmatropic Claisen rearrangement strategy. 
5.1.3 Total Synthesis of epi-Sessilifoliamide J and Sessilifoliamide J  
The synthesis of (–)-sessilifoliamide C by Wipf and Hoye represented the first total synthesis of 
a member of the sessilifoliamide family.109g  Since this report, the total synthesis of 9-epi-
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sessilifoliamdie J (5-34) and (–)-sessilifoliamide J (5-35) have been disclosed by Huang and co-
workers.119  Sessilifoliamide J was isolated in 2008 and its structure and relative configuration 
was established by single crystal X-ray analysis (Scheme 46).112b  The first approach to 
sessilifoliamide J featured chiral building block 5-28 as a platform for the assembly of the 
tetracyclic scaffold (Scheme 46).  This strategy was an extension of the continuing efforts in the 
Huang group to develop 3-hydroxyglutarimide-based synthetic methodologies.120  The key 
glutarimide intermediate 5-28 was obtained in 5 steps and 56% overall yield from D-glutamic 
acid (Scheme 46).119a  Installation of the requisite butenolide fragment was accomplished by a 
vinylogous Mannich reaction121 of bicyclic N,O-acetal 5-29 and siloxyfuran 5-30.  The final 
spirolactone moiety was constructed via the SmI2-mediated coupling of methacrylate (5-33) with 
ketone 5-32 to provide a mixture of 4 isomers. The major component was assigned as 9-epi-
sessilifoliamide J (5-34) and one of the minor component was (–)-sessilifoliamide J (5-35), 
allowing for the absolute configuration of 5-35 to be established (Scheme 46).119a   
 
 
Scheme 46.  Asymmetric total synthesis of 9-epi-sessilifoliamide J and (–)-sessilifoliamide J. 
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Two years after they reported on the synthesis of 9-epi-sessilifoliamide J, Huang and co-
workers published an alternative approach to (–)-sessilifoliamide J starting from known 
indolizindinone 5-36 (Scheme 47).119b,122  In light of their previous results, they sought to install 
the correct stereochemistry at C-8 using the lactonization conditions reported by Corey and 
Zheng.123  This method provided a separable 2:1 diastereomeric mixture of lactones and the 
major isomer was the desired spirolactone 5-37 (Scheme 47).  Functional group interconversions 
of 5-37 generated the desired alcohol 5-38. Construction of the final butenolide moiety via 
oxidation of 5-38 and subsequent addition of the organozinc reagent of 5-39 afforded a separable 
1:1 mixture of diasteromers at C-13.  Hydrogenation of the desired isomer 5-40 furnished (–)-
sessilifoliamide J (5-35, Scheme 47).119b  
 
 
Scheme 47.  Total synthesis of (–)-sessilifoliamide J. 
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5.2 RESULTS AND DISCUSSION 
5.2.1 Second Generation Approach:  Mitsunobu Reaction and Addition of in situ 
Generated Organoalanes to Acyliminium Ions 
Our initial goal for the 2nd generation synthesis of sessilifoliamide C was to improve and 
streamline the synthesis of intermediate 5-12.  The 1st generation synthesis suffered from low 
stereoisomeric ratio at C-9a, low material throughput due to the use of a chiral resolution to 
generate fragment 5-15, and the general difficulties in the scale up of the vinylpyrrolidinone 5-
14.  To circumvent these issues, we envisioned installation of the vinyl group to proceed via 
addition of in situ generated organoalanes to the corresponding N-acyliminium ion of pivaloate 
5-42 as described in Section 4.1 of this document.  Pivaloate 5-42 would be accessed by a 
Mitsunobu reaction124 of 5-44 with succinimide (5-43).  Asymmetric Mukaiyama aldol 
reaction125 between cinnamaldehyde (5-46) and methylacetate (5-47) would generate the 
requisite fragment 5-45. 
 
Scheme 48.  Second-generation retrosynthetic analysis to intermediate 5-12. 
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In the 1st generation approach, the synthesis of alcohol 5-21 was 6 steps and required a 
chiral resolution and a deprotection/reprotection sequence.  To streamline this route and increase 
material throughput, we envisioned using an asymmetric a aldol reaction to access alcohol 5-44 
in 4 steps without chiral resolution and protection/deprotection sequences.  The preparation of 
the enantiomer of 5-44 has been reported and was synthesized via catalytic asymmetric 
Mukaiyama aldol reaction in the presence of Carreira’s chiral Ti(IV) complex 5-49 in 95% yield 
and with 98% ee (Scheme 49).126  Using this approach, we prepared the requisite catalyst 5-49 
and silyl ketene acetal 5-48 according to literature protocols.126c,127 Subjecting of 
cinnamaldehyde to the aforementioned conditions provided 5-50 in a modest yield and good 
enantiomeric ratio (Scheme 49).  The entiomeric ratio was determined by chiral HPLC analysis 
on a CHIRALCEL® OD column using a racemic standard (rac-5-50).  
 
Scheme 49.  Catalytic enantioselective Mukaiyama aldol additions using chiral Ti(IV) complex 5-49. 
 
At this point we chose to proceed with the synthesis of intermediate 5-53 using racemic 
alcohol rac-5-44 (Scheme 50).  This would allow for racemic standards of each intermediate and 
rapid material throughput to evaluate the feasibility of the synthetic route.  To this end, aldol 
reaction of methyl acetate and cinnamaldehyde followed by TBS protection of the resulting 
alcohol provided rac-5-45 in 88% yield over two steps (Scheme 50).128  Primary alcohol rac-5-
44 was readily accessed by a two-step reduction of ester rac-5-45.  With desired alcohol 
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fragment rac-5-44 in hand, the Mitsunobu alkylation of succinimide was explored.  While both 
DEAD and DBAD provided the desired product 5-51 in good yields, separation of the 
corresponding hydrazide byproducts was difficult.  Therefore, the crude material was subjected 
to NaBH4.  The presence of the hydrazide byproduct was inconsequential, and the desired 
alcohol 5-51 was isolated as a 1:1 mixture of diastereomers in good yield over the two steps 
(Scheme 50).  
 
 
Scheme 50.  Racemic synthesis of alcohol 5-51. 
 
The protection of alcohol 5-51 as the pivaloate required the use NaH as the base to ensure 
complete conversion of the starting material to key intermediate 5-52 (Scheme 51).  Formation 
of hexenylalane and addition to the in situ generated iminium ion of 5-52 provided the desired 
RCM precursor 5-53 in 11% yield as a 1:1 mixture of diastereomers at C-9a (Scheme 51).  
Although the reaction did result in complete consumption of starting material, neither 5-51 nor 5-
52 were isolated.  This may be due to the acidic workup, which would result in cleavage of both 
the pivalyl and siloxy protecting groups.  The polar nature of the resulting diol would render 
isolation from silica gel chromatography difficult. 
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Scheme 51.  Addition of hexenylalane to the in situ generated iminium ion of 5-52. 
 
During the synthesis of 5-53, we had been working on the addition of in situ generated 
vinyl alane to N-acyliminium ions (Section 4.2).   In light of the success of this aforementioned 
method, we sought to utilize this strategy to circumvent the problems faced in the addition of 
hexenyl alane to 5-52.  At this point, we realized that the installation of a vinyl group would 
allow us generate intermediate 5-13 in the first generation synthesis.  To achieve the second-
generation synthesis of sessilifoliamide C (5-7), the previously synthesized alcohol 5-21109g was 
used as the Mitsunobu coupling partner.  The Mitsunobu reaction of 5-21 with succinimide (5-
43), followed by reduction and pivolate protection afforded 5-55 in good yields over three steps.  
Gratifyingly, in situ generation of the vinyl alane and addition to pivaloate 5-55 provided 5-13 in 
modest yield as a 1:1 mixture of diastereomers. 
 
 
Scheme 52.  Vinyl alane addition to 5-55. 
 
We successfully prepared 5-13, a building block in our previous synthesis of 
sessilifoliamide C (Scheme 48).  This second generation approach featured direct installation of 
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the requisite vinyl group via addition of in situ generated vinyl alane to an N-acyliminium ion.  
This method eliminates the synthesis of pyrrolidinone 5-19, which was difficult to perform on 
scale in a reproducible manner.  Although the synthesis of alcohol 5-21 is manageable on large 
scale (40 g), it is 7 linear steps, includes a chiral resolution, and a deprotection/reprotection 
sequence.  The enantioselective Mukiayama aldol reaction in this second generation approach 
streamlines this sequence to 4 steps and eliminates the chiral resolution and 
deprotection/reprotection sequence, greatly enhancing material throughput.  Additionally, the 
Mitsunobu reaction of commercially available succinimide (5-43) and 5-21 provides an 
attractive, more reproducible alternative to the phase transfer conditions used for the N-
alkylation.  Although we were able to make improvements upon the first generation synthesis, 
the diastereomeric ratio at C-9a will require further optimization to generate a synthetically 
tractable route.  
 
5.2.2 Third Generation Approach:  Alkylation and Addition of in situ Generated 
Organoalanes to Acyliminium Ions Bearing a Chiral Auxiliary  
To address the low diastereomeric ratio (dr) obtained from the vinyl alane addition 
reaction in Scheme 52, we designed a new synthetic strategy (Scheme 53).   The key feature of 
this route would be the use of auxiliary R* to generate a chiral N-acyliminium ion equivalent.  
Cleavage of the chiral auxiliary (R*) and subsequent alkylation with iodide fragment 5-58 would 
provide the requisite RCM precursor 5-56.  Fragment 5-58 would arise from straightforward 
iodination of the previously synthesized alcohol 5-44. 
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Scheme 53.  Revised retrosynthesis of key intermediate 5-12 using a chiral auxiliary (R*). 
 
Prior to installation of a chiral auxiliary, a model system was prepared according to 
Scheme 54.129  Beginning with commercially available succinimide (5-43), benzyl protection and 
mono-reduction worked well to provide pyrrolidinone 5-61.  Treatment of 5-61 with pivalyl 
chloride in the presence of DMAP afforded the desired N-acyliminium precursor 5-62.  Addition 
of the in situ generated vinyl alane to the pivaloate 5-62 proceeded smoothly to afford 5-63 in 
good yield.  
 
 
Scheme 54.  Model system for the asymmetric vinyl alane addition to pivaloate 5-62. 
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  The first chiral auxiliary explored was S-(–)-phenylethyl (5-65).  Synthesis of the 
requisite chiral N-acyliminium ion precursor 5-69 followed a literature protocol (Scheme 55).130 
Formation of succinimide 5-67 was achieved by treatment of succinic anhydride (5-64) with S-(–
)-phenylethylamine and acetic anhydride in THF at reflux.  Reduction of 5-67 afforded 5-68 as a 
ca. 10:1 mixture of diastereomers, as indicated by 1H and 13C NMR.  At this point, we chose to 
use the sulfinate protecting group, rather the pivalyl due to the greater stability and ease of 
preparation of the sulfinate. Treatment of this mixture with toluenesulfinic acid afforded the 
desired sulfinate protected substrate 5-69 as a 1:1 mixture of diastereomers.  In situ generation of 
the chiral N-acyliminium ion of 5-69 and addition of vinyl alane proceeded smoothly; however, 
the dr was only 1:0.7.   
 
 
Scheme 55.  Synthesis of chiral N-acyliminium precursor 5-69 and vinyl alane addition. 
 
To increase the dr of the vinyl addition we synthesized the S-(–)-naphthylethyl derivative 
5-72 in the same manner as Scheme 55 (Scheme 56).  Condensation of S-(–)-naphthylethylamine 
with succinic anhydride and reduction of 5-72 with lithium triethylborohydride furnished 5-73 in 
good yield and dr.  Protection of the alcohol as the sulfinate gave 5-74 in excellent yields with a 
1:1 dr. Addition of in situ generated vinyl alane to chiral N-acyliminium ion of 5-74 provided 5-
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75 as a 1:0.3 mixture of diastereomers.  Although the dr was improved compared with the 
corresponding S-(–)-phenylethyl derivative 5-70, optimization was still required to obtain a 
synthetically useful method. 
 
 
Scheme 56.  Synthesis of chiral N-acyliminium precursor 5-74 and vinyl alane addition. 
 
To further explore the effect of the chiral auxiliary on the dr, we synthesized 5-78 using 
L-phenylalaninol.  We envisioned L-phenylalaninol would selectively delivery the organoalane 
via a chelated transition state and thus enhance the dr.  This chiral induction strategy has been 
successfully applied to the addition of nucleophiles such as cuprates, silanes, and phosphites.131  
We were pleased to find that treatment of 5-77 with NaBH4 gave us the desired product 5-78.  
The crude material was taken on to the vinyl alane addition, but gave low yields of the desired 
product and poor diastereoselectivity.         
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Scheme 57.  Chiral induction via a chelated N-acyliminium ion of 5-78. 
5.2.3 Fourth Generation Approach: Transannular Ring Closure 
It was evident that installation of the requisite vinyl functionality at C-X could not be achieved 
with optimal diastereoselectivity.  Therefore, we redesigned our synthetic strategy to avoid the 
installation of this moiety and investigate a less traditional, more novel synthetic strategy.  We 
envisioned the key feature of this route would be the constructing the pyrrolo[1,2-a]azepine core 
of sessilifoliamide C via a transannular ring closure of 10-membered lactam 5-82 (Scheme 58).  
Installation of the butenolide moiety would be dependent upon the method employed for the 
heteroannulation step.  An asymmetric hydrogenation of the resulting double bond would allow 
for the simultaneous installation of C-9 and C-9a configurations in a stereocontrolled manner.  
The requisite intermediate 5-82 would be accessed via macrolactamization of amino acid 5-83.  
This revised route represents a novel entry to the pyrrolo[1,2-a]azepine scaffold, and represents a 
potential unified approach to the synthesis of a number of Stemona alkaloids contain this 
characteristic feature. 
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Scheme 58. Revised retrosynthetic strategy featuring a novel transannular ring closure to construct the pyrrolo[1,2-
a]azepine core. 
 
At the outset of this route, we recognized that the construction of the requisite 10-
membered lactam 5-82 represented a synthetic challenge.  The difficultly in forming medium-
sized rings (8 to 11-membered) is attributed to the ring strain that develops during the transition 
state as a result of trannsannular interactions.132  These interactions result in substantial torsional 
and/or bond angle distortion.  In lactam 5-69, the ring strain will be further exacerbated by the 
inclusion of the alkyne moiety, which prefers to adopt bond angles of 180°.  We reasoned that 
while construction of the 10-membered lactam would be challenging, the inherent ring strain 
would allow us to achieve the subsequent key heteroannulation reaction. 
To this end, we chose to access the macrolactam by amide bond formation of the 
corresponding amino acid.  Although closure of medium-sized ring lactams via amide C-N bond 
formation is demanding, successful approaches have been reported and reviewed.133  To test the 
feasibility of this transformation we synthesized amino acid 5-83 according to Scheme 59.  We 
began with protection of 5-pentyn-1-ol as the tetrahydropyranyl ether (5-85). Treatment of 5-85 
with n-BuLi followed by dibromobutane provided the desired coupled product 5-86 in good 
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yield.  Protection of the primary alcohol in 5-84 was necessary to obtain acceptable yields in the 
coupling reaction, in addition to mitigating the need for 2 equivalents of n-BuLi.  Bromide 5-86 
was converted to the azide using NaN3 in DMF at 80 °C.  Gratifyingly, THP removal and 
oxidation of the resulting alcohol was achieved in one step using Jones reagent.  Staudinger 
reduction134 of the azide went smoothly using PPh3; however, purification of amino acid 5-83 
was difficult due to contamination with triphenylphosphine oxide.  Switching to 1,2-
bis(diphenylphosphino)ethane provided the desired amino acid in good yields and allowed for 
isolation of pure 5-83 as the hydrochloride salt.  
 
 
Scheme 59.  Synthesis of requisite amino acid 5-83. 
 
With the requisite amino acid 5-83 in hand, we explored lactamization conditions to 
access 5-82.  We were pleased to find that treatment of 5-83 with EDC and HOBt under high 
dilution conditions provided the desired macrolactam in modest yield (Scheme 60).  Formation 
of the undesired dimerized macrolactam 5-88 was also observed (<10%); however, product 
isolation was difficult due to the polarity of 5-88.  Elution of compound 5-88 from a silica gel 
column required an eluent mixture of >5% MeOH in CH2Cl2.  As a result, it was isolated as an 
inseparable mixture with HOBt, and an isolated yield was not calculated.   
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The structure of 5-82 was confirmed by X-ray crystallographic analysis (Scheme 60).  
Notably, the crystal structure shows that angles of the alkyne deviates from the ideal angle of 
180°, with values of 167.3° and 171.7° (Appendix A.3).  Additionally, the amide adopts a trans 
configuration with a dihedral angle (ω) of -162.6° (Appendix A.3).  A survey of the literature 
revealed crystal structures of 10-membered rings containing either the alkyne and amide 
moieties, but not both.135 The bond angles associated with compounds containing a cyclodecyne 
core ranged from 167.7° to 169.4° and are in good agreement with those found for compound 5-
82.135b The corresponding dihedral angles (ω) for known 10-membered lactams were between -
167.1° and -168.3°, which are slightly larger than the dihedral angle in 5-82.135a The distortion of 
the amide bond in 5-82 is presumably due to the presence of the alkyne.  
 
 
Scheme 60.  Lactamization of 5-83 and the X-ray structure of 5-82.  
 
Next, we attempted to optimize the amide coupling conditions to favor the formation of 
desired lactam 5-82.  Dilution of the reaction mixture or heating to reflux gave comparable 
results (Table 12, entries 1 vs. 2 and 3), while the use of pentafluorophenyl diphenylphosphinate 
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(FDPP)136 resulted in formation of the desired product 5-82 with good mass recovery.  
Unfortunately, the separation of 5-82 from the phosphine oxide byproducts could not be 
achieved.  Similar purification issues were also encountered when HATU137 and HOAt137 were 
employed. 
 
Table 12.  Optimization of the macrolactamization of 5-83 to provide lactam 5-82. 
 
entry conditions temp, time results a 
1 EDC, HOBt, Et3N, CH2Cl2 (5 mM) rt, 2.5 d 5-82 (44%) 
2 EDC, HOBt, Et3N, CH2Cl2 (1 mM) rt, 2 d 5-82 (28%) 
3 EDC, HOBt, Et3N, CH2Cl2 (5 mM) reflux, 2 d 5-82 (26%) 
4 FDPP, DIPEA, CH2Cl2 (5 mM) rt, 2 d 5-82 (29%, 90% pure) 
5 HATU, HOAt, CH2Cl2 (5 mM) rt, 2 d 
5-82 (inseparable sideproduct;  
100% mass recovery) 
a <10% of dimer 5-88 was observed in each of these reaction, but an isolated yield was not obtained. 
 
At this stage, EDC and HOBt were the best conditions for the formation and isolation of 
the requisite macrolactam 5-82 and were therefore employed for the scale-up of intermediate 5-
82.  With the key precursor in hand, we set out to explore the transannular ring closure.  We 
began by investigating the electrophilic cyclization of 5-82 to access the halo-substituted 
pyrrolo[1,2-a]azepine.  To our knowledge, halo-cyclization of cyclic alkynylamides to form γ-
halo-γ-butyrolactams has not been investigated.  Nonetheless, there are examples of 
intramolecular electrophilic cyclizations of acyclic Z-alkenylamides 5-89138 and alkynylanilines 
5-91139 with ICl and I2, respectively (Scheme 61).
140  In each case, the desired products are 
obtained in good yields and arise from 5-exo rather than 6-endo ring closure. 
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Scheme 61.  Electrophilic cyclization of acyclic alkynylamides to access γ-iodo lactams.138-139 
 
Based on these precedents, 5-82 was treated with I2 and Na2CO3 in THF at room 
temperature.  Unfortunately, the undesired quinolizinone 5-95 was formed exclusively in 
moderate yield (Table 13, entry 1).  Compound 5-95 can be distinguished from compound 5-94 
on the basis of the lactam carbonyl 13C shift.  The five-membered ring products generally exhibit 
a 13C shift of ca. 174–180 ppm, while in the six-membered ring the carbonyl shift is at ca. 168–
172 ppm.   Performing the reaction in the presence of AgNO3 did not change the selectivity of 
the cyclization.  Using an alternative source of iodine, such as Barluenga’s reagent,141 also 
provided modest yields of the undesired 6-endo cyclized product 5-95.   
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Table 13.  Iodocyclization of lactam 5-82. 
 
entry conditions results 
1 I2, Na2CO3, THF, rt, 1.5 h 5-95 (55%) 
2 I2, AgNO3, Na2CO3, THF, rt, o/n 5-95 (54%) 
3 IPy2BF4·HBF4, CH2Cl2, -60 °C, o/n 5-95 (39%)a 
a SM was recovered. 
 
Iodocyclization was unsuccessful in generating the desired pyrrolo[1,2-a]azepine core; 
therefore, we explored alternative electrophilic cyclization conditions that would provide the 
corresponding enamide rather than the vinyl iodide.  To this end, the gold-catalyzed cyclization 
of β-alkynylamide 5-96 has been reported to provide alkylidenelactam 5-97 (Scheme 62).142  The 
authors note that the use of catalytic Et3N in addition to AuCl(PPh3) strongly favored the 
formation of the 5-exo monocyclization to provide lactam 5-97.142  Surprisingly, application of 
these reaction conditions to lactam 5-82 resulted in the exclusive formation of the 6-endo 
cyclized product 5-98 (Scheme 63). 
 
 
Scheme 62.  Gold-catalyzed cyclization reaction of bispropargylic amide 5-96.142 
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Scheme 63.  Electrophilic cyclization of 5-82.  
 
At this stage it became evident that the inherent properties of our system favored 6-endo 
ring closure under electrophilic cyclization conditions.  Therefore, we investigated methods for 
nucleophilic cyclization.  To our knowledge, nucleophilic cyclization of cyclic β-alkynylamides 
to γ-alkylidene-γ-butyrolactams has not been investigated.  A survey of the literature revealed 
that the most optimal conditions for the intramolecular nucleophilic cyclization of β-
alkynylamides (5-99) are exposure to KHMDS and 18-crown-6 in THF at room temperature 
(Scheme 64).143  The cyclization of β-alkynylamide 5-82 under these conditions furnished an 
inseparable 1.5:1.0 mixture of the desired pyrrolo[1,2-a]azepine 5-101 with the undesired 
quinolizinone 5-98 (Table 14, entry 1).   
 
 
Scheme 64.  Intramolecular cyclization of β-alkynylamides to γ-alkylidene-γ-butyrolactams.143a 
 
Pleased with these initial results, we set out to optimize the reaction conditions to obtain 
higher yields of 5-101 while suppressing the formation of 5-98.  We began by investigating the 
effect of the additives.  The use of AgOTf in place of 18-crown-6 favored the formation of the 6-
endo cyclization product 5-98, while in the absence of any additive there was little preference for 
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either cyclization pathway (Table 14, entries 2 and 3).  These results indicate that sequestration 
of the potassium cations to provide a “naked” anion enhances the selectivity for the desired 5-
endo pathway.  Based on this observation, we hypothesized that the use of a more polar solvent 
would also increase the preference for the desired product 5-101.  Gratifyingly, performing the 
cyclization reaction in DMF afforded the desired product 5-101 as a 2.5:1 ratio with the 
undesired product 5-98 (Table 14, entry 4).  Further attempts to enhance the ratio in favor of the 
desired product 5-101 by lowering the reaction temperature or modifying the concentration were 
not successful (Table 14, entries 5-7).  We also explored alternative bases such as NaH, KH, and 
KOt-Bu, but could not improve the ratio beyond 2.5:1 in favor of the desired product 5-101. 
 
Table 14.  Optimization of the intramolecular nucleophilic cyclization of β-alkynylamide 5-82. 
 
entry conditionsa yield (5-101:5-98) 
1 KHMDS, 18-crown-6, THF, rt, 1 h 15 min 91% (1.5:1.0) 
2 KHMDS, AgOTf, toluene, rt to 60 °C, 21 h 90% (1.0:2.0) 
3 KHMDS, THF, rt, 45 min 79% (0.7:1.0) 
4 KHMDS, 18-crown-6, DMF, rt, 40 min 81% (2.5:1.0) 
5 KHMDS, 18-crown-6, DMF, 0 °C, 20 min 83% (2.5:1.0) 
6 KHMDS, 18-crown-6, DMF (0.005 M), 0 °C, 30 min 87% (2.5:1.0) 
7 KHMDS, 18-crown-6, DMF (0.2 M), 0 °C, 20 min 60% (2.5:1.0) 
a All reactions were carried out at 0.03 M unless otherwise stated.    
 
The mixture of products was taken on to investigate the functionalization of the enamide 
(Scheme 65).  Initial attempts to generate vinyl bromide 5-102 resulted in over-bromination or 
decomposition.  Formylation of the enamide using Vilsmeier reagent afforded a mixture of 
products, with the undesired formylated product 5-104 as the major constituent.   
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Scheme 65.  Attempts to functionalize a mixture of enamides 5-101 and 5-98. 
5.3 CONCLUSION 
We have developed a second-generation approach toward sessilifoliamide C utilizing a method 
previously developed by our group.  This strategy allowed us to address and improve upon 
several issues in the first generation synthesis, namely the elimination of the chiral resolution and 
N-alkylation steps, as well as the installation of the vinyl moiety.  Additionally, we achieved a 
novel entry to the pyrrolo[1,2-a]azepine core of the Stemona alkaloids by a transannular ring 
closure of a β-alkynyl lactam.  Functionalization and elaboration of the pyrrolo[1,2-a]azepine 
enamide is currently underway. 
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6.0  EXPERIMENTAL PART 
6.1 GENERAL EXPERIMENTAL 
All glassware was dried in an oven at 140 °C for 2 h or flame dried and cooled under dry 
N2 or Ar prior to use.  All moisture sensitive reactions were performed using syringe-septum cap 
techniques under an atmosphere of dry N2 or Ar.  Reactions carried out below 0 °C employed an 
acetone/dry ice bath or a cyrocool and an isopropanol/ethanol bath.  THF, Et2O, and 1,4-dioxane 
were distilled from sodium/benzophenone ketyl; i-Pr2NH, i-Pr2NEt, and Et3N were distilled from 
CaH2 and stored over KOH; and CH2Cl2 and toluene were purified by passage through an 
activated alumina filtration system or by distillation from CaH2.  All other materials were 
obtained from commercial sources and used as received unless otherwise stated.  
Reactions were monitored by thin-layer chromatography analysis using pre-coated silica 
gel 60 F254 plates (EMD, 250 μm thickness) and visualization was accomplished with a 254 nm 
UV light and by staining with a KMnO4 solution (1.5 g of KMnO4 and 1.5 g of K2CO3 in 100 
mL of a 0.1% NaOH solution) or Vaughn’s reagent (4.8 g of (NH4)6Mo7O24•4 H2O and 0.2 g of 
Ce(SO4)2 in 100 mL of a 3.5 N H2SO4 solution).  Flash chromatography on SiO2 (Silicycle, Silia-
P Flash Silica Gel or SiliaFlash® P60, 40-63 μm) or Florisil® (100-200 mesh) was used to 
purify crude reaction mixtures.  Concentrating under reduced pressure refers to the use of a 
rotary evaporator connected to a membrane vacuum pump or a PIAB Lab Vac H40 to remove 
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solvent.  All desired products were placed under high vacuum (0.5-4 mmHg) to remove trace 
solvent. 
Melting points were determined using a Laboratory Devices Mel-Temp II in open 
capillary tubes and are uncorrected.  Infrared spectra were determined as neat solids or oils on a 
Smiths Detection IdentifyIR FT-IR spectrometer.  Mass spectra were obtained on a Micromass 
Autospec UK Limited double focusing instrument, a Q-TOF Ultima API, or a Thermo Scientific 
Exactive Orbitrap LC-MS. Microwave reactions were performed using a Biotage Initiator 
microwave reactor.  1H and 13C NMR spectra were recorded on a Bruker Avance 300 MHz, 400 
MHz, 500 MHz, or 600 MHz instruments.  Chemical shifts (δ) were reported in parts per million 
with the residual solvent peak used as an internal standard δ 1H / 13C (Solvent); 7.26 / 77.16 
(CDCl3); 2.50 / 39.52 (DMSO-d6); and are tabulated as follows: chemical shift, multiplicity (s = 
singlet, d = doublet, t = triplet, q = quartet, quint = quintet, sext = sextet, sept = septet, m = 
multiplet), number of protons, and coupling constant(s).  13C NMR spectra were obtained using a 
proton-decoupled pulse sequence and are tabulated by observed peak.  CDCl3 was filtered 
through dried basic alumina prior to sample preparation.     
6.2 CHAPTER 1 EXPERIMENTAL PART 
 
1-22a 
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2,7-Dichloro-4-(3-methoxyphenyl)quinazoline (1-22a).  To a reaction vial was added 
1-2121 (0.040 g, 0.17 mmol), Pd(OAc)2 (0.0020 g, 0.009 mmol), and PPh3 (0.007 g, 0.026 mmol). 
The reaction mixture was flushed with N2.  3-Methoxyphenylboronic acid (0.029 g, 0.19 mmol) 
in freshly distilled and degassed DME (1.7 mL) and Na2CO3 (0.056 g, 0.53 mmol) in H2O (0.30 
mL) were added via syringe. The reaction mixture was sealed and heated at 80 C for 16 h. The 
mixture was extracted with CH2Cl2 (4 x 5 mL).  The combined organic layers were washed with 
brine (5 mL), dried (MgSO4), and concentrated under reduced pressure.  The crude residue was 
purified by chromatography on SiO2 (1:20, EtOAc:hexanes) to provide 1-22a (0.045 g, 86%) as 
a fluffy white solid:  1H NMR (DMSO-d6, 300 MHz,) δ 8.19 (d, 1 H, J = 0.9 Hz), 8.14 (d, 1 H, J 
= 5.4 Hz), 7.80 (dd, 1 H, J = 5.4, 1.2 Hz), 7.56 (app t, 1 H, J = 4.8 Hz), 7.36–7.31 (m, 2 H), 7.34 
(dd, 1 H, J = 4.8, 1.2 Hz), 3.85 (s, 3 H). 
 
 
1-22b 
2,7-Dichloro-4-phenylquinazoline (1-22b).  To a reaction vial was added 1-2121 (0.041 
g, 0.17 mmol), phenylboronic acid (0.023 g, 0.19 mmol), Pd(OAc)2 (0.0020 g, 0.0087 mmol), 
and PPh3 (0.0075 g, 0.028 mmol). Freshly distilled and degassed DME (1.5 mL) and Na2CO3 
(0.057 g, 0.54 mmol) in H2O (0.30 mL) were added via syringe, and the reaction mixture was 
sealed and heated at reflux for 18 h.  The reaction mixture was cooled to room temperature, 
filtered through a pad of silica gel with EtOAc washings, and concentrated under reduced 
pressure. The crude residue was purified by chromatography on SiO2 (1:50 EtOAc:hexanes to 
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1:20 EtOAc:hexanes) to provide 1-22b (0.033 g, 70%) as a pale green solid:  1H NMR (DMSO-
d6, 300 MHz) δ 8.18 (d, 1 H, J = 2.1 Hz), 8.12 (d, 1 H, J = 9.0 Hz), 7.80 (dd, 1 H, J = 7.5, 1.8 
Hz), 7.83–7.78 (m, 2 H), 7.70–7.62 (m, 3 H); 13C NMR (75 MHz, DMSO-d6) δ 171.5, 157.0, 
152.9, 140.4, 135.1, 131.0, 130.1, 129.6, 129.5, 128.8, 126.4, 120.0; MS (EI) m/z 274 ([M]+, 58), 
239 (100), 203 (43), 77 (51); HRMS (EI) m/z calcd for C14H8N2Cl2 (M
+) 274.0065, found 
274.0060. 
 
 
1-22c 
2,7-Dichloro-4-(thiophen-2-yl)quinazoline (1-22c).  To a reaction vial was added 1-2121 
(0.040 g, 0.11 mmol), Pd(OAc)2 (0.0020 g, 0.0087 mmol), PPh3 (0.0068 g, 0.026 mmol), and 
thiophene-2-boronic acid (0.024 g, 0.19 mmol). The reaction mixture was flushed with N2. 
Freshly distilled and degassed DME (1.5 mL) and Na2CO3 (0.056 g, 0.53 mmol) in H2O (0.15 
mL) were added via syringe.  The reaction mixture was sealed and heated at reflux for 12 h.  
H2O (5 mL) was added and the mixture was extracted with CH2Cl2 (4 x 10 mL).  The combined 
organic layers were washed with H2O (10 mL), dried (MgSO4), and concentrated under reduced 
pressure.  The crude residue was purified by chromatography on SiO2 (1:20, EtOAc:hexanes) to 
provide 1-22c (0.034 g, 71%) as a yellow-green solid:  1H NMR (DMSO-d6, 300 MHz) δ 8.59 
(d, 1 H, J = 9.0 Hz), 8.14 (dd, 1 H, J = 3.9, 0.9 Hz), 8.10 (dd, 1 H, J = 5.1, 0.9 Hz), 8.08 (d, 1 H, 
J = 1.8 Hz), 7.80 (dd, 1 H, J = 9.0, 2.1 Hz), 7.39 (dd, 1 H, J = 5.1, 3.9 Hz); 13C NMR (DMSO-d6, 
75 MHz) δ 162.9, 156.5, 153.3, 140.4, 138.7, 134.0, 133.9, 129.6, 129.4, 128.9, 126.5, 118.4; 
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MS (EI) m/z 280 ([M]+, 95), 245 (68), 209 (43); HRMS (EI) m/z calcd for C12H6Cl2N2S (M
+) 
279.9629, found 279.9620.  
 
 
1-22d 
2,7-Dichloro-4-(4-ethylphenyl)quinazoline (1-22d).  To a reaction vial was added 1-
2121 (0.040 g, 0.17 mmol), Pd(OAc)2 (0.0019 g, 0.0086 mmol), and PPh3 (0.0068 g, 0.026 
mmol). The reaction mixture was flushed with N2. 4-Ethylphenylboronic acid (0.027 g, 0.18 
mmol) in freshly distilled and degassed DME (1.7 mL) and Na2CO3 (0.056 g, 0.53 mmol) in H2O 
(0.20 mL) were added via syringe. The reaction mixture was stirred at 80 °C under a N2 
atmosphere for 36 h.  H2O (1 mL) was added and the mixture was extracted with CH2Cl2 (4 x  
5 mL).  The combined organic layers were washed with brine (5 mL), dried (MgSO4), and 
concentrated under reduced pressure.  The crude residue was purified by chromatography on 
SiO2 (1:20, EtOAc:hexanes) to provide 1-22d (0.025 g, 49%) as a light green solid:  
1H NMR 
(DMSO-d6, 300 MHz) δ 8.19–8.13 (m, 2 H), 7.80 (dd, 1 H, J = 9.0, 2.1 Hz), 7.75 (d, 2 H, J = 8.1 
Hz), 7.50 (d, 2 H, J = 7.8 Hz), 2.75 (q, 2 H, J = 7.5 Hz), 1.26 (t, 3 H, J = 7.5 Hz).  
 
1-22e 
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2,7-Dichloro-4-m-tolylquinazoline (1-22e).  To a reaction vial was added 1-2121 (0.061 
g, 0.26 mmol), Pd(OAc)2 (0.0030 g, 0.013 mmol), and PPh3 (0.011 g, 0.041 mmol). The reaction 
mixture was flushed with N2.  3-Methylphenylboronic acid (0.036 g, 0.26 mmol) in freshly 
distilled and degassed DME (1.0 mL) and Na2CO3 (0.085 g, 0.80 mmol) in H2O (0.30 mL) were 
added via syringe. The reaction mixture was sealed and heated at reflux for 21 h.  H2O was 
added and the mixture was extracted with CH2Cl2 (4 x 15 mL).  The combined organic layers 
were washed with H2O, dried (MgSO4), and concentrated under reduced pressure.  The crude 
residue was purified by chromatography on SiO2 (1:50, EtOAc:hexanes) to provide 1-22e  
(0.025 g, 33%) as a light green solid:  1H NMR (DMSO-d6, 300 MHz) δ 8.15 (d, 1 H, J = 2.1 
Hz), 8.11 (d, 1 H, J = 9.0 Hz), 7.78 (dd, 1 H, J = 9.0, 2.1 Hz), 7.61–7.48 (m, 4 H), 2.44 (s, 3 H); 
13C NMR (DMSO-d6, 75 MHz) δ 171.6, 157.0, 152.9, 140.4, 138.3, 135.0, 131.7, 130.4, 129.6, 
129.4, 128.7, 127.4, 126.3, 120.0, 21.0; MS (EI) m/z 288 ([M]+, 79), 273 (76), 253 (86); HRMS 
(EI) m/z calcd for C15H10Cl2N2 (M
+) 288.0221, found 288.0215. 
 
 
1-23a 
7-Chloro-4-(3-methoxyphenyl)-2-m-tolylquinazoline (1-23a).  To a reaction vial was 
added 1-22a (0.030 g, 0.098 mmol), Pd(OAc)2 (0.0011 g, 0.0049 mmol), and PPh3 (0.0039 g, 
0.015 mmol).  The reaction mixture was flushed with N2.  3-Methylphenylboronic acid (0.014 g, 
0.010 mmol) in freshly distilled and degassed DME (1.0 mL) and Na2CO3 (0.032 g, 0.30 mmol) 
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in H2O (0.15 mL) were added via syringe. The reaction mixture was sealed and heated at reflux 
for 22 h. The mixture was extracted with CH2Cl2 (4 x 5 mL).  The combined organic layers were 
washed with H2O (5 mL), dried (MgSO4), and concentrated under reduced pressure.  The crude 
residue was purified by chromatography on SiO2 (1:50, EtOAc:hexanes) to provide 1-23a  
(0.030 g, 85%) as an off-white sticky solid:  IR (ATR) 3047, 2999, 2918, 1560, 1539, 1331, 
1288, 1243, 1049, 773 cm-1; 1H NMR (DMSO-d6, 300 MHz) δ 8.36 (m, 2 H), 8.16 (d, 1 H, J = 
2.1 Hz), 8.07 (d, 1 H, J = 9.0 Hz), 7.68 (dd, 1 H, J =9.0, 2.1 Hz), 7.56 (app t, 1 H, J = 8.1 Hz), 
7.48–7.34 (m, 4 H), 7.23 (dd, 1 H, J = 7.5, 1.8 Hz), 3.86 (s, 3 H), 2.43 (s, 3 H); 13C NMR 
(DMSO-d6, 75 MHz) δ 168.0, 160.1, 159.3, 151.8, 139.1, 137.9, 137.0, 131.8, 129.9, 129.1, 
128.72, 128.66, 128.4, 127.3, 125.6, 122.2, 119.8, 115.8, 115.4, 55.4, 21.1; MS (EI) m/z 360 
([M]+, 42), 345 (8), 325 (34); HRMS (EI) m/z calcd for C22H17ClN2O (M
+) 360.1029, found 
360.1022.  
 
 
1-23b 
7-Chloro-4-(3-methoxyphenyl)-2-(thiophen-2-yl)quinazoline (1-23b).  To a reaction 
vial was added 1-22a (0.025 g, 0.082 mmol), Pd(OAc)2 (0.0010 g, 0.0047 mmol), and PPh3 
(0.0033 g, 0.012 mmol). The reaction mixture was flushed with N2.  2-Thiopheneboronic acid 
(0.011 g, 0.086 mmol) in freshly distilled and degassed DME (0.80 mL) and Na2CO3 (0.027 g, 
0.24 mmol) in H2O (0.15 mL) were added via syringe. The reaction mixture was sealed and 
 101 
heated at reflux for 15 h. The mixture was extracted with CH2Cl2 (4 x 5 mL).  The combined 
organic layers were washed with H2O (5 mL), dried (MgSO4), and concentrated under reduced 
pressure.  The crude residue was purified by chromatography on SiO2 (1:50, EtOAc:hexanes) to 
provide 1-23b (0.018 g, 61%, 77% BRSM) as a pale green solid:  1H NMR (DMSO-d6,  
300 MHz) δ 8.14–8.11 (m, 2 H), 8.06 (d, 1 H, J = 9.0 Hz), 7.85 (dd, 1 H, J = 5.1, 1.2 Hz), 7.68 
(dd, 1 H, J = 9.0, 2.1 Hz), 7.57 (app t, 1 H, J 8.3 Hz), 7.40–7.36 (m, 2 H), 7.29–7.22 (m, 2 H), 
3.87 (s, 3 H).  
 
 
1-23c 
2,7-Dichloro-4-(3-methoxyphenyl)quinazoline (1-23c).  To a reaction vial was added 1-
22c (0.022 g, 0.080 mmol), Pd(OAc)2 (0.0010 g, 0.0045 mmol), and PPh3 (0.0030 g, 0.012 
mmol). The reaction mixture was flushed with N2.  3-Methylphenylboronic acid (0.012 g, 0.085 
mmol) in freshly distilled and degassed DME (0.70 mL) and Na2CO3 (0.025 g, 0.24 mmol) in 
H2O (0.15 mL) were added via syringe. The reaction mixture was sealed and heated at 75 °C for 
24 h. The mixture was poured into H2O (3.0 mL) and extracted with CH2Cl2 (4 x 10 mL).  The 
combined organic layers were washed with H2O (10 mL), dried (MgSO4), and concentrated 
under reduced pressure.  The crude residue was purified by chromatography on SiO2 (1:50, 
EtOAc:hexanes) to provide 1-23c (0.012 g, 45%) as a yellow-green solid:  1H NMR (DMSO-d6, 
500 MHz) δ 8.61 (d, 1 H, J = 9.0 Hz), 8.39–8.35 (m, 2 H), 8.16 (d, 1 H, J = 2.5 Hz), 8.15 (dd,  
1 H, J = 4.0, 1.0 Hz), 8.04 (dd, 1 H, J = 5.0, 0.5 Hz), 7.75 (dd, 1 H, J = 9.0, 2.0 Hz), 7.48 (app t, 
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1 H), 7.42–7.38 (m, 2 H), 2.45 (s, 3 H); 13C NMR (DMSO-d6, 75 MHz) δ 159.9, 159.7, 152.4, 
140.7, 139.1, 137.9, 136.7, 132.4, 132.3, 131.9, 129.1, 128.7, 128.6, 128.5, 128.4, 127.4, 125.4, 
118.3, 21.2; MS (EI) m/z 336 ([M]+, 44), 280 (84), 245 (68), 209 (33), 149 (74), 57 (100); 
HRMS (EI) m/z calcd for C19H13ClN2S (M
+) 336.0488, found 336.0474.  
 
 
1-23d 
7-Chloro-2-(3-methoxyphenyl)-4-phenylquinazoline (1-23d).  To a reaction vial was 
added 1-22b (0.030 g, 0.098 mmol), Pd(OAc)2 (0.0011 g, 0.0049 mmol), and PPh3 (0.0039 g, 
0.015 mmol). The reaction mixture was flushed with N2.  3-Methoxyphenylboronic acid  
(0.014 g, 0.010 mmol) in freshly distilled and degassed DME (1.0 mL) and Na2CO3 (0.032 g, 
0.30 mmol) in H2O (0.15 mL) were added via syringe. The reaction mixture was sealed and 
heated under microwave irradiation at 120 °C for 40 min. The mixture was extracted with 
CH2Cl2 (4 x 5 mL).  The combined organic layers were washed with H2O (5 mL), dried 
(MgSO4), and concentrated under reduced pressure.  The crude residue was purified by 
chromatography on SiO2 (1:50, EtOAc:hexanes) to provide 1-23d (0.028 g, 75%) as a light 
yellow solid:  IR (ATR) 3077, 3056, 1599, 1554, 1538, 1461, 1334, 1247, 1072, 1042, 932, 872, 
833 cm-1; 1H NMR (DMSO-d6, 300 MHz) δ 8.23 (d, 1 H, J = 2.1 Hz), 8.19 (d, 1 H, J = 7.8 Hz), 
8.14–8.08 (m, 2 H), 7.90 (dd, 2 H, J = 6.0, 2.1 Hz), 7.73 (dd, 1 H, J = 9.0, 2.1 Hz), 7.70–7.64 (m, 
3 H), 7.50 (app t, 1 H, J = 8.1 Hz), 7.16 (dd, 1 H, J = 7.5, 1.8 Hz), 3.87 (s, 3 H); HRMS (ESI) 
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m/z calcd for C21H16ClN2O ([M+H]
+) 347.0951, found 347.0932. 
 
 
1-25 
2,7-Dichloro-4-(phenylthio)quinazoline (1-25).  To a solution of 1-2121 (0.300 g, 1.28 
mmol) in freshly distilled and degassed THF (21.0 mL) cooled to 0 °C was added a premixed 
solution of thiophenol (0.151 g, 1.33 mmol) and NaH (0.034 g, 1.42 mmol) in THF (2.0 mL) 
dropwise.  The mixture was stirred for 15.5 h, warmed to room temperature, poured into ice cold 
H2O, and extracted with EtOAc (5 x 50 mL).  The combined organic layers were washed with 
H2O, dried (MgSO4), and concentrated under reduced pressure to give a light yellow residue. 
The crude residue was purified by chromatography on SiO2 (1:10 EtOAc:hexanes) to provide 1-
25 (0.294 g, 74%) as a light yellow-green solid:  IR (ATR) 3047, 3062, 1549, 1461, 1329, 1137, 
738 cm-1; 1H NMR (DMSO-d6, 300 MHz,) δ 8.31 (d, 1 H, J = 8.7 Hz), 8.05 (d, 1 H, J = 2.1 Hz), 
7.83 (dd, 1 H, J = 9.0, 2.1 Hz), 7.70–7.66 (m, 2 H), 7.59–7.55 (m, 3 H); 13C NMR (DMSO-d6, 75 
MHz) δ 174.4, 156.1, 150.1, 140.5, 135.5, 130.4, 129.8, 129.3, 126.6, 126.0, 125.4, 119.7; MS 
(EI) m/z 305 (M+, 100), 271 (21), 197 (18), 136 (53); HRMS (EI) m/z calcd for C14H8Cl2N2S 
(M+) 305.9785, found 305.9782. 
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1-26a 
7-Chloro-4-(phenylthio)-2-(thiophen-2-yl)quinazoline (1-26a). To a reaction vial was 
added 1-25 (0.039 g, 0.13 mmol), Pd(OAc)2 (0.0015 g, 0.0060 mmol), PPh3 (0.016 g,  
0.060 mmol), and thiophene-2-boronic acid (0.017 g, 0.13 mmol).  The reaction mixture was 
flushed with N2.  Freshly distilled and degassed DME (1.0 mL) and Na2CO3 (0.043 g,  
0.40 mmol) in H2O (0.15 mL) were added via syringe and the reaction mixture was sealed and 
heated at reflux for 23 h. The solution was extracted with CH2Cl2 (4 x 10 mL).  The combined 
organic layers were washed with H2O, dried (MgSO4), and concentrated under reduced pressure.  
The crude residue was purified by chromatography on SiO2 (1:20 EtOAc/hexanes) to provide 1-
26a (0.040 g, 87%) as a pale green solid:  IR (ATR) 3060, 2920, 2851, 1601, 1536, 831, 740  
cm-1; 1H NMR (DMSO-d6, 300 MHz) δ 8.22 (d, 1H, J = 8.7 Hz), 8.01 (d, 1 H, J = 2.1 Hz), 7.76–
7.70 (m, 4 H), 7.63–7.59 (m, 3 H), 7.55 (dd, 1 H, J = 3.6, 1.2 Hz), 7.13 (dd, 1 H, J = 5.1, 3.9 Hz); 
MS (EI) m/z 354 (M+, 72), 319 (12), 245 (100); HRMS (EI) m/z calcd for C18H11ClN2S2 (M
+) 
354.0052, found 354.0045. 
 
 
1-28 
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2,7-Dichloro-4-(isopropylthio)quinazoline (1-28).  To a solution of 1-2121 (0.300 g, 
1.28 mmol) in freshly distilled and degassed THF (13.0 mL) cooled to 0 °C was added a 
premixed solution of i-PrSH (0.12 mL, 1.28 mmol) and NaH (0.032 g, 1.35 mmol) in THF  
(2.0 mL) dropwise.  The mixture was stirred for 16 h, warmed to room temperature, poured into 
ice cold H2O, and extracted with EtOAc (5 x 25 mL).  The combined organic layers were washed 
with H2O, dried (MgSO4), and concentrated under reduced pressure to give a light yellow 
residue. The residue was purified by chromatography on SiO2 (1:50, EtOAc:hexanes) to provide 
1-28 (0.291 g, 83%) as a light yellow crystalline solid:  Mp 89.1–90.1 °C (EtOAc); IR (ATR) 
3075, 2965, 2881, 1551, 1459, 1321, 1224, 1133, 852 cm-1; 1H NMR (DMSO-d6, 300 MHz)  
 8.07 (d, 1 H, J = 9.0 Hz), 7.98 (d, 1 H, J = 2.1 Hz), 7.72 (dd, 1 H, J = 9.0, 2.1 Hz), 4.18 (sept,  
1 H, J = 6.9 Hz), 1.46 (d, 6 H, J = 6.9 Hz); 13C NMR (DMSO-d6, 75 MHz)  174.8, 156.0, 149.7, 
140.1, 128.9, 126.6, 125.9, 120.2, 36.0, 22.2; MS (EI) m/z 272 ([M]+, 33), 230 (100), 195 (48), 
161 (37); HRMS (EI) m/z calcd for C11H10Cl2N2S (M
+) 271.9942, found 271.9946. 
 
 
1-29a 
7-Chloro-4-(isopropylthio)-2-(thiophen-2-yl)quinazoline (1-29a).  General Protocol 
A.  To a reaction vial was added 1-28 (0.025 g, 0.092 mmol), Pd(OAc)2 (0.0010 g, 0.0046 
mmol), PPh3 (0.0036 g, 0.014 mmol), Na2CO3 (0.030 g, 0.28 mmol), and thiophene-2-boronic 
acid (0.023 g, 0.18 mmol).  The reaction mixture was flushed with N2.  Freshly distilled and 
degassed DME and H2O (DME:H2O, 10:1) were added via syringe to generate a 0.1 M solution 
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of 1-28, and the reaction mixture was stirred at 75 °C under a N2 atmosphere for 24 h.  H2O (1 
mL) was added and the mixture was extracted with CH2Cl2 (4 x 5 mL).  The combined organic 
layers were washed with brine (5 mL), dried (MgSO4), and concentrated under reduced pressure.  
The crude residue was purified by chromatography on SiO2 (1:50, EtOAc:hexanes) to give 1-29a 
(0.029 g, 99%) as a light yellow solid:  Mp 122.7–124.7 °C (DMSO); IR (ATR) 2973, 2917, 
2855, 1524, 1437, 1327, 1236, 988, 837, 773, 714 cm-1; 1H NMR (DMSO-d6, 300 MHz)  8.06 
(dd, 1 H, J = 3.6, 1.2 Hz), 8.00 (d, 1 H, J = 8.7 Hz), 7.95 (d, 1 H, J = 2.1 Hz), 7.84 (dd, 1 H, J = 
5.1, 1.5 Hz), 7.61 (dd, 1 H, J = 9.0, 2.1 Hz), 7.26 (dd, 1 H, J = 4.8, 3.6 Hz), 4.30 (sept, 1 H, J = 
6.9 Hz), 1.53 (d, 6 H, J = 6.9 Hz); 13C NMR (DMSO-d6, 75 MHz)  171.2, 156.0, 149.0, 142.8, 
139.2, 131.7, 129.8, 128.8, 127.6, 127.0, 125.8, 120.0, 35.7, 22.4 ; MS (ESI) m/z 321 ([M+1]+, 
100), 277 (65); HRMS (ESI) m/z calcd for C15H14ClN2S2 ([M+1]
+) 321.0287, found 321.0271. 
 
 
1-29b 
7-Chloro-4-(isopropylthio)-2-phenylquinazoline (1-29b).  According to General 
Protocol A, 1-28 (0.040 g, 0.15 mmol), Pd(OAc)2 (0.0016 g, 0.0073 mmol), PPh3 (0.0058 g, 
0.022 mmol), Na2CO3 (0.048 g, 0.45 mmol), and phenylboronic acid (0.027 g, 0.22 mmol) were 
heated at 75 °C for 33 h and provided a crude residue that was purified by chromatography on 
SiO2 (1:50, EtOAc:hexanes) to afford 1-29b (0.042 g, 92%) as a pale green fluffy solid:  Mp 
130.3–131.1 °C (DMSO); IR (ATR) 2956, 2924, 2863, 1552, 1530, 1329, 1301, 844, 773 cm-1; 
1H NMR (DMSO-d6, 300 MHz)  8.57–8.52 (m, 2 H), 8.08 (d, 1 H, J = 9.0 Hz), 8.06 (d, 1 H,  
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J = 1.5 Hz), 7.68 (dd, 1 H, J = 8.7, 2.1 Hz), 7.62–7.57 (m, 3 H), 4.42 (sept, 1 H, J = 6.9 Hz), 1.55 
(d, 6 H, J = 6.9 Hz); 13C NMR (DMSO-d6, 75 MHz)  171.2, 158.9, 149.2, 139.1, 137.0, 131.3, 
128.8, 128.2, 128.1, 127.5, 125.7, 120.4, 35.4, 22.4; HRMS (ESI) m/z calcd for C17H16ClN2S 
([M+H]+) 315.0723, found 315.0726. 
 
 
1-29c 
7-Chloro-4-(isopropylthio)-2-m-tolylquinazoline (1-29c). According to General 
Protocol A, 1-28 (0.030 g, 0.11 mmol), Pd(OAc)2 (0.0012 g, 0.0055 mmol), PPh3 (0.0044 g, 
0.016 mmol), Na2CO3 (0.036 g, 0.34 mmol), and 3-methylphenylboronic acid (0.018 g,  
0.13 mmol) were heated at 75 °C for 36 h and provided a crude residue that was purified by 
chromatography on SiO2 (1:50, EtOAc:hexanes) to afford 1-29c (0.032 g, 90%) as a white 
crystalline solid:  Mp 114.4–115.1 °C (DMSO); IR (ATR) 2969, 2920, 2859, 1530, 1329, 768, 
719 cm-1 ; 1H NMR (DMSO-d6, 300 MHz)  8.37–8.30 (m, 2H), 8.07 (d, 1 H, J = 6.5 Hz), 8.05 
(s, 1 H), 7.67 (dd, 1 H, J = 8.9, 2.0 Hz), 7.47 (app t, 1 H, J = 7.6 Hz), 7.40 (d, 1 H, J = 7.6 Hz), 
4.40 (sept, 1 H, J = 6.8 Hz), 2.44 (s, 3 H), 1.55 (d, 6 H, J = 6.8 Hz); 13C NMR (DMSO-d6,  
75 MHz)  171.2, 159.0, 149.2, 139.0, 138.0, 137.0, 131.9, 128.8, 128.7, 128.0, 127.5, 125.7, 
125.5, 120.3, 35.4, 22.4, 21.2; MS (EI) m/z 328 ([M]+, 47), 286 (100), 253 (87), 91 (75); HRMS 
(EI) m/z calcd for C18H17ClN2S 328.0801 (M
+), found 328.0804.  
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1-29d 
7-Chloro-2-(4-ethylphenyl)-4-(isopropylthio)quinazoline (1-29d). According to 
General Protocol A, 1-28 (0.040 g, 0.15 mmol), Pd(OAc)2 (0.0016 g, 0.0073 mmol), PPh3 
(0.0058 g, 0.022 mmol), Na2CO3 (0.048 g, 0.45 mmol), and 4-ethylphenylboronic acid (0.033 g, 
0.22 mmol) were heated at 75 °C for 33 h and provided a crude residue that was purified by 
chromatography on SiO2 (1:50, EtOAc:hexanes) to afford 1-29d (0.048 g, 95%) as a pale green 
solid:  Mp 124.1–125.9 °C (DMSO); IR (ATR) 3064, 2920, 1552, 1532, 1329, 1301, 990, 762, 
699 cm-1; 1H NMR (DMSO-d6, 300 MHz)  8.46 (d, 2 H, J = 8.4 Hz), 8.07 (d, 1 H, J = 9.0 Hz), 
8.04 (d, 1 H, J = 2.1 Hz), 7.66 (dd, 1 H, J = 8.7, 2.1 Hz), 7.42 (d, 2 H, J = 8.1 Hz), 4.41 (sept,  
1 H, J = 6.9 Hz), 2.71 (q, 2 H, J = 7.5 Hz), 1.55 (d, 6 H, J = 6.9 Hz), 1.24 (t, 3 H, J = 7.5 Hz); 
13C NMR (DMSO-d6, 150 MHz)  171.1, 159.0, 149.2, 147.4, 139.0, 134.6, 128.31, 128.27, 
127.9, 127.4, 125.7, 120.3, 35.4, 28.2, 22.4, 15.4; HRMS (ESI) m/z calcd for C19H20ClN2S 
([M+H]+) 343.1036, found 343.1015. 
 
 
1-29e 
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2-(4-tert-Butylphenyl)-7-chloro-4-(isopropylthio)quinazoline (1-29e). According to 
General Protocol A, 1-28 (0.040 g, 0.15 mmol), Pd(OAc)2 (0.0016 g, 0.0073 mmol), PPh3 
(0.0058 g, 0.022 mmol), Na2CO3 (0.048 g, 0.45 mmol), and 4-tert-butylbenzeneboronic acid 
(0.039 g, 0.22 mmol) were heated at 75 °C for 25 h and provided a crude residue that was 
purified by chromatography on SiO2 (1:50, EtOAc:hexanes) to afford 1-29e (0.051 g, 93%) as a 
tan colored sticky solid:  IR (ATR) 2959, 2864, 1551, 1528, 1465, 1327, 991, 848, 779 cm-1; 1H 
NMR (DMSO-d6, 300 MHz)  8.46 (d, 2 H, J = 8.5 Hz), 8.06 (d, 1 H, J = 8.7 Hz), 8.04 (d, 1 H,  
J = 1.3 Hz), 7.66 (dd, 1 H, J = 8.7, 2.1 Hz), 7.60 (d, 2 H, J = 8.5 Hz), 4.40 (sept, 1 H, J = 6.8 
Hz), 1.55 (d, 6 H, J = 6.8 Hz), 1.34 (s, 9 H) ; 13C NMR (DMSO-d6, 150 MHz)  171.5, 159.4, 
154.6, 149.7, 139.4, 134.8, 128.5, 128.3, 127.9, 126.2, 126.1, 120.7, 35.9, 35.2, 31.4, 22.9; MS 
(EI) m/z 370 ([M]+, 50), 328 (95), 313 (100), 240 (48); HRMS (EI) m/z calcd for C21H23ClN2S 
(M+) 370.1270, found 370.1259. 
 
 
1-29f 
7-Chloro-4-(isopropylthio)-2-(4-(trifluoromethyl)phenyl)quinazoline (1-29f). 
According to General Protocol A, 1-28 (0.040 g, 0.15 mmol), Pd(OAc)2 (0.0016 g, 0.0073 
mmol), PPh3 (0.0058 g, 0.022 mmol), Na2CO3 (0.048 g, 0.45 mmol), and 4-
trifluoromethylphenylboronic acid (0.042 g, 0.22 mmol) were heated at 75 °C for 13 h and 
provided a crude residue that was purified by chromatography on SiO2 (1:50, EtOAc:hexanes) to 
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afford 1-29f (0.049 g, 88%) as an off-white solid:  Mp 142.1–144.0 °C (DMSO); IR (ATR) 
2963, 2928, 2866, 1536, 1551, 1319, 1303, 1105, 1064, 852, 779 cm-1; 1H NMR (DMSO-d6,  
323 K, 300 MHz)  8.69 (d, 2 H, J = 8.0 Hz), 8.09 (d, 1 H, J = 8.9 Hz), 8.05 (d, 1 H, J = 2.0 Hz), 
7.92 (d, 2 H, J = 8.3 Hz), 7.69 (dd, 1 H, J = 8.8, 2.1 Hz), 4.43 (sept, 1 H, J = 6.8 Hz), 1.57 (d,  
6 H, J = 6.8 Hz); 13C NMR (DMSO-d6, 323 K, 75 MHz)  171.5, 157.4, 148.7, 140.6, 139.0, 
130.9, 130.5, 128.5, 128.3, 127.3, 125.7, 125.4, 125.34, 125.29, 125.2, 122.1, 120.3, 35.3, 22.2; 
MS (ESI) m/z 383 ([M+H]+, 100), 313 (10); HRMS (ESI) m/z calcd for C18H15ClF3N2S 
([M+H]+) 383.0597, found 383.0563. 
 
 
1-29g 
7-Chloro-4-(isopropylthio)-2-(3-methoxyphenyl)quinazoline (1-29g). According to 
General Protocol A, 1-28 (0.040 g, 0.15 mmol), Pd(OAc)2 (0.0016 g, 0.0073 mmol), PPh3 
(0.0058 g, 0.022 mmol), Na2CO3 (0.048 g, 0.45 mmol), and 3-methoxyphenylboronic acid 
(0.034 g, 0.22 mmol) were heated at 75 °C for 17 h and provided a crude residue that was 
purified by chromatography on SiO2 (1:50, EtOAc:hexanes) to afford 1-29g (0.045 g, 89%) as an 
off-white solid:  Mp 109.7–111.3 °C (EtOAc/hexanes); IR (ATR) 3068, 2920, 2859, 1599, 1552, 
1534, 1452, 1329, 1047, 772 cm-1; 1H NMR (DMSO-d6, 300 MHz)  8.10 (d, 1 H, J =  
7.8 Hz), 8.07–7.99 (m, 3 H), 7.64 (dd, 1 H, J = 8.9, 2.0 Hz), 7.48 (app t, 1 H, J = 8.0 Hz), 7.14 
(dd, 1 H, J = 8.2, 2.5 Hz), 4.35 (sept, 1 H, J = 6.8 Hz), 3.86 (s, 3 H), 1.54 (d, 6 H, J = 6.8 Hz); 
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13C NMR (DMSO-d6, 75 MHz)  171.1, 159.6, 158.6, 149.0, 139.0, 138.4, 129.9, 128.1, 127.5, 
125.7, 120.6, 120.3, 116.9, 113.2, 55.2, 35.5, 22.4; MS (ESI) m/z 345 ([M+H]+, 100), 227 (27), 
229 (21); HRMS (ESI) m/z calcd for C18H18ClN2OS ([M+H]
+) 345.0801, found 345.0828. 
 
 
1-29h 
2-(Benzofuran-2-yl)-7-chloro-4-(isopropylthio)quinazoline (1-29h). According to 
General Protocol A, 1-28 (0.040 g, 0.15 mmol), Pd(OAc)2 (0.0016 g, 0.0073 mmol), PPh3 
(0.0058 g, 0.022 mmol), Na2CO3 (0.048 g, 0.45 mmol), and benzo[b]furan-2-boronic acid  
(0.036 g, 0.22 mmol) were heated at 75 °C for 33 h and provided a crude residue that was 
purified by chromatography on SiO2 (1:100, EtOAc:hexanes) to afford 1-29h (0.041 g, 79%) as a 
pale green solid:  Mp 168.7–169.9 °C (EtOAc/hexanes); IR (ATR) 3056, 2961, 2920, 2864, 
1579, 1547, 1528, 1470, 1336, 954, 848, 754 cm-1; 1H NMR (DMSO-d6, 300 MHz)  8.11 (d,  
1 H, J = 2.0 Hz), 8.08 (d, 1 H, J = 8.8 Hz), 7.93 (s, 1 H), 7.84 (d, 1 H, J = 7.7 Hz), 7.78 (d, 1 H,  
J = 8.1 Hz), 7.70 (dd, 1 H, J = 8.8, 1.9 Hz), 7.48 (app t, 1 H, J = 7.6 Hz), 7.36 (app t, 1 H, J =  
7.7 Hz), 4.41 (sept, 1 H, J = 6.8 Hz), 1.55 (d, 6 H, J = 6.8 Hz); 13C NMR (DMSO-d6, 308 K,  
75 MHz)  171.3, 155.4, 153.1, 152.5, 148.7, 139.2, 128.2, 127.7, 127.3, 126.5, 125.6, 123.5, 
122.4, 120.4, 111.7, 110.8, 35.5, 22.3; MS (EI) m/z 354 ([M]+, 43), 312 (100), 279 (50); HRMS 
(EI) m/z calcd for C19H15ClN2OS (M
+) 354.0594, found 354.0590. 
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1-29i 
7-Chloro-2-(1H-indol-5-yl)-4-(isopropylthio)quinazoline (1-29i). According to 
General Protocol A, 1-28 (0.040 g, 0.15 mmol), Pd(OAc)2 (0.0047 g, 0.0029 mmol), PPh3 
(0.0058 g, 0.022 mmol), Na2CO3 (0.048 g, 0.45 mmol), and indole-5-boronic acid (0.027 g,  
0.22 mmol) were heated at 75 °C for 48 h and provided a crude residue that was purified by 
chromatography on SiO2 (1:100 to 1:10, EtOAc:hexanes) to afford 1-29i (0.031 g, 60%) as a tan 
colored solid:  Mp 191.7–193.2 °C (DMSO); IR (ATR) 3176, 2958, 2920, 2863, 1470, 1526, 
1333, 1318, 1232, 850, 764, 731 cm-1; 1H NMR (DMSO-d6, 300 MHz)  11.38 (s, 1 H), 8.82 (s, 
1 H), 8.35 (dd, 1 H, J = 8.6, 1.6 Hz), 7.98 (d, 1 H, J = 8.9 Hz), 7.97 (d, 1 H, J = 2.0 Hz), 7.56 
(dd, 1 H, J = 8.6, 2.2 Hz), 7.54 (d, 1 H, J = 8.6 Hz), 7.44 (app t, 1 H, J = 2.7 Hz), 6.62 (app t,  
1 H, J = 2.0 Hz), 4.42 (sept, 1 H, J = 6.8 Hz), 1.55 (d, 6 H, J = 6.8 Hz); 13C NMR (DMSO-d6,  
75 MHz)  170.4, 160.4, 149.5, 138.7, 137.9, 128.0, 127.9, 127.1, 127.0, 126.7, 125.6, 121.6, 
121.4, 121.3, 120.0, 111.6, 102.5, 35.2, 22.5; MS (EI) m/z 353 ([M]+, 10), 311 (12), 278 (18); 
HRMS (EI) m/z calcd for C19H16ClN3S (M
+) 353.0753, found 353.0756. 
 
1-29k 
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7-Chloro-4-(isopropylthio)-2-(pyridin-4-yl)quinazoline (1-29k). According to General 
Protocol A, 1-28 (0.040 g, 0.15 mmol), Pd(OAc)2 (0.0016 g, 0.0073 mmol), PPh3 (0.0058 g, 
0.022 mmol), Na2CO3 (0.048 g, 0.45 mmol), and pyridine-4-boronic acid (0.027 g, 0.22 mmol) 
were heated at 75 °C for 48 h and provided a crude residue that was purified by chromatography 
on SiO2 (1:100 to 1:5, EtOAc:hexanes) to afford 1-29k (0.025 g, 53%) as a tan-colored solid:  
Mp 154.3–155.8 °C (DMSO); IR (ATR) 3023, 2969, 2920, 2864, 1599, 1547, 1526, 1464, 1331, 
1310, 1239, 993, 824, 775 cm-1; 1H NMR (DMSO-d6, 300 MHz)  8.85–8.81 (m, 2 H), 8.41-8.36 
(m, 2 H), 8.15 (s, 1 H), 8.13 (d, 1 H, J = 5.8 Hz), 7.77 (dd, 1 H, J = 8.9, 2.1 Hz), 4.45 (sept, 1 H, 
J = 6.8 Hz), 1.56 (d, 6 H, J = 6.8 Hz); 13C NMR (DMSO-d6, 75 MHz)  171.8, 157.0, 150.3, 
148.6, 144.0, 139.1, 128.7, 127.5, 125.5, 121.6, 120.7, 35.4, 22.2; MS (EI) m/z 317 ([M+2]+, 22), 
315 ([M]+, 38), 272 (18), 240 (40), 78 (61); HRMS (EI) m/z calcd for C16H14ClN3S (M
+) 
315.0597, found 315.0602. 
 
 
1-23f 
7-Chloro-2-phenyl-4-m-tolylquinazoline (1-23f).  General Protocol B.  To a reaction 
vial was added 1-29b (0.028 g, 0.090 mmol), CuTC (0.038 g, 0.20 mmol), Pd(PPh3)4 (0.0057 g, 
0.0045 mmol), and 3-methylphenylboronic acid (0.027 g, 0.20 mmol).  The reaction mixture was 
flushed with N2 and freshly distilled and degassed THF was added via syringe to generate a  
0.06 M solution of 1-29b.  The reaction mixture was stirred vigorously at 50 °C under a N2 
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atmosphere for 26 h.  A saturated solution of NaHCO3 (1 mL) was added and the solution was 
extracted with CH2Cl2 (4 x 5 mL), dried (MgSO4), and concentrated under reduced pressure.  
The crude residue was purified by chromatography on SiO2 (1:100, EtOAc:hexanes) to afford 1-
23f (0.028 g, 89%) as a pale yellow sticky solid:  IR (ATR) 3058, 3030, 2914, 2851, 1556, 1532, 
1336, 913, 766, 695, 682 cm-1; 1H NMR (DMSO-d6, 300 MHz)  8.63–8.56 (m, 2 H), 8.22 (d,  
1 H, J = 2.1 Hz), 8.11 (d, 1 H, J = 9.0 Hz), 7.73 (dd, 1 H, 9.0, 2.1 Hz), 7.70 (s, 1 H), 7.67 (d, 1 H, 
J = 7.6 Hz), 7.62–7.57 (m, 3 H), 7.54 (d, 1 H, J = 7.5 Hz), 7.49 (d, 1 H, J = 7.4 Hz), 2.47 (s,  
3 H); 13C NMR (DMSO-d6, 75 MHz)  168.3, 160.0, 151.9, 139.1, 138.1, 137.1, 136.6, 131.2, 
131.0, 130.4, 129.1, 128.8, 128.6, 128.4, 128.3, 127.3, 127.2, 119.8, 21.1; MS (EI) m/z 330 
([M]+, 17), 329 ([M-1]+, 43), 238 (43), 91 (100); HRMS (EI) m/z calcd for C21H15ClN2 (M
+) 
330.0924, found 330.0930. 
 
 
1-23g 
7-Chloro-2-(4-ethylphenyl)-4-m-tolylquinazoline (1-23g).   According to General 
Protocol B, 1-29d (0.028 g, 0.083 mmol), CuTC (0.035 g, 0.18 mmol), Pd(PPh3)4 (0.0053 g, 
0.0041 mmol), and 3-methylphenylboronic acid (0.025 g, 0.18 mmol) were heated at 50 °C for 
19 h and provided a crude residue that was purified by chromatography on SiO2 (1:100, 
EtOAc:hexanes) to afford 1-23g (0.027 g, 89%) as a pale yellow sticky solid:  IR (ATR) 2963, 
2935, 2883, 1599, 1552, 1528, 1336, 846, 786, 701 cm-1; 1H NMR (DMSO-d6, 300 MHz)  8.49 
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(d, 2 H, J = 8.3 Hz), 8.17 (d, 1 H, J = 2.0 Hz), 8.07 (d, 1 H, J = 8.9 Hz), 7.69 (dd, 1 H, J = 9.0, 
2.1 Hz), 7.68 (s, 1 H), 7.64 (d, 1 H, J = 7.5 Hz), 7.54 (t, 1 H, J = 7.5 Hz), 7.48 (d, 1 H, J =  
7.6 Hz), 7.41 (d, 2 H, J = 8.4 Hz), 2.71 (q, 2 H, J = 7.6 Hz), 2.47 (s, 3 H), 1.24 (t, 3 H, J =  
7.6 Hz); 13C NMR (DMSO-d6, 75 MHz)  168.3, 160.1, 151.9, 147.3, 139.0, 138.2, 136.6, 134.7, 
131.0, 130.4, 129.2, 128.6, 128.4, 128.2, 127.23, 127.20, 119.7, 28.2, 21.1, 15.4; MS (EI) m/z 
358 ([M]+, 32), 357 ([M-1]+, 81), 91 (100); HRMS (EI) m/z calcd for C23H19ClN2 (M
+) 358.1237, 
found 358.1230. 
 
 
1-23h 
7-Chloro-2-(4-ethylphenyl)-4-(3-methoxyphenyl)quinazoline (1-23h). According to 
General Protocol B, 1-29d (0.046 g, 0.13 mmol), CuTC (0.057 g, 0.30 mmol), Pd(PPh3)4  
(0.0086 g, 0.0067 mmol), and 3-methoxyphenylboronic acid (0.045 g, 0.30 mmol) were heated at 
50 °C for 22 h and provided a crude residue that was purified by chromatography on SiO2 (1:200 
to 1:20, EtOAc:hexanes) to afford 1-23h (0.042 g, 83%) as a yellow solid:  Mp 88.3–89.7 °C 
(EtOAc/hexanes); IR (ATR) 3064, 3002, 2959, 2930, 2827, 1597, 1554, 1528, 1334, 1247, 1236, 
1042, 909, 783 cm-1; 1H NMR (DMSO-d6, 300 MHz)  8.51 (d, 2 H, J = 8.3 Hz), 8.19 (d, 1 H,  
J = 2.1 Hz), 8.11 (d, 1 H, J = 9.0 Hz), 7.71 (dd, 1 H, J = 8.9, 2.2 Hz), 7.58 (t, 1 H, J = 8.3 Hz), 
7.45–7.38 (m, 4 H), 7.27–7.22 (m, 1 H), 3.87 (s, 3 H), 2.71 (q, 2 H, J = 7.6 Hz), 1.24 (t, 3 H,  
J = 7.6 Hz); 13C NMR (DMSO-d6, 75 MHz)  168.0, 160.1, 159.3, 151.9, 147.3, 139.1, 138.0, 
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134.7, 129.92, 129.88, 129.2, 128.5, 128.3, 127.2, 122.2, 119.8, 115.9, 115.3, 55.4, 28.2, 15.4; 
MS (ESI) m/z 375 ([M+1]+, 100), 227 (30); HRMS (ESI) m/z calcd for C23H20ClN2O ([M+H]
+) 
375.1264, found 375.1259. 
 
 
1-23i 
7-Chloro-2-(4-methoxyphenyl)-4-(4-(trifluoromethyl)phenyl)quinazoline (1-23i). 
According to General Protocol B, 1-29g (0.031 g, 0.091 mmol), CuTC (0.038 g, 0.20 mmol), 
Pd(PPh3)4 (0.0058 g, 0.0045 mmol), and 4-trifluoromethylphenylboronic acid (0.038 g,  
0.20 mmol) were heated at 50 °C for 19 h and provided a crude residue that was purified by 
chromatography on SiO2 (1:50, EtOAc:hexanes) to afford 1-23i (0.033 g, 87%) as a white solid:  
Mp 159.0–159.9 °C (DMSO); IR (ATR) 2950, 2918, 2844, 1538, 1321, 1278, 1167, 1122, 1105, 
1064, 1043, 777 cm-1; 1H NMR (DMSO-d6, 600 MHz)  8.22 (d, 1 H, J = 2.0 Hz), 8.15 (d, 1 H, J 
= 7.7 Hz), 8.09 (d, 2 H, J = 8.1), 8.08 (s, 1 H), 8.05 (d, 1 H, J = 8.9 Hz), 8.02 (d, 2 H, J = 8.2 
Hz), 7.71 (dd, 1 H, J = 8.9, 2.0 Hz), 7.48 (t, 1 H, J = 8.0 Hz), 7.15 (dd, 1 H, J = 8.0, 2.3 Hz), 3.86 
(s, 3 H); 13C NMR (DMSO-d6, 150 MHz)  166.9, 159.8, 159.7, 151.8, 140.5, 139.4, 138.3, 
130.9, 130.7, 130.5, 130.3, 129.9, 128.82, 128.79, 127.4, 125.7, 125.64, 125.61, 125.0, 123.2, 
120.8, 119.8, 119.1, 117.0, 113.4, 55.3; HRMS (ESI) m/z calcd for C22H15ClF3N2O ([M+H]
+) 
415.0825, found 415.0806. 
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1-23k 
2-(4-tert-Butylphenyl)-7-chloro-4-(4-ethylphenyl)quinazoline (1-23k). According to 
General Protocol B, 1-29e (0.047 g, 0.13 mmol), CuTC (0.053 g, 0.28 mmol), Pd(PPh3)4  
(0.0080 g, 0.0063 mmol), and 4-ethylphenylboronic acid (0.042 g, 0.28 mmol) were heated at  
50 °C for 19 h and provided a crude residue that was purified by chromatography on SiO2 (1:50, 
EtOAc:hexanes) to afford 1-23k (0.043 g, 86%) as a white crystalline solid:  IR (ATR) 2959, 
2866, 1599, 1552, 1528, 1472, 1388, 1336, 850, 786, 703 cm-1; 1H NMR (DMSO-d6, 600 MHz) 
 8.46 (d, 2 H, J = 8.5 Hz), 8.12 (d, 1 H, J = 2.1 Hz), 8.06 (d, 1 H, J = 8.9 Hz), 7.77 (d, 2 H, J = 
8.0 Hz), 7.64 (dd, 1 H, J = 8.9, 2.1 Hz), 7.56 (d, 2 H, J = 8.6 Hz), 7.46 (d, 2 H, J = 8.1 Hz), 2.74 
(q, 2 H, J = 7.6 Hz), 1.32 (s, 9 H), 1.26 (t, 3 H, J = 7.6 Hz); 13C NMR (DMSO-d6, 150 MHz)  
 167.9, 160.1, 153.9, 152.0, 146.4, 138.9, 134.5, 134.1, 130.1, 129.1, 128.2, 128.12, 128.09, 
127.2, 125.5, 119.6, 34.6, 31.0, 28.1, 15.5; HRMS (ESI) m/z calcd for C26H26ClN2 ([M+H]
+) 
401.1785, found 401.1775. 
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1-23m 
2-(Benzofuran-2-yl)-4-(4-tert-butylphenyl)-7-chloroquinazoline (1-23m). According 
to General Protocol B, 1-29h (0.036 g, 0.10 mmol), CuTC (0.043 g, 0.22 mmol), Pd(PPh3)4 
(0.0064 g, 0.0051 mmol), and 4-tert-butylphenylboronic acid (0.040 g, 0.22 mmol) were heated 
at 50 °C for 27 h and provided a crude residue that was purified by chromatography on SiO2 
(1:100, EtOAc:hexanes) to afford 1-23m (0.039 g, 91%) as a yellow crystalline solid:  Mp 
193.7–195.4 °C (DMSO); IR (ATR) 2961, 2920, 2864, 1552, 1523, 1474, 1334, 846, 783, 759 
cm-1; 1H NMR (DMSO-d6, 300 MHz)  8.26 (d, 1H, J = 1.8 Hz), 8.14 (d, 1 H, J = 8.9 Hz), 7.96 
(s, 1 H), 7.84 (d, 2 H, J = 8.2 Hz), 7.83–7.72 (m, 3 H), 7.70 (d, 2 H, J = 8.2 Hz), 7.48 (t, 1 H, J = 
7.6 Hz), 7.36 (t, 1 H, J = 7.5 Hz), 1.40 (s, 9 H); 13C NMR (DMSO-d6, 323 K, 75 MHz)  168.1, 
155.2, 153.6, 153.3, 153.1, 151.4, 139.1, 133.2, 129.5, 129.0, 128.4, 127.7, 126.9, 126.3, 125.2, 
123.3, 122.1, 119.7, 111.5, 110.3, 34.4, 30.7; MS (EI) m/z 412 ([M]+, 100), 397 (59), 355 (33), 
251 (74); HRMS (EI) m/z calcd for C26H21ClN2O (M
+) 412.1342, found 412.1338. 
 
1-23n 
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7-Chloro-4-phenyl-2-(thiophen-2-yl)quinazoline (1-23n).  According to General 
Protocol B, 1-29a (0.025 g, 0.078 mmol), CuTC (0.033 g, 0.17 mmol), Pd(PPh3)4 (0.0041 g, 
0.0039 mmol), and phenylboronic acid (0.021 g, 0.17 mmol) were heated at 50 °C for 13 h and 
provided a crude residue that was purified by chromatography on SiO2 (1:50, EtOAc:hexanes) to 
afford 1-23n (0.024 g, 97%) as an off-white flaky solid:  Mp 172.9–174.0 °C (DMSO); IR 
(ATR) 3066, 2917, 1526, 1426, 770, 701 cm-1; 1H NMR (DMSO-d6, 300 MHz)  8.16–8.10 (m, 
2 H), 8.05 (d, 1 H, J = 9.0 Hz), 7.88–7.81 (m, 3 H), 7.72–7.63 (m, 4 H), 7.27 (dd, 1 H J = 5.1, 
3.6 Hz); 13C NMR (DMSO-d6, 75 MHz)  168.4, 157.2, 151.8, 142.9, 139.4, 136.2, 131.7, 130.5, 
130.0, 129.3, 128.8, 128.1, 126.8, 119.6; MS (EI) m/z 322 ([M]+, 100), 321 ([M-1]+, 74), 287 
(75), 245 (30); HRMS (EI) m/z calcd for C18H11ClN2S2 (M
+) 322.0331, found 322.0327. 
 
 
1-23o 
7-Chloro-2-(4-ethylphenyl)-4-(1H-indol-5-yl)quinazoline (1-23o). According to 
General Protocol B, 1-29d (0.015 g, 0.044 mmol), CuTC (0.018 g, 0.096 mmol), Pd(PPh3)4 
(0.0028 g, 0.0022 mmol), and indole-5-boronic acid (0.016 g, 0.096 mmol) were heated at 50 °C 
for 48 h and provided a crude residue that was purified by chromatography on SiO2 (1:20, 
THF:toluene) to afford 1-23o (0.012 g, 66%, 90% pure) as a yellow solid:  Mp 172.8–174.2 °C 
(THF/Toluene); IR (ATR) 3213, 3205, 2956, 2915, 2848, 1599, 1551, 1530, 1461, 1336, 852, 
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772, 729 cm-1; 1H NMR (DMSO-d6, 300 MHz)  11.48 (s, 1 H), 8.53 (d, 2 H, J = 8.3 Hz), 8.23 
(d, 1 H, J = 9.0 Hz), 8.15 (d, 1 H, J = 2.1 Hz), 8.13 (s, 1 H), 7.70 (dd, 1 H, J = 8.9, 2.2 Hz), 7.66 
(s, 2 H), 7.53 (t, 1 H, J = 2.8 Hz), 7.42 (d, 2 H, J = 8.4 Hz), 6.65 (dd, 1 H, J = 2.8, 2.0 Hz), 2.71 
(q, 2 H, J = 7.6 Hz), 1.24 (t, 3 H, J = 7.6 Hz) ; 13C NMR (DMSO-d6, 75 MHz)  169.2, 160.0, 
152.2, 147.1, 138.6, 137.1, 135.0, 129.8, 128.4, 128.2, 127.9, 127.6, 127.5, 127.1, 127.0, 123.3, 
122.9, 119.9, 111.7, 102.3, 28.2, 15.4; MS (ESI) m/z 384 ([M+1]+, 100), 343 (80); HRMS (ESI) 
m/z calcd for C24H19ClN3 ([M+H]
+) 384.1268, found 384.1273. 
 
 
1-24b 
7-(4-Ethylphenyl)-2-(3-methoxyphenyl)-4-(4-(trifluoromethyl)phenyl)quinazoline (1-
24b). According to General Protocol A, 1-23i (0.028 g, 0.067 mmol), Pd(OAc)2 (0.0015 g, 
0.0067 mmol), PPh3 (0.0053 g, 0.020 mmol), Na2CO3 (0.044 g, 0.42 mmol), and 4-
ethylphenylboronic acid (0.040 g, 0.27 mmol) were heated at reflux for 34 h and provided a 
crude residue that was purified by chromatography on SiO2 (1:100, EtOAc:hexanes) to afford 1-
24b (0.026 g, 81%) as an off-white solid:  Mp 173.0–174.1 °C (EtOAc/hexanes); IR (ATR) 
2963, 2922, 2850, 1618, 1538, 1333, 1105, 1068, 788 cm-1; 1H NMR (DMSO-d6, 600 MHz)  
 8.40 (d, 1 H, J = 1.7 Hz), 8.22 (d, 1 H, J = 7.8 Hz), 8.16 (d, 1 H, J = 2.5 Hz), 8.15 (d, 2 H, J = 
8.2 Hz), 8.12 (d, 1 H, J = 8.7 Hz), 8.07 (dd, 1 H, J = 8.1, 1.7 Hz), 8.05 (d, 2 H, J = 8.0 Hz), 7.88 
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(d, 2 H, J = 8.2 Hz), 7.51 (t, 1 H, J = 7.9 Hz), 7.42 (d, 2 H, J = 8.2 Hz), 7.16 (dd, 1 H, J = 8.0, 
2.5 Hz), 3.88 (s, 3 H), 2.7 (q, 2 H, J = 7.6 Hz), 1.25 (t, 3 H, J = 7.6 Hz); 13C NMR (DMSO-d6, 
150 MHz)  166.4, 159.7, 159.2, 151.8, 145.9, 144.9, 140.9, 138.8, 135.6, 130.9, 130.4, 130.1, 
129.9, 128.8, 127.4, 127.28, 127.25, 125.7, 125.6, 125.08, 125.05, 123.3, 120.7, 120.0, 116.7, 
113.2, 55.3, 27.9, 15.5; HRMS (ESI) m/z calcd for C30H24F3N2O ([M+H]
+) 485.1841, found 
485.1835.  This structure was confirmed by X-ray analysis (Appendix A.1). 
 
 
1-24c 
2-(4-tert-Butylphenyl)-4-(4-ethylphenyl)-7-(3-methoxyphenyl)quinazoline (1-24c).  
According to General Protocol A, 1-23k (0.038 g, 0.094 mmol), Pd(OAc)2 (0.0021 g,  
0.0094 mmol), PPh3 (0.0075 g, 0.028 mmol), Na2CO3 (0.062 g, 0.58 mmol), and 3-
methoxyphenylboronic acid (0.057 g, 0.38 mmol) were heated at reflux for 22 h and provided a 
crude residue that was purified by chromatography on SiO2 (1:200 to 1:50, EtOAc:hexanes) to 
afford 1-24c (0.038 g, 86%) as a pale green solid:  Mp 89.2–91.0 °C (EtOAc); IR (ATR) 3063, 
2959, 2866, 1552, 1528, 1338, 852, 773 cm-1; 1H NMR (DMSO-d6, 300 MHz)  8.55 (d, 2 H, J = 
8.6 Hz), 8.37 (d, 1 H, J = 1.7 Hz), 8.18 (d, 1 H, J = 8.7 Hz), 8.03 (dd, 1 H, J = 8.8, 1.8 Hz), 7.86 
(d, 2 H, J = 8.1 Hz), 7.61 (d, 2 H, J = 8.6 Hz), 7.52 (d, 2 H, J = 8.2 Hz), 7.51–7.49 (m, 1 H), 7.47 
(dd, 2 H, J = 7.1, 1.7 Hz), 7.11–7.03 (m, 1 H), 3.89 (s, 3 H), 2.78 (q, 2 H, J = 7.5 Hz), 1.35 (s,  
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9 H), 1.30 (t, 3 H, J = 7.6 Hz); 13C NMR (DMSO-d6, 75 MHz)  167.6, 159.9, 159.6, 153.6, 
151.8, 146.3, 145.4, 140.0, 134.9, 134.5, 130.4, 130.1, 128.2, 128.1, 127.6, 126.9, 125.6, 125.5, 
120.2, 119.7, 114.7, 112.7, 55.3, 34.7, 31.1, 28.1, 15.5; MS (EI) m/z 472 ([M]+, 100), 457 (79); 
HRMS (EI) m/z calcd for C33H32N2O (M
+) 472.2515, found 472.2510. 
 
 
1-24d 
2-(4-ethylphenyl)-7-(1H-indol-5-yl)-4-(3-methoxyphenyl)quinazoline (1-24d). According to 
General Protocol A, 1-23h (0.025 g, 0.067 mmol), Pd(OAc)2 (0.0015 g, 0.0067 mmol), PPh3 
(0.0053 g, 0.020 mmol), Na2CO3 (0.044 g, 0.41 mmol), and indole-5-boronic acid (0.043 g,  
0.27 mmol) were heated at reflux for 48 h and provided a crude residue that was purified by 
chromatography on SiO2 (toluene to 1:20 THF/toluene) to afford 1-24d (0.020 g, 66%) as a 
yellow solid:  Mp 81.7–82.2 °C (EtOAc); IR (ATR) 3418, 2958, 2926, 2851, 1716, 1606, 1532, 
1340, 1236, 1044, 794 cm-1; 1H NMR (DMSO-d6, 300 MHz)  11.31 (s, 1H), 8.55 (d, 2 H, J = 
8.3 Hz), 8.34 (d, 1 H, J = 1.3 Hz), 8.16–8.12 (m, 2 H), 8.09 (dd, 1 H, J = 8.8, 1.6 Hz), 7.69 (dd, 1 
H, J = 8.6, 1.7 Hz), 7.63–7.55 (m, 2 H), 7.48–7.40 (m, 5 H), 7.25 (ddd, 1 H, J = 8.3, 2.5,  
0.9 Hz), 6.59–6.55 (m, 1 H), 3.89 (s, 3 H), 2.72 (q, 2 H, J = 7.6 Hz), 1.26 (t, 3 H, J = 7.6 Hz); 13C 
NMR (DMSO-d6, 75 MHz)  167.4, 159.5, 159.4, 151.9, 147.4, 146.8, 138.5, 136.3, 135.3, 
129.8, 129.3, 128.4, 128.3, 128.2, 127.3, 127.2, 126.6, 124.5, 122.2, 120.7, 119.5, 119.4, 115.6, 
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115.3, 112.3, 102.0, 55.4, 28.2, 15.4; HRMS (ESI) m/z calcd for C31H25N3O ([M+H]
+) 456.2076, 
found 456.2091. 
6.3 CHAPTER 2 EXPERIMENTAL PART 
 
2-20 
3,6-Dichloro-1-(isopropylthio)isoquinoline (2-20).  To a solution of 2-19 (0.20 g, 0.83 
mmol) in freshly distilled THF (7.0 mL) cooled to 0 °C under an atmosphere of N2 was added a 
premixed solution of NaH (0.022 g, 0.92 mmol) and i-PrSH (0.087 mL, 0.92 mmol) in THF  
(2.0 mL) dropwise. The mixture was stirred for 24 h at 0 °C.  After 16 h an additional amount of 
NaH (0.011 g, 0.046 mmol) and i-PrSH (0.04 mL) premixed in THF (1 mL) was added 
dropwise. The mixture continued to stir at 0 °C until the starting material was completely 
consumed as indicated by TLC. The reaction mixture was warmed to room temperature, poured 
into ice cold H2O, and extracted with EtOAc (4 x 15 mL).  The combined organic layers were 
washed with H2O (10 mL), dried (MgSO4), and concentrated under reduced pressure to provide 
2-20 (0.23 g, 100%) as an off-white solid:  Mp 94.1–95.4 °C (EtOAc); IR (ATR) 3064, 2967, 
2924, 1605, 1539, 1472, 1347, 1331, 1277, 1077, 986 cm-1; 1H NMR (DMSO-d6, 300 MHz)  
 8.13–8.06 (m, 2 H), 7.71 (d, 1 H, J = 0.3 Hz), 7.68 (dd, 1 H, J = 8.9, 2.2 Hz), 4.12 (sept, 1 H, J 
= 6.8 Hz), 1.45 (d, 6 H, J = 6.8 Hz); 13C NMR (DMSO-d6, 75 MHz)  160.8, 144.4, 138.0, 
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136.7, 128.5, 126.4, 125.7, 123.3, 114.9, 35.4, 22.6; MS (ESI) m/z 272 ([M+1]+, 80), 227 (100); 
HRMS (ESI) m/z calcd for C12H12Cl2NS ([M+H]
+) 272.0068, found 272.0044. 
 
 
2-23 
3,6-Dichloroisoquinolin-1-ol (2-23).  To a solution of 2-19 (0.030 g, 0.13 mmol) in THF 
(1.2 mL) was added KOSiMe3 (0.17 g, 1.2 mmol). The vial was sealed and the mixture was 
stirred at 80 °C for 3 h. The white slurry was cooled to room temperature, diluted with CH2Cl2  
(2 mL) and EtOAc (2 mL).  Sat. aq. NH4Cl (2 mL) was added and the mixture was extracted 
with EtOAc (4 x 15 mL).  The combined organic layers were washed with H2O (10 mL), dried 
(MgSO4), and concentrated under reduced pressure to provide 2-23 (0.029 g, 100%) as a white 
solid: Mp 243.1–244.6 °C (EtOAc); IR (ATR) 2857, 1655, 1616, 1595, 1543, 1452, 1422, 1321, 
1245, 1150, 1073 cm-1; 1H NMR (DMSO-d6, 300 MHz)  12.43 (s, 1 H), 8.12 (d, 1 H, J = 8.6 
Hz), 7.76 (s, 1 H), 7.51 (dd, 1 H, J = 8.5, 1.5 Hz), 6.75 (s, 1 H); 13C NMR (DMSO-d6,  
75 MHz)  161.7, 139.0, 138.0, 129.1, 126.9, 125.0; MS (EI) m/z 213 ([M]+, 89), 178 (63), 123 
(100); HRMS (EI) m/z calcd for C9H5Cl2NO (M
+) 212.9748, found 212.9740. 
 
 
2-24 
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3,6-Dichloro-1-methoxyisoquinoline (2-24).  To a solution of 1,3,6-trichloro-
isoquinoline (2-19) 17 (1.00 g, 4.3 mmol) in anhyd. MeOH (43 mL) was added NaOMe (1.39 g, 
25.7 mmol). The solution was stirred at reflux under an atmosphere of N2 for 4 h. The mixture 
was cooled to room temperature, diluted with EtOAc, quenched with 1 M HCl, and stirred for  
5 min. The reaction mixture was poured into H2O and extracted with EtOAc.  The combined 
organic layers were washed with brine, dried (MgSO4), and concentrated under reduced pressure 
to provide 2-24 (0.950 g, 97%) as a white solid: Mp 106.2107.1 C; IR (ATR, neat) 3077, 3085, 
3027, 2152, 1616, 1564, 1448, 1376, 1357, 1322, 1195, 1089, 902, 874, 822, 662 cm-1; 1H NMR 
(DMSO-d6, 400 MHz)  8.10 (d, 1 H, J = 8.9 Hz), 7.98 (d, 1 H, J = 2.0 Hz), 7.60 (dd, 1 H, J = 
8.9, 2.1 Hz), 7.50 (s, 1 H), 4.06 (s, 3 H); 13C NMR (DMSO-d6, 100 MHz)  160.1, 142.5, 140.0, 
136.8, 127.8, 126.0, 124.7, 115.8, 112.4, 54.6; HRMS (ESI) m/z calcd for C10H8NOCl2 ([M+H]
+) 
227.9983, found 227.9985. 
 
 
2-25 
6-Chloro-1-methoxy-N-phenylisoquinolin-3-amine (2-25).  To a reaction vial 
containing 2-24 (0.500 g, 2.19 mmol), Pd(OAc)2 (0.098 g, 0.438 mmol), Xantphos (0.317 g, 
0.548 mmol), and Cs2CO3 (1.44 g, 4.38 mmol) under an atmosphere of Ar was added toluene  
(73 mL) and aniline (0.22 mL, 2.41 mmol). The reaction was heated to 80 C under an 
atmosphere of Ar for 2.5 h. The reaction mixture was cooled to room temperature, filtered 
through Celite with EtOAc washings, and concentrated under reduced pressure to give a 
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brown-orange residue. The residue was adsorbed onto SiO2 and purified by chromatography on 
SiO2 (100% hexanes, 2:98 to 10:90, EtOAc:hexanes) to provide 2-25 (0.303 g, 49%, 57% 
BRSM) as a yellow solid: Mp 98.3100.1C; IR (ATR, neat) 3353, 3049, 3031, 2952, 1622, 
1596, 1558, 1374, 1316, 1303, 1169 cm-1; 1H NMR (DMSO-d6, 400 MHz)  9.02 (s, 1 H), 7.95 
(d, 1 H, J = 8.8 Hz), 7.73 (d, 1 H, J = 1.9 Hz), 7.55 (d, 2 H, J = 7.7 Hz), 7.29 (t, 2 H, J = 7.5 Hz), 
7.18 (dd, 1 H, J = 8.8, 2.0 Hz), 6.91 (t, 1 H, J = 7.3 Hz), 6.65 (s, 1 H), 4.07 (s, 3 H); 13C NMR 
(DMSO-d6, 100 MHz)  159.8, 150.7, 141.5, 141.4, 135.8, 128.8, 126.0, 123.3, 122.7, 120.7, 
118.5, 111.6, 92.5, 53.9; HRMS (ESI) m/z calcd for C16H14N2OCl ([M+H]
+) 285.0795, found 
285.0782. 
 
 
2-27 
6-(3-Aminophenyl)-1-methoxy-N-phenylisoquinolin-3-amine (2-27).  To a reaction 
vial containing 2-25 (0.419 g, 1.47 mmol), KF (0.256 g, 4.41 mmol), Pd2(dba)3 (0.273 g,  
0.294 mmol), and 3-aminophenylboronic acid (0.470 g, 2.94 mmol) under an atmosphere of Ar 
was added P(t-Bu)3 (0.124 g, 0.588 mmol) dissolved in freshly distilled and degassed 1,4-
dioxane (2.0 mL) followed by an additional amount of 1,4-dioxane (7.5 mL). The reaction vial 
was sealed and heated to 120 C for 3 h. The reaction mixture was cooled to room temperature 
and filtered through Celite with EtOAc washings. The combined organic layers were 
concentrated under reduced pressure to give an orange-yellow residue.  The polarity of the 
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impurities required two chromatographic separations for optimal purification.  The residue was 
adsorbed onto SiO2 and purified by chromatography on SiO2 (100% CH2Cl2, 2:98, 
MeOH:CH2Cl2) to provide the desired product as a mixture with a more apolar impurity. In order 
to separate the mixture further, the material was absorbed onto SiO2 and purified by 
chromatography on SiO2 (100% hexanes, 5% EtOAc/hexanes, 20% EtOAc/hexanes, 100% 
EtOAc) to provide 2-27 (0.359 g, 72%) as a red-brown solid: Mp  165.7167.5 C (CHCl3); IR 
(ATR, neat) 3375, 3029, 2393, 1623, 1594, 1573, 1493, 1446, 1422, 1374, 1336, 1299, 1158, 
1105, 688 cm-1; 1H NMR (DMSO-d6, 400 MHz)  8.89 (s, 1 H), 8.01 (d, 1 H, J = 8.6 Hz), 7.75 
(s, 1 H), 7.57 (d, 2 H, J = 8.1 Hz), 7.43 (d, 1 H, J = 8.4 Hz), 7.28 (t, 2 H, J = 7.7 Hz), 7.13 (t,  
1 H, J = 7.7 Hz), 6.996.85 (m, 3 H), 6.75 (s, 1 H), 6.61 (d, 1 H, J = 7.9 Hz), 5.20 (s, 2 H), 4.09 
(s, 3 H); 13C NMR (DMSO-d6, 125 MHz)  159.6, 149.9, 149.2, 143.1, 142.0, 140.7, 140.3, 
129.4, 128.7, 124.2, 121.70, 121.65, 120.2, 118.1, 114.7, 113.7, 112.42, 112.39, 93.8, 53.8; 
HRMS (ESI) m/z calcd for C22H20N3O ([M+H]
+) 342.1606, found 342.1623. 
 
 
2-15 
6-(3-Aminophenyl)-3-(phenylamino)isoquinolin-1(2H)-one  (2-15). To a flask 
containing 2-27 (0.241 g, 0.705 mmol) under an atmosphere of Ar was added 4 M HCl in 1,4-
dioxane (24.1 mL). The reaction vial was sealed and heated to 80 C for 28 h. (Note: The 
reaction progress was monitored by 1H NMR of an aliquot from the crude reaction mixture.) The 
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reaction mixture was cooled to room temperature and concentrated under reduced pressure to 
provide a yellow-brown solid. The solid was suspended in H2O and neutralized (pH 7) with sat. 
aq. NaHCO3. The suspension was filtered and washed with H2O and ether to provide 2-15  
(0.190 g, 82%) as a light yellow-brown solid: Mp 184.7 C (dec); IR (ATR, neat) 3316, 1635, 
1594, 1551, 1495, 1484, 1437, 1340, 1288 cm-1; 1H NMR (DMSO-d6, 400 MHz)  10.72 (s,  
1 H), 8.04 (d, 1 H, J = 8.3 Hz), 7.99 (s, 1 H), 7.58 (d, 1 H, J = 1.5 Hz), 7.407.31 (m, 3 H), 7.20 
(d, 2 H, J = 7.6 Hz), 7.12 (t, 1 H, J = 7.8 Hz), 7.00 (t, 1 H, J = 7.4 Hz), 6.94 (t, 1 H, J = 1.8 Hz), 
6.87 (d, 1 H, J = 7.6 Hz), 6.61 (dd, 1 H, J = 8.0, 1.4 Hz), 6.13 (s, 1 H), 5.39 (bs, 2 H); 13C NMR 
(DMSO-d6, 125 MHz)  162.0, 148.7, 144.7, 141.7, 140.7, 140.4, 140.2, 129.44, 129.35, 127.2, 
122.3, 121.9, 121.5, 120.0, 119.2, 114.9, 114.0, 112.6, 85.0; HRMS (ESI) m/z calcd for 
C21H18N3O ([M+H]
+) 328.1450, found 328.1478. 
 
 
2-16 
6-(3-Aminophenyl)-3-(phenylamino)isoquinolin-1(2H)-one TFA salt (2-16). To a 
flask containing 2-15 (0.220 g, 0.673 mmol) suspended in CH2Cl2 under an atmosphere of N2 
was added trifluoroacetic acid (60.6 μL, 0.808 mmol). The suspension was stirred at room 
temperature for 10 min, filtered, and washed with H2O and a minimal amount of CH2Cl2 and 
Et2O.  Product 2-16 was isolated as a yellow-brown solid (0.222 g, 75%):  Mp 197.1 C (dec); IR 
(ATR, neat) 3001, 1687, 1638, 1597, 1555, 1497, 1476, 1437, 1343, 1200, 1120 cm-1; 1H NMR 
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(DMSO-d6, 400 MHz)  10.75 (bs, 1 H), 8.06 (d, 1 H, J = 8.3 Hz), 7.99 (bs, 1 H), 7.62 (d, 1 H,  
J = 1.4 Hz), 7.39 (dd, 1 H, J = 8.4, 1.7 Hz), 7.33 (d, 2 H, J = 7.5 Hz), 7.307.24 (m, 1 H), 7.21 
(d, 2 H, J = 7.6 Hz), 7.177.11 (m, 2 H), 7.01 (t, 1 H, J = 7.3 Hz), 6.87–6.81 (m, 1 H), 6.13 (s, 1 
H); 13C NMR (DMSO-d6, 100 MHz)  162.0, 143.7, 142.0, 141.9, 140.6, 140.5, 129.9, 129.4, 
127.4, 122.5, 122.0, 121.3, 120.2, 119.9, 119.4, 117.7, 116.4, 84.7; HRMS (ESI) m/z calcd for 
C21H18N3O ([M+H]
+) 328.1450, found 328.1479.  ICP (Pd) = 18 ppm. 
6.4 CHAPTER 3 EXPERIMENTAL PART 
6.4.1 Thieno[3,2-d]pyrimidine-Based Inhibitors 
 
3-10 
Thieno[3,2-d]pyrimidine-2,4-diol (3-10).75  To a solution of methyl 3-aminothiophene-
2-carboxylate 3-9 (5.00 g, 31.8 mmol) in glacial AcOH (35.0 mL) and H2O (31 mL) was added 
KOCN (8.06 g, 95.4 mmol) in H2O (18.0 mL) dropwise. The resulting slurry was stirred at room 
temperature for 20 h, and filtered. The solid was placed in a flask, flushed with N2, treated with  
2 N aq. NaOH (85 mL), and stirred at room temperature for 3 h. The slurry was filtered to 
remove any undissolved material. The solution was acidified with conc. aq. HCl until a pH of 5-
6 was obtained. The precipitate was filtered and the solid was dried at 50 C to provide 3-10 
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(3.49 g, 65%) as a white solid:  1H NMR (DMSO-d6, 300 MHz)  11.56 (s, 1 H), 11.21 (s, 1 H), 
8.05 (d, 1 H, J = 5.3 Hz), 6.90 (d, 1 H, J = 5.3 Hz).  
 
 
3-11 
2,4-Dichlorothieno[3,2-d]pyrimidine (3-11).75  To a solution of 3-10 (0.500 g,  
2.97 mmol) and N,N-dimethylaniline (0.29 mL, 2.23 mmol) in MeCN (2.5 mL) cooled to 0 C 
was slowly added POCl3 (1.4 mL, 14.9 mmol). The purple slurry was heated to 80–85 C and 
stirred for 48 h. A second portion of POCl3 (1.0 mL) was added after 24 h. The resulting clear 
purple solution was poured into ice and water and stirred for 5 min. The slurry was filtered, and 
the solid was dried at 45 C. The solid was dissolved in EtOAc, washed with sat. aq. NaHCO3, 
and stirred with activated charcoal. The solution was filtered through Celite and concentrated 
to provide 3-11 (0.482 g, 79%) as a yellow solid: Mp 138.8–139.3 °C (H2O); IR (ATR, neat) 
3066, 3088, 1545, 1508, 1307, 1204, 798 cm-1; 1H NMR (DMSO-d6, 300 MHz)  8.70 (d, 1 H,  
J = 5.4 Hz), 7.74 (d, 1 H, J = 5.4 Hz); 13C NMR (DMSO-d6, 75 MHz)  163.6, 154.8, 154.7, 
142.4, 129.3, 124.1; HRMS (EI) m/z calcd for C6H2N2SCl2 (M
+) 203.9316, found 203.9312. 
 
 
3-12 
2-Chlorothieno[3,2-d]pyrimidine (3-12).76  To a solution of 3-11 (0.044 g, 0.022 mmol) 
and NaHCO3 (0.027 g, 0.32 mmol) in EtOH (2.0 mL) was added 10% Pd/C (0.0089 g, 20% by 
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wt). The suspension was stirred at room temperature under an atmosphere of H2 for 23 h. A 
second portion of 10% Pd/C (0.0089 g, 20% by wt) was added after 12 h. The reaction mixture 
was filtered through Celite with EtOAc washings. The filtrate was washed with H2O/brine 
(4:1), dried (MgSO4), and concentrated under reduced pressure to provide 3-12 (0.033 g, 90%) as 
white solid: Mp 164.9–165.5 °C (EtOAc); IR (ATR, neat) 3105, 3051, 2924, 1543, 1515, 1456, 
1420, 1334, 1349, 1301, 1159, 794 cm-1; 1H NMR (DMSO-d6, 300 MHz)  9.50 (s, 1 H), 8.64 
(d, 1 H, J = 5.4 Hz), 7.64 (d, 1 H, J = 5.4 Hz); 13C NMR (DMSO-d6, 75 MHz)  162.7, 156.3, 
155.3, 142.2, 130.1, 122.9; MS (EI) m/z 170 (M+, 100), 135 (72); HRMS (EI) m/z calcd for 
C6H3N2SCl (M
+) 169.9705, found 169.9700. 
 
 
3-13 
2-Methoxythieno[3,2-d]pyrimidine (3-13).  To a solution of 3-12 (0.146 g, 0.86 mmol) 
in MeOH (20 mL) was added NaOMe (0.130 g, 2.41 mmol). The solution was heated at reflux 
for 37 h. An additional 1.4 equiv of NaOMe (0.065 g) was added after 24 h (Note: The reaction 
was complete in 7 h with comparable yields when 4.2 equiv of NaOMe were added at the start of 
the reaction). The reaction mixture was cooled to room temperature, quenched with 1 N aq. HCl 
(2.0 mL), and extracted with CH2Cl2 (4 x 10 mL). The combined organic layers were washed 
with H2O (10 mL), dried (MgSO4), and concentrated under reduced pressure to provide 3-13 
(0.125 g, 88%) as an off-white solid: Mp 167.0–168.5 °C (CH2Cl2); IR (ATR, neat) 3071, 3025, 
2917, 1558, 1528, 1478, 1379, 1295, 1249, 1031, 796, 677 cm-1; 1H NMR (DMSO-d6, 300 MHz) 
 9.30 (d, 1 H, J = 0.6 Hz), 8.45 (d, 1 H, J = 5.4 Hz), 7.47 (dd, 1 H, J = 5.4, 0.7 Hz), 3.96 (s,  
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3 H); 13C NMR (DMSO-d6, 75 MHz)  163.4, 162.4, 154.8, 139.9, 124.8, 122.9, 54.6; MS (EI) 
m/z 166 (M+, 29), 84 (100); HRMS (EI) m/z calcd for C7H6N2OS (M
+) 166.0201, found 
166.0201. 
 
 
3-16 
Methyl 2-methoxythieno[3,2-d]pyrimidine-6-carboxylate (3-16).  To a reaction vial 
charged with TMPMgClLiCl (0.13 mL, 0.16 mmol) cooled to –50 C was added a solution of 3-
13 (0.020 g, 0.12 mmol) in THF (0.25 mL) dropwise. The solution was stirred at –50 C for 2 h. 
Methyl cyanoformate (11 μL, 0.14 mmol) in THF (0.12 mL) was added dropwise at –50 C and 
the solution was warmed to 0 C over 1 h. The reaction was quenched at 0 C with sat. aq. 
NH4Cl (0.5 mL). The reaction mixture was diluted with EtOAc and the organic layer was 
washed with sat. aq. NH4Cl (2 x 2 mL). The aqueous layers were then extracted with EtOAc (4 x 
5 mL). The combined organics were washed with brine (5 mL), dried (MgSO4), and concentrated 
under reduced pressure to give an orange residue. The residue was adsorbed onto SiO2 and 
purified by chromatography on SiO2 (1:20 EtOAc:hexanes, 1:10 EtOAc:hexanes, 1:4 
EtOAc:hexanes) to provide 3-16 (0.015 g, 53%, 93% pure) as a pale green solid: Mp 176.6–
177.7 °C (EtOAc); IR (ATR) 2959, 1713, 1569, 1478, 1431, 1385, 1174 cm-1; 1H NMR (DMSO-
d6, 300 MHz)  9.45 (s, 1 H), 8.03 (s, 1 H), 3.98 (s, 3 H), 3.93 (s, 3 H); 13C NMR (DMSO-d6,  
75 MHz)  163.7, 161.8, 160.5, 156.8, 143.0, 128.2, 127.0, 54.9, 53.3; MS (ESI) m/z 247 
([M+Na]+, 95), 227 (100), 223 (65); HRMS (ESI) m/z calcd for C9H8N2O3S ([M+Na]
+) 
247.0153, found 247.0134. 
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3-20 
7-Bromo-2-methoxythieno[3,2-d]pyrimidine (3-20). To a reaction vial containing 3-13 
(0.100 g, 0.602 mmol) and AcOH (1.5 mL) under an atmosphere of N2 was added Br2 (93.0 μL, 
1.81 mmol). The reaction vial was sealed and heated to 70 C for 24 h. The mixture was cooled 
to room temperature, quenched with sat. aq. NaHCO3, and extracted with EtOAc. The combined 
organic layers were washed with sat. aq. Na2S2O3, sat. aq. NaHCO3, and brine, dried (MgSO4) 
and concentrated under reduced pressure to give a white solid. The solid was adsorbed onto SiO2 
and purified by chromatography on SiO2 (1:20 EtOAc:hexanes, 1:10 EtOAc:hexanes, 3:20 
EtOAc:hexanes, 100% EtOAc) to provide 3-20 (0.0583 g, 40%) as a white solid:  Mp 115.3–
115.9 °C (EtOAc); IR (ATR, neat) 3090, 3019, 2956, 1567, 1524, 1474, 1463, 1370, 1312, 1271 
cm-1; 1H NMR (DMSO-d6, 300 MHz)  9.34 (s, 1 H), 8.61 (s, 1 H), 4.01 (s, 3 H); 13C NMR 
(DMSO-d6, 75 MHz)  163.9, 158.4, 155.8, 136.7, 124.0, 106.8, 54.8; HRMS (EI) m/z calcd for 
C7H5N2OSBr (M
+) 243.9306, found 243.9304. 
 
 
3-21 
Methyl 7-bromo-2-methoxythieno[3,2-d]pyrimidine-6-carboxylate (3-21). To a 
reaction vial containing 3-20 (0.040 g, 0.16 mmol) and THF (0.6 mL) cooled to –55 to –60 C 
under an atmosphere of argon was added TMPMgCl·LiCl (0.17 mL, 0.22 mmol) dropwise. The 
white slurry became a clear yellow solution after the addition of TMPMgCl·LiCl and was stirred 
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for 2 h at –55 to –60 C, turning into a pale yellow slurry at the end of this time. Methyl 
cyanoformate (0.016 mL, 0.20 mmol) in THF (0.10 mL) was added dropwise at –50 C and the 
solution was stirred for 2 h while warming to 0 C. The pale yellow slurry turned pale yellow-
orange as it warmed to 0 C. The reaction was quenched at 0 C with sat. aq. NH4Cl (0.5 mL).  
The mixture was diluted with EtOAc and the organic layer was washed with sat. aq. NH4Cl (2 x 
5 mL). The combined aqueous layers were extracted with EtOAc (2 x 5 mL). The combined 
organic layers were washed with brine (5 mL), dried (MgSO4), and concentrated under reduced 
pressure to provide 3-21 (0.048 g, 97%) as a yellow solid: Mp 180.9–181.4 °C (EtOAc); IR 
(ATR, neat) 2956, 2915, 2848, 1735, 1569, 1472, 1382, 1213, 1031, 788 cm-1; 1H NMR 
(DMSO-d6, 300 MHz)  9.49 (s, 1 H), 4.04 (s, 3 H), 3.95 (s, 3 H); 13C NMR (DMSO-d6,  
75 MHz)  164.1, 160.6, 158.3, 157.4, 136.3, 124.8, 113.9, 55.0, 53.3; MS (EI) m/z 302 (M+, 
100), 274 (45); HRMS (ESI) m/z calcd for C9H8BrN2O3S ([M+H]
+) 302.9439, found 302.9418. 
 
 
kmg-NB4-23 
2-Methoxy-7H,8H,9H-1,4-thiazepino[7',6'-5,4]thiopheno[3,2-d]pyrimidin-6-one 
(kmg-NB4-23).  To a solution of 3-21 (0.041 g, 0.14 mmol) in DMF (1.3 mL) under an 
atmosphere of N2 was added cysteamine·HCl (0.063 g, 0.54 mmol) in one portion and DBU 
(0.17 mL, 1.1 mmol) dropwise. The reaction mixture turned dark blue upon addition of DBU and 
after stirring for 20 min, the mixture was a pale purple colored slurry. The reaction mixture was 
stirred at room temperature for 1.5 h, and then heated to 70 C for 9 h 50 min. The resulting 
yellow slurry was diluted with EtOAc, washed with 2 M aq. HCl, and filtered (H2O and EtOAc 
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washings). Residual DMF was removed by azeotropic distillation with heptane to provide kmg-
NB4-23 (0.025 g, 68%) as a pale yellow solid: Mp 308 °C (dec); IR (ATR, neat) 3260, 3153, 
3015, 1636, 1554, 1495, 1467, 1374, 1269, 1353, 1323 cm-1; 1H NMR (DMSO-d6, 300 MHz)  
 9.36 (s, 1 H), 8.70 (t, 1 H, J = 5.4 Hz), 3.98 (s, 1 H), 3.68 (app dd, 2 H, J = 6.0 Hz), 3.40–3.36 
(m, 2 H); 13C NMR (DMSO-d6, 75 MHz)  164.2, 163.1, 159.6, 155.9, 138.5, 129.7, 124.1, 54.8, 
42.7, 31.9; HRMS (ESI) m/z calcd for C10H10N3O2S2 ([M+H]
+) 268.0214, found 268.0237.  This 
structure was confirmed by X-ray analysis (Appendix A.2) and the structure has been deposited 
at the Cambridge Crystallographic Data Centre (CCDC 822403). 
 
General Procedure for Solubility Determination of kmg-NB4-23 Formulations. 
Preparation of DMSO/H2O solutions.  Solutions of DMSO and HPLC-grade H2O were prepared 
in volumetric flasks by dissolving the appropriate amount of DMSO in HPLC-grade H2O to 
generate a 20% (w/v) solution. 
Solubility measurements.  To a 1-dram vial containing kmg-NB4-23 was added the appropriate 
formulation solution.  The solution was stirred overnight at 60-90 °C and cooled to room 
temperature.  An aliquot of the solution was filtered through 0.45 μm syringe filters and diluted 
with the appropriate volume of DMSO/H2O (20%, w/v).  The solution was analyzed by UV/VIS 
(366.5 nm) and the concentration was determined using a previously generated calibration curve 
(y = 8200.2x + 0.0233). 
 
 
kmg-NB4-69A 
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2-Hydroxy-7H,8H,9H-1,4-thiazepino[7',6'-5,4]thiopheno[3,2-d]pyrimidin-6-one 
(hydrochloride salt) (kmg-NB4-69A). To a reaction vial containing kmg-NB4-23 (0.050 g, 
0.19 mmol) was added HCl in dioxane (5 mL). The reaction vial was sealed and heated to 80 C 
for 32 h. The reaction mixture was cooled to room temperature and concentrated under reduced 
pressure to give an orange solid.  Starting material still remained by crude 1H NMR and the solid 
was resubjected to the above reaction condition for an additional 48 h.  The reaction mixture was 
cooled to room temperature and concentrated under reduced pressure to give an orange solid.  
Starting material still remained by crude 1H NMR and the solid was resubjected to HCl in 
dioxane (11 mL) and stirred at 80 C for 3 d.  The solvent was evaporated in vacuo and the 
resulting orange solid was washed with THF and dried to provide kmg-NB4-69A (0.046 g, 85%) 
as an orange solid:  Mp 335.9 °C (dec); IR (ATR) 3452, 3267, 3176, 2591, 2032, 1912, 1700, 
1623, 1463, 1240 cm-1; 1H NMR (DMSO-d6, 400 MHz)  9.20 (s, 1 H), 8.74 (t, 1 H, J = 6.2 Hz), 
7.79 (bs, 1 H), 3.68–3.60 (m, 2 H), 3.39–3.32 (m, 2 H); 13C NMR (DMSO-d6, 100 MHz)  
 164.0, 161.0, 159.7, 153.6, 140.9, 128.4, 119.6, 42.6, 32.2; HRMS (ESI) m/z calcd for 
C9H8N3O2S2 ([M+H]
+)  254.0058, found 254.0041. 
 
 
kmg-NB4-77A3 
2-Hydroxy-7H,8H,9H-1,4-thiazepino[7',6'-4,5]thiopheno[3,2-d]pyrimidin-6-one 
(kmg-NB4-77A3).  To a flask containing kmg-NB4-69A (0.015 g, 0.052 mmol) dissolved in 
MeOH (30 mL) was added poly(4-vinylpyridine) (0.015 g, 0.14 mmol).  The solution was stirred 
at room temperature for 10 min. The solution was filtered and the filtrate was concentrated under 
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reduced pressure to provide kmg-NB4-77A3 (0.012 g, 90%) as a yellow-orange solid:  Mp 280.1 
°C (dec); IR (ATR, neat) 3264, 3008, 2917, 1618, 1566, 1491, 1452, 1387, 1338 cm-1; 1H NMR 
(DMSO-d6, 600 MHz)  8.86 (s, 1 H), 8.53 (t, 1 H, J = 5.3 Hz), 3.65–3.60 (m, 2 H), 3.51 (bs,  
1 H), 3.30–3.26 (m, 2 H); 13C NMR (DMSO-d6, 100 MHz)  164.9, 164.7, 162.1, 153.5, 135.5, 
129.4, 115.4, 42.8, 31.9; HRMS (ESI) m/z calcd for C9H8N3O2S2 ([M+Na]
+) 275.9877, found 
275.9899. 
 
 
3-23 
2,4-Dimethoxythiopheno[3,2-d]pyrimidine (3-23).  To a solution of 3-11 (0.082 g,  
0.40 mmol) in MeOH (8.0 mL) was added NaOMe (0.091 g, 1.69 mmol). The solution was 
heated at reflux for 2 d.  After the first 24 h, an additional portion of NaOMe (2.1 equiv) was 
added. The reaction mixture was cooled to room temperature and quenched with 1 M aq. HCl 
(2.0 mL) and extracted with CH2Cl2 (4 x 10 mL).  The combined organic layers were washed 
with H2O (10 mL), dried (MgSO4), and concentrated under reduced pressure to provide 3-23 
(0.073 g, 92%) as a light yellow solid: Mp 271.3 °C (dec); IR (ATR, neat) 3079, 3016, 2988, 
2947, 2917, 2848, 1575, 1547, 1484, 1465, 1333, 1307, 1197 cm-1; 1H NMR (DMSO-d6,  
400 MHz)  8.25 (d, 1 H, J = 5.3 Hz), 7.40 (d, 1 H, J = 5.4 Hz), 4.05 (s, 3 H), 3.93 (s, 3 H); 13C 
NMR (DMSO-d6, 100 MHz)  165.2, 163.6, 163.0, 136.4, 123.4, 110.9, 54.6, 54.2; HRMS (ESI) 
m/z calcd for C8H9N2O2S ([M+H]
+) 197.0385, found 197.0396. 
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3-24 
7-Bromo-2,4-dimethoxythiopheno[3,2-d]pyrimidine (3-24). To a vial containing 3-23 
(0.10 g, 0.51 mmol) dissolved in AcOH (3.3 mL, 0.15 M) was added Br2 (0.08 mL). The reaction 
vial was sealed and stirred at room temperature for 32 h.  The reaction mixture was quenched 
with sat. aq. NaHCO3 and extracted with EtOAc (3 x 10 mL). The combined organic layers were 
washed with sat. aq. Na2S2O3 (3 x 5 mL) and NaHCO3 (5 mL), dried (MgSO4), and concentrated 
under reduced pressure to give a white solid.  The solid was adsorbed onto SiO2 and purified by 
chromatography on SiO2 (100% hexanes, 1:100 EtOAc:hexanes, 1:50 EtOAc:hexanes, 1:20 
EtOAc:hexanes) to provide 3-24 (0.083 g, 59%, 69% BRSM) as a white solid:  Mp 189.3–191.2 
°C (EtOAc); IR (ATR, neat) 3079, 2947, 2848, 1569, 1547, 1467, 1329, 1199 cm-1; 1H NMR 
(DMSO-d6, 400 MHz)  8.47 (s, 1 H), 4.10 (s, 3 H), 4.00 (s, 3 H); 13C NMR (DMSO-d6,  
100 MHz)  165.5, 164.2, 159.1, 133.1, 110.5, 107.3, 54.8, 54.7; MS (EI) m/z 274 ([M]+, 100), 
244 (50). HRMS (ESI) m/z calcd for C8H8N2O2SBr ([M+H]
+) 274.9490, found 274.9495. 
 
 
3-25 
Methyl 7-bromo-2,4-dimethoxythiopheno[4,5-d]pyrimidine-6-carboxylate (3-25). To 
a reaction vial containing 3-24 (0.050 g, 0.18 mmol) and THF (0.4 mL) cooled to –50 °C under 
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an atmosphere of Ar was added TMPMgCl·LiCl (0.3 mL, 0.29 mmol) dropwise. The white 
slurry became a clear yellow solution after the addition of TMPMgCl·LiCl and was stirred for  
2 h at –45 to –50 °C. Methyl cyanoformate (0.02 mL, 0.24 mmol) in THF (0.2 mL) was added 
dropwise via syringe at –50 °C, and the solution was stirred for 1 h while warming to 0 °C. The 
yellow solution became a white slurry upon addition of methyl cyanoformate. The reaction was 
quenched at 0 °C with sat. aq. NH4Cl (2 mL). The reaction mixture was diluted with EtOAc and 
the organic layer was washed with sat. aq. NH4Cl (4 x 5 mL). The combined aqueous layers were 
extracted with EtOAc (3 x 5 mL). The combined organic extracts were washed with sat. aq. 
NH4Cl (5 mL) and brine (5 mL), dried (MgSO4), and concentrated under reduced pressure to 
give a white solid.  The solid was adsorbed onto SiO2 and purified by chromatography on SiO2 
(1:100 EtOAc:hexanes, 1:50 EtOAc:hexanes, 1:20 EtOAc:hexanes, 100% EtOAc) to provide 3-
25 (0.050 g, 82%) as a white solid: Mp 197.8–198.5°C (EtOAc); IR (ATR, neat) 3014, 2958, 
2867, 1728, 1575, 1541, 1502, 1474, 1452, 1329, 1225 cm-1; 1H NMR (DMSO-d6, 400 MHz)  
 4.12 (s, 3 H), 4.02 (s, 3 H), 3.93 (s, 3 H); 13C NMR (DMSO-d6, 100 MHz)  165.9, 164.3, 
160.5, 159.1, 133.5, 114.6, 112.6, 55.2, 55.0, 53.3; MS (EI) m/z 332 (M+, 100). HRMS (ESI) m/z 
calcd for C10H10N2O4SBr ([M+H]
+) 332.9545, found 332.9563. 
 
 
kmg-NB5-13C 
2,4-Dimethoxy-7H,8H,9H-1,4-thiazepino[7',6'-5,4]thiopheno[3,2-d]pyrimidin-6-one 
(kmg-NB5-13C). To a solution of 3-25 (0.100 g, 0.300 mmol) in DMF (3.0 mL) under an 
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atmosphere of Ar was added cysteamine hydrochloride (0.139 g, 1.20 mmol) in one portion and 
DBU (0.38 mL, 2.49 mmol) dropwise. The white slurry became a clear yellow solution after the 
addition of DBU, and after stirring for 5 min a white precipitate formed. The pale yellow slurry 
was stirred at room temperature for 3 h. The slurry was diluted with EtOAc (10 mL) and H2O  
(2 mL), and poured into an Erlenmeyer flask. 2 M aq. HCl (0.65 mL) was added, and the mixture 
was stirred for 5 minutes. The solid was collected by suction filtration and washed with H2O and 
EtOAc to provide kmg-NB5-13C (0.069 g, 77%) as a white solid:  Mp 288.0 °C (dec); IR (ATR, 
neat) 3321, 1642, 1579, 1545, 1491, 1476, 1458, 1346, 1331, 1206 cm-1; 1H NMR (DMSO-d6, 
500 MHz)  8.65 (t, 1 H, J = 5.7 Hz), 4.09 (s, 3 H), 3.96 (s, 3 H), 3.69–3.64 (m, 2 H), 3.38–3.34 
(m, 2 H); 13C NMR (DMSO-d6, 125 MHz)  165.5, 164.1, 163.5, 159.9, 135.9, 130.3, 111.5, 
54.74, 54.72, 42.8, 31.8. 
 
 
kmg-NB5-15A 
4-Hydroxy-2-methoxy-7H,8H,9H-1,4-thiazepino[7',6'-5,4]thiopheno[3,2-
d]pyrimidin-6-one (kmg-NB5-15A). To a reaction vial containing kmg-NB5-13C (0.015 g, 
0.050 mmol) in THF (0.5 mL) was added KOSiMe3 (0.029 g, 0.202 mmol). The white slurry 
turned to a clear yellow solution after the addition of KOSiMe3, and after 2 min a white 
precipitate formed. The slurry was stirred at 80 °C for 22 h. After 18 h, an additional amount of 
KOSiMe3 (0.014 g, 0.101 mmol) was added. The reaction mixture was diluted with EtOAc and 
quenched with sat. aq. NH4Cl (2 mL). The solid was collected by suction filtration and washed 
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with H2O to provide kmg-NB5-15 (0.0069 g, 48%) as a white solid.  An additional amount of 
kmg-NB5-15 (0.0041 g, 29%) was isolated from extraction of the filtrate.   In total, 0.011 g 
(77%) of kmg-NB5-15A was isolated as a white solid:  Mp 295.0 °C (dec); IR (ATR, neat) 
3266, 3170, 2740, 1674, 1646, 1603, 1465, 1407, 1316 cm-1; 1H NMR (DMSO-d6, 400 MHz)  
 12.72 (s, 1 H), 8.56 (t, 1 H, J = 5.2 Hz), 3.94 (s, 3 H), 3.66–3.60 (m, 2 H), 3.32–3.28 (m, 2 H); 
13C NMR (DMSO-d6, 125 MHz)  164.0, 158.4, 156.8, 153.8, 135.7, 130.6, 118.6, 54.9, 42.7, 
31.9; MS (EI) m/z 283 (M+, 100). HRMS (ESI) m/z calcd for C10H9N3O3S2Na ([M+Na]
+) 
305.9983, found 305.9995. 
6.4.2 Thieno[3,2-b]-Based Inhibitors 
 
3-30 
1-(Hydroxyimino)-1-(3-thienyl)ethane (3-30).82 To a solution of NH2OH·HCl (3.27 g, 
46.6 mmol) in EtOH (116 mL) was added 3-acetylthiophene (3-29) (3.00 g, 23.3 mmol) in EtOH 
(23.3 mL). A solution of Na2CO3 (2.47 g, 23.3 mmol) in H2O (23.3 mL) was added dropwise 
over 20 min, and the resulting slurry was heated at 60–65 °C for 12 h.  The reaction mixture was 
cooled to room temperature and concentrated under reduced pressure until most of the EtOH was 
removed. The reaction mixture was diluted with H2O (50 mL) and extracted with ether (3 x 50 
mL). The combined organic layers were dried (MgSO4) and concentrated under reduced 
pressure.  The white solid was adsorbed onto SiO2 and purified by chromatography on SiO2 
(1:50 to 1:10, EtOAc:hexanes) to provide 3-30 (2.80 g, 85%) as a white crystalline solid: Mp 
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118.8  119.6 °C (EtOAc); IR (ATR, neat) 3282, 3210, 3102, 3088, 2915, 1644, 1467, 1420, 
1364, 1281, 1199, 1096, 1003, 947, 887, 865, 781, 759, 721 cm-1; 1H NMR (CDCl3, 300 MHz)  
 8.37 (bs, 1 H), 7.47 (dd, 1 H, J = 2.9, 1.3 Hz), 7.42 (dd, 1 H, J = 5.1, 1.3 Hz), 7.31 (dd, 1 H, J = 
5.1, 2.9 Hz), 2.28 (s, 3 H); 13C NMR (CDCl3, 125 MHz)  152.5, 138.7, 126.4, 125.1, 124.0, 
12.7; HRMS (ESI) m/z calcd for C6H7NOS (M
+) 141.0248, found 141.0238. 
 
 
3-32 
5-Chlorothiopheno[3,2-b]pyridine (3-32).81 N-(3-thienyl)acetamide (3-31).81a A 
solution of 3-30 (1.71 g, 12.1 mmol) in PPA (10 mL) was stirred at 100 °C for 30 min.  The 
viscous suspension became a clear, bright orange viscous semi-liquid after 10 min. The solution 
was poured into sat. aq. Na2CO3 and extracted twice with EtOAc. The combined organic layers 
were washed with sat. aq. NaHCO3, H2O, and brine, and concentrated under reduced pressure to 
give a tan colored crystalline solid that turned green upon standing.  The material was absorbed 
onto SiO2 and purified by chromatography on SiO2 (1:4 EtOAc:hexanes, 1:1 EtOAc:hexanes, 
100% EtOAc) to provide 3-31 (1.46 g, 85% crude) as a tan colored crystalline solid. The mixture 
was taken on without further purification.  Diagnostic peaks: 1H NMR (CDCl3, 300 MHz)  7.55 
(dd, 1 H, J = 3.2, 1.3 Hz), 7.22 (dd, 1 H, J = 5.2, 3.2 Hz), 6.98 (dd, 1 H, J = 5.2, 1.4 Hz), 2.16 (s, 
3 H). 
5-Chlorothiopheno[3,2-b]pyridine (3-32).81b  To a reaction vial containing DMF  
(0.80 mL, 10.3 mmol) cooled to 0 °C under an atmosphere of Ar was added POCl3 (2.73 mL, 
29.0 mmol) dropwise.  Freshly distilled 1,2-dichloroethane (6.9 mL) was added followed by a 
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solution of 3-31 (1.46 g, 10.3 mmol) in 1,2-dichloroethane (20.5 mL).  The clear orange solution 
was stirred at room temperature for 15 minutes, and a solid white precipitate formed.  The 
mixture was heated at reflux for 21 h, and the precipitate dissolved upon heating. After 21 h, the 
clear orange solution was cooled to room temperature and poured into water containing NaOAc 
(4.28 g, 51.7 mmol) and stirred at reflux for 30 minutes. The mixture was extracted with EtOAc. 
The combined organic layers were washed with sat. aq. NaHCO3 and brine, dried (MgSO4), and 
concentrated under reduced pressure to give a dark red residue that solidified upon standing. The 
crude material was adsorbed onto SiO2 and purified by chromatography on SiO2 (100% hexanes, 
1:100 EtOAc:hexanes, 1:20 EtOAc:hexanes, 100% EtOAc) to provide 3-32 (0.94 g, 46% from 3-
31) was isolated as a white crystalline solid: Mp 75.776.9°C (EtOAc); IR (ATR, neat) 3102, 
3090, 3075, 3062, 1558, 1536, 1482, 1385, 1148, 1118, 1077, 1036, 904, 889, 816, 771, 703, 677 
cm-1; 1H NMR (CDCl3, 400 MHz)  8.10 (dd, 1 H, J = 8.5, 0.6 Hz), 7.78 (d, 1 H, J = 5.5 Hz), 
7.48 (dd, 1 H, J = 5.6, 0.6 Hz), 7.25 (d, 1 H, J = 8.4 Hz); 13C NMR (CDCl3, 100 MHz)  155.9, 
149.1, 132.8, 132.4, 131.7, 124.6, 119.4; HRMS (ESI) m/z calcd for C7H4ClNS (M
+) 168.9753, 
found 168.9768. 
 
 
3-33 
5-Methoxythiopheno[3,2-b]pyridine (3-33).  To a vial containing 3-32 (0.296 g,  
1.75 mmol) was added 25% wt. NaOMe in MeOH (8.9 mL). The reaction vial was sealed and 
heated at 80 °C for 21 h. The reaction mixture was cooled to room temperature, quenched with  
2 M aq. HCl, and extracted with EtOAc (3 x 15 mL). The combined organic layers were washed 
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with brine (15 mL), dried (MgSO4), and concentrated under reduced pressure to give a yellow 
liquid. The crude liquid was purified by chromatography on SiO2 (1:50, EtOAc:hexanes) to 
provide 3-33 (0.213 g, 80%) as a pale yellow liquid:  IR (ATR, neat) 3102, 3074, 3003, 2975, 
2943, 1577, 1553, 1497, 1446, 1387, 1327, 1256, 1199, 1143, 1018 cm-1; 1H NMR (CDCl3,  
400 MHz)  7.95 (d, 1 H, J = 8.6 Hz), 7.63 (d, 1 H, J = 5.3 Hz), 7.39 (d, 1 H, J = 5.4 Hz), 6.74 
(d, 1 H, J = 8.7 Hz), 4.01 (s, 3 H); 13C NMR (CDCl3, 100 MHz)  162.8, 153.6, 132.5, 130.0, 
126.2, 124.3, 108.6, 53.4; HRMS (ESI) m/z calcd for C8H8NOS (M
+) 312.0299, found 312.0266. 
 
 
3-34 
2,3,6-Tribromo-5-methoxythiopheno[3,2-b]pyridine (3-34). To a vial containing 3-33 
(0.032 g, 0.192 mmol) dissolved in AcOH (1.3 mL, 0.15 M) was added Br2 (0.03 mL) dropwise. 
The reaction vial was sealed and stirred at room temperature for 1 h.  The reaction mixture was 
quenched with sat. aq. NaHCO3, stirred for 5 minutes, and extracted with EtOAc (3 x 10 mL).  
The combined organics were washed with sat. aq. Na2S2O3 (3 x 5 mL) and sat. aq. NaHCO3  
(5 mL), dried (MgSO4), and concentrated under reduced pressure to provide 3-34 (0.057 g, 73%) 
as a fluffy white solid:  Mp 192.7–193.3 °C (EtOAc); IR (ATR, neat) 3102, 3055, 2992, 2945, 
2917, 2891, 2850, 1562, 1480, 1459, 1372, 1232, 1048, 1003, 762, 747 cm-1; 1H NMR (DMSO-
d6, 400 MHz)  8.79 (s, 1 H), 4.04 (s, 3 H); 13C NMR (DMSO-d6, 100 MHz)  158.4, 147.5, 
136.3, 126.8, 119.8, 112.1, 104.7, 54.6. GC-MS m/z 400 (M+, 100). 
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3-36 
3-Bromo-5-chlorothieno[3,2-b]pyridine (3-36). To a reaction vial containing 3-32 
(0.401 g, 2.36 mmol) dissolved in AcOH (16.0 mL) was added Br2 (0.37 mL, 7.09 mmol). The 
reaction vial was sealed and stirred at 80 C for 9 h. The reaction mixture was cooled to room 
temperature, diluted with EtOAc, and poured into sat. aq. NaHCO3. The reaction mixture was 
then extracted with EtOAc (3x), and the combined organic layers were washed with sat. aq. 
Na2S2O3, sat. aq. NaHCO3, and brine. The organic layers were dried (MgSO4) and concentrated 
under reduced pressure to provide a light pink solid.  The material was adsorbed onto SiO2 and 
purified by chromatography on SiO2 (100% hexanes, 1:99 EtOAc:hexanes) to provide 3-36 as a 
white solid (0.409 g, 63%, 90% pure).  The material was taken on to the next step without further 
purification:  Mp 112.8114.0 °C (Et2O); IR (ATR, neat) 3109, 3044, 1553, 1527, 1486, 1381, 
1297, 1146, 1118, 964, 772 cm-1; 1H NMR (CDCl3, 400 MHz)  8.13 (d, 1 H, J = 8.5 Hz), 7.81 
(s, 1 H), 7.36 (d, 1 H, J = 8.4 Hz); 13C NMR (CDCl3, 125 MHz)  152.0, 150.4, 133.3, 130.9, 
129.0, 120.8, 109.4; HRMS (ESI) m/z calcd for C7H3BrClNS (M
+) 246.8858, found 246.8835. 
 
 
3-37 
Methyl 3-bromo-5-chlorothieno[3,2-b]pyridine-2-carboxylate (3-37). To a solution of 
3-36 (0.300 g, 1.09 mmol) in THF (3.3 mL) cooled to –50 C under an atmosphere of Ar was 
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added TMPMgClLiCl (1.85 mL, 1.74 mmol). The solution was stirred at –40 C to –50 C for  
2 h. Methyl cyanoformate (0.11 mL, 1.43 mmol) was added and the solution was allowed to 
warm to 0 C over 1 h 45 min. The solution was quenched at 0 C with sat. aq. NH4Cl and stirred 
for 5 min at 0 C. The reaction mixture was then diluted with EtOAc and the organic layer was 
washed with sat. aq. NH4Cl (3x). The combined aqueous layers were then extracted with EtOAc 
(3x). The combined organic layers were washed with sat. aq. NH4Cl (3x) and brine, dried 
(MgSO4), and concentrated under reduced pressure to give a yellow residue. The crude residue 
was purified by chromatography on SiO2 (100% hexanes, 1:99 to 5:95 EtOAc:hexanes) to 
provide 3-37 (0.254 g, 76%, 95% pure) as a white solid:  Mp 195.3197.0 °C (Et2O); IR (ATR, 
neat) 3103, 2949, 1719, 1508, 1236, 1118, 1092, 936, 831 cm-1; 1H NMR (CDCl3, 500 MHz)  
 8.14 (d, 1 H, J = 8.5 Hz), 7.46 (d, 1 H, J = 8.5 Hz), 4.01 (s, 3 H); 13C NMR (CDCl3, 125 MHz) 
 161.3, 152.3, 151.3, 133.5, 132.43, 132.39, 123.5, 116.2, 53.1; HRMS (ESI) m/z calcd for 
C9H5BrClNO2S (M
+) 304.8913, found 304.8938. 
 
 
kmg-NB6-19B 
9-(2-Aminoethylthio)-2H,3H,4H-1,4-thiazepino[7',6'-4,5]thiopheno[3,2-b]pyridin-5-one 
(kmg-NB6-19B).  To a solution of 3-37 (0.0500 g, 0.155 mmol) in DMF (1.5 mL) under a 
atmosphere of Ar was added cysteamine hydrochloride (0.0720 g, 0.620 mmol) in one portion 
and DBU (189 μL, 1.24 mmol) dropwise. The reaction mixture was stirred at room temperature 
for 1.5 h, and then sealed and heated to 70 C for 12 h. The solution was cooled to room 
temperature, diluted with EtOAc, and 1 M aq. HCl was added.  The mixture was extracted with 
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EtOAc (3x). A precipitate formed in the aqueous extracts and was collected by suction filtration 
to provide kmg-NB6-19B (0.031 g, 58%) as a yellow-green solid: Mp 263.7 °C (dec, H2O); IR 
(ATR, neat) 3262, 3157, 3016, 2917, 2587, 1635, 1558, 1489, 1463, 1387, 1342, 1234, 1133  
cm-1; 1H NMR (DMSO-d6, 500 MHz)  8.57 (t, 1 H, J = 6.0 Hz), 8.36 (d, 1 H, J = 8.6 Hz), 8.09 
(bs, 2 H), 7.49 (d, 1 H, J = 8.6 Hz), 3.72-3.66 (m, 2 H), 3.45 (t, 2 H, J = 6.5 Hz), 3.393.35 (m, 2 
H), 3.30  3.25 (m, 2 H); 13C NMR (DMSO-d6, 100 MHz)  164.4, 155.3, 152.5, 133.0, 131.7, 
130.8, 129.4, 120.6, 42.9, 38.0, 31.7, 27.4; HRMS (ESI) m/z calcd for C12H14N3OS3 ([M+H]
+) 
312.0299, found 312.0266. 
 
 
kmg-NB6-22A 
9-Chloro-2H,3H,4H-1,4-thiazepino[7',6'-4,5]thiopheno[3,2-b]pyridin-5-one (kmg-
NB6-22A). To a colorless solution of 3-37 (0.020 g, 0.062 mmol) in DMF (0.62 mL) under an 
atmosphere of Ar was added cysteamine hydrochloride (0.011 g, 0.093 mmol) in one portion and 
DBU (28 μL, 0.19 mmol) dropwise. The reaction mixture was stirred at room temperature under 
an atmosphere of Ar for 1 h. the reaction mixture was diluted with EtOAc, and H2O was added 
and the solution was extracted with EtOAc (3 x 5 mL). The combined organic layers were 
washed with H2O (4 x 5 mL) and brine (5 mL), dried (MgSO4), and concentrated under reduced 
pressure to give the desired product as a light green solid.  The material was adsorbed onto SiO2 
and purified by chromatography on SiO2 (100% CH2Cl2, 2:98 MeOH:CH2Cl2) to provide kmg-
NB6-22A (0.015 g, 91%) as a light yellow-green solid: Mp 273.3 °C (dec, MeOH/CH2Cl2); IR 
(ATR, neat) 3256, 3156, 3025, 2919, 1637, 1553, 1532, 1495, 1456, 1389, 1344, 1158, 1131, 
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971, 813 cm-1; 1H NMR (CDCl3, 300 MHz)  8.61 (t, 1 H, J = 4.9 Hz), 8.57 (d, 1 H, J = 8.6 Hz), 
7.63 (d, 1 H, J = 8.5 Hz), 3.743.64 (m, 2 H), 3.423.35 (m, 2 H); 13C NMR (CDCl3, 125 MHz) 
 164.2, 152.4, 148.0, 134.7, 134.5, 132.0, 130.7, 122.2, 42.8, 31.8; HRMS (ESI) m/z calcd for 
C10H8ClN2OS2 ([M+H]
+) 270.9767, found 270.9798. 
 
 
kmg-NB6-38 
9-Methoxy-2H,3H,4H-1,4-thiazepino[7',6'-4,5]thiopheno[3,2-b]pyridin-5-one (kmg-
NB6-38). To a reaction vial containing kmg-NB6-22A (0.050 g, 0.19 mmol) was added 25% wt. 
NaOMe in MeOH (1.7 mL). The solution was heated to 80 C for 14 h. The reaction mixture was 
cooled to room temperature and extracted with EtOAc (3x), washed with brine, dried (MgSO4), 
and concentrated under reduced pressure to provide kmg-NB6-38 (0.024 g, 49%) as a white 
solid: Mp 289.1291.1 °C (EtOAc); IR (ATR, neat) 3262, 3148, 3018, 2917, 1629, 1575, 1493, 
1458, 1389, 1346, 1267, 1232, 1143, 1087 cm-1; 1H NMR (CDCl3, 400 MHz)  8.48 (t, 1 H, J = 
4.3 Hz), 8.34 (d, 1 H, J = 7.0 Hz), 7.01 (d, 1 H, J = 7.0 Hz), 3.93 (s, 3 H), 3.693.65 (m, 2 H), 
3.36  3.33 (m, 2 H); 13C NMR (CDCl3, 100 MHz)  164.6, 162.0, 149.9, 133.9, 132.5, 130.7, 
126.3, 111.4, 53.2, 42.9, 31.7; HRMS (ESI) m/z calcd for C11H11N2O2S2 ([M+H]
+) 267.0262, 
found 267.0291. 
 
kmg-NB6-41 
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9-Hydroxy-2H,3H,4H-1,4-thiazepino[7',6'-4,5]thiopheno[3,2-b]pyridin-5-one (kmg-
NB6-41). To a reaction vial containing kmg-NB6-38 (0.012 g, 0.046 mmol) was added 4 M aq. 
HCl in 1,4-dioxane (1.0 mL). The reaction vial was sealed and heated to 80 °C for 24 h. The 
reaction mixture was cooled to room temperature and concentrated under reduced pressure to 
provide a bright yellow solid. The solid was suspended in H2O and the pH was adjusted to 7 with 
sat. aq. Na2CO3. The solid was collected by suction filtration to provide kmg-NB6-41 (0.014 g, 
63%) as a tan-colored solid: Mp 263.7 °C (dec, Et2O); IR (ATR, neat) 3262, 3143, 3010, 2910, 
1625, 1560, 1472, 1418 cm-1; 1H NMR (DMSO-d6, 500 MHz)  11.29 (bs, 1 H), 8.47 (t, 1 H, J = 
5.7 Hz), 8.23 (d, 1 H, J = 8.6 Hz), 6.79 (d, 1 H, J = 5.9 Hz), 3.693.62 (m, 2 H), 3.343.30 (m, 2 
H); HRMS (ESI) m/z calcd for C10H9N2O2S2  ([M+H]
+) 253.0105, found 253.0130. 
6.5 CHAPTER 4 EXPERIMENTAL PART 
 
4-18 
2-(Pent-4-enyl)-3-vinylisoindolin-1-one (4-18).  To a flask containing AlCl3 (3.73 g, 
27.9 mmol) in CH2Cl2 (16 mL) cooled to 0 °C under an atmosphere of Ar was added 
vinylmagnesium bromide (1.0 M in THF, 83.6 mL, 8.39 mmol) dropwise over 20 minutes. The 
solution was stirred at 0 °C for 4 h. Compound 4-797 (3.00 g, 9.95 mmol) in CH2Cl2 (9.0 mL) 
was added in one portion and the reaction was allowed to stirred at 0 °C for 1 h and then warmed 
to room temperature and stirred for 3 h. The reaction mixture was cooled to 0 °C and carefully 
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quenched with 1 M aq. HCl, warmed to room temperature, and extracted with CH2Cl2.  The 
combined organic extracts were washed with brine, dried (MgSO4), and concentrated under 
reduced pressure to provide a brown residue. The residue was purified by chromatography on 
SiO2 (100% hexanes, 5:95 to 10:90 EtOAc:hexanes) to provide 4-18 (1.80 g, 80%) as an orange 
oil:  IR (ATR, neat) 3074, 2923, 1685, 1639, 1614, 1596, 1467, 1437, 1400, 1312, 1275, 1094 
cm-1; 1H NMR (CDCl3, 500 MHz)  7.83 (d, 1 H, J = 7.5 Hz), 7.52 (t, 1 H, J = 7.5 Hz), 7.46 (t,  
1 H, J = 7.5 Hz), 7.34 (d, 1 H, J = 7.4 Hz) 5.82 (dddd, 1 H, J = 16.9, 13.2, 10.2, 6.6 Hz), 5.65–
5.56 (m, 1 H), 5.52–5.42 (m, 2 H), 5.04 (d, 1 H, J = 17.2 Hz), 4.97 (d, 1 H, J = 10.2 Hz), 4.87 (d, 
1 H, J = 8.2 Hz), 3.87 (ddd, 1 H, J = 14.5, 7.6, 7.6 Hz), 3.22 (ddd, 1 H, J = 14.0, 8.6, 5.5 Hz), 
2.14–2.05 (m, 2 H), 1.80–1.65 (m, 2 H); 13C NMR (CDCl3, 125 MHz)  168.2, 144.2, 137.8, 
135.3, 132.2, 131.6, 128.6, 123.6, 123.1, 120.9, 115.2, 64.3, 40.1, 31.2, 27.7; HRMS (ESI) m/z 
calcd for C15H18NO ([M+H]
+) 228.1383, found 228.1380. 
 
 
4-9 
7H, 8H, 9H, 11aH-Azepino[7,1-a]isoindolin-5-one (4-9). To a solution of 4-18 (0.060 
g, 0.26 mmol) in toluene (50 mL) at room temperature under an atmosphere of N2 was added 
Grubbs 2nd generation catalyst (0.011 g, 0.013 mmol). The solution was stirred at room 
temperature for 15.5 h. The entire reaction mixture was directly applied to a column of Florisil® 
and eluted with 100% hexanes and then 30:70 EtOAc:hexanes to afford 4-9 (0.041 g, 77%) as a 
crude yellow oil; 1H NMR (CDCl3, 500 MHz)  7.79 (d, 1 H, J = 7.6 Hz), 7.53 (t, 1 H, J =  
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7.5 Hz), 7.47–7.40 (m, 2 H), 5.85–5.75 (m, 2 H), 5.20 (s, 1 H), 4.32 (ddd, 1 H, J = 13.6, 9.1, 4.2 
Hz), 3.35 (ddd, 1 H, J = 10.6, 6.7, 3.9 Hz), 2.36–2.30 (m, 2 H), 2.10–2.01 (m, 1 H), 1.95–1.88 
(m, 1 H); 13C NMR (CDCl3, 125 MHz)  168.3, 145.2, 132.2, 131.9, 131.7, 128.2, 127.3, 123.6, 
122.0, 60.7, 43.5, 28.4, 26.0; HRMS (ESI) m/z calcd for C13H14NO ([M+H]
+) 200.1070, found 
200.1067. 
 
 
4-17 
10b-Hydroxy-2H, 3H, 4H, 10cH, 1aH-isoindolino[2,1-a]oxirano[2,3-c]azaperhydro-
pin-6-one (4-17). To a solution of 4-18 (0.050 g, 0.220 mmol) in toluene (40 mL) at room 
temperature under an atmosphere of N2 was added Grubbs 2
nd generation catalyst (0.009 g,  
0.011 mmol). The solution was stirred at room temperature for 14 h. The reaction mixture was 
concentrated under reduced pressure to provide 4-9 as a crude residue.  The residue was taken 
onto the next step without further purification.  
To a flask containing crude 4-9 in CH2Cl2 (4.0 mL) at room temperature open to air was 
added NaHCO3 (0.185 g, 2.20 mmol) and m-CPBA (0.542 g, 2.20 mmol). The reaction mixture 
was stirred at room temperature open to air for 33 h.  The reaction mixture was diluted with 
CH2Cl2 and washed with sat. aq. NaHCO3 and sat. aq. Na2CO3. The aqueous layers were then 
extracted with CH2Cl2.  The combined organic layers were washed with brine, dried (MgSO4), 
and concentrated under reduced pressure to provide 4-17 (0.057 g, 11% from 4-18) as a colorless 
residue: ca. 5:1 dr by LCMS and NMR analysis; major diastereomer:  1H NMR (CDCl3,  
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500 MHz)  7.68–7.64 (m, 2 H), 7.60 (t, 1 H, J = 7.5 Hz), 7.49–7.45 (m, 1 H), 3.86 (d, 1 H,  
J = 14.5 Hz), 3.54 (d, 1 H, J = 4.2 Hz), 3.46–3.41 (m, 1 H), 3.37–3.31 (m, 2 H), 2.84–2.77 (m, 1 
H), 2.49–2.41 (m, 1 H), 2.18–2.09 (m, 1 H), 1.69–1.61 (m, 1 H); 13C NMR (CDCl3, 125 MHz)  
166.9, 145.9, 132.7, 131.0, 130.3, 123.7, 121.8, 89.6, 59.2, 57.8, 37.9, 28.0, 24.2; HRMS (ESI) 
m/z calcd for C13H14NO ([M+H]
+) 232.0968, found 232.0966. 
6.6 CHAPTER 5 EXPERIMENTAL PART 
6.6.1 Second Generation Approach 
 
5-48 
(1-Methoxyvinyloxy)trimethylsilane (5-48).127a To a solution of i-Pr2NH (2.3 mL,  
16.2 mmol) in THF (16 mL) at 0 °C under an atmosphere of N2 was added n-BuLi (1.6 M 
solution in hexanes, mL, 9.2 mL) dropwise. The solution was stirred for 30 min at 0 °C and 
cooled to -78 °C. A mixture of MeOAc (5-47) (1.1 mL, 13.5 mmol) and TMSCl (2.05 mL,  
16.2 mmol) in THF (7.5 mL) was added. Once addition was complete, the resulting solution was 
warmed to room temperature and stirred for 3 h. The THF was evaporated and hexanes was 
added. The resulting precipitate was removed by filtration through a pad of Celite® with hexanes 
washings. The combined filtrate was concentrated under reduced pressure and purified by 
distillation. The solvent was removed at 50 mmHg at room temperature and the product was 
collected at 30 mmHg and 55 °C to provide 5-48 (0.385 g, 19%) as a clear, colorless liquid.  The 
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product was used in the next reaction without further purification: 1H NMR (CDCl3, 300 MHz)  
 3.55 (s, 3 H), 3.22 (d, 1 H, J = 2.8 Hz), 3.11 (d, 1 H, J = 2.8 Hz), 0.23 (s, 9 H). 
 
 
5-50 
(3S,4E)-Methyl 3-hydroxy-5-phenylpent-4-enoate (5-50).126a,b To a solution of 5-
49126c,127b (0.086 g, 0.17 mmol) in toluene (65 mL) at room temperature under an atmosphere of 
N2 was added Ti(i-PrO)4 (0.022 mL, 0.075 mmol). The solution was stirred at room temperature 
for 1 h. At this time, 3,5-di-tert-butylsalicylic acid (0.023 g, 0.090 mmol) in toluene (5 mL) was 
added and the solution was stirred at room temperature for an additional 1 h. The solvent was 
removed under reduced pressure, and the residue was taken up in Et2O (30 mL) and cooled to  
–78 °C. Cinnamaldehyde (5-46) (0.19 mL, 1.5 mmol) and 5-48 (0.263 g, 1.80 mmol) were added 
sequentially and the solution was kept at –10 °C for 20 h. The solution was warmed to  
0 °C for 4 h.  The reaction mixture was quenched by addition of sat. aq. NaHCO3 and was 
extracted with Et2O. The combined organic layers were washed with brine, dried (MgSO4), and 
concentrated under reduced pressure to yield a yellow residue. The residue was taken up in THF 
and cooled to 0 °C. TBAF (0.90 mL, 1.6 mmol, 1 M in THF) was added and the solution was 
stirred at 0 °C for 30 min. The reaction was quenched with sat. aq. NaHCO3 was added and 
extracted with Et2O. The organic layers were washed with brine, dried (MgSO4), and 
concentrated under reduced pressure to provide a yellow residue. The residue was adsorbed onto 
SiO2 and purified by chromatography on SiO2 (100% hexanes to 30:70 EtOAc:hexanes) to afford 
5-50 (0.18 g, 58%) as a yellow oil: 85:15 er (determined by chiral HPLC analysis on a 
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CHIRALCEL® OD column; 90:10, hexanes:i-PrOH; 1.0 mL/min; R: 13.74 min, S: 18.21 min); 
1H NMR (DMSO-d6, 500 MHz)  7.38 (d, 2 H, J = 7.3 Hz), 7.32 (t, 2 H, J = 7.3 Hz), 7.25 (t,  
1 H, J = 5.2 Hz), 6.66 (d, 1 H, J = 15.9 Hz), 6.22 (dd, 1 H, J = 15.9, 6.2 Hz), 4.73 (dddd, 1 H, J = 
7.7, 6.0, 4.6, 1.3 Hz), 3.73 (s, 3 H), 2.70–2.60 (m, 2 H). 
 
 
rac-5-50 
(E)-Methyl 3-hydroxy-5-phenylpent-4-enoate (rac-5-50).128 To a solution of 
diisopropylamine (0.59 mL, 4.1 mmol) in anhyd. THF (10 mL) at -78 °C under an atmosphere of 
N2 was slowly added n-BuLi (1.6 M in hexanes, 2.6 mL, 4.1 mmol). The resulting solution was 
warmed to 0 C and stirred for 15 min. The solution was cooled to –78 C and MeOAc (5-47) 
(0.3 mL, 3.8 mmol) was added. The solution was stirred at –78 C for 5 min and trans-
cinnamaldehyde (5-46) (0.48 mL, 3.75 mmol) in anhyd. THF (2.5 mL) was added over 5 min. 
The resulting solution was stirred at –78 C for 2 h. The reaction was quenched by the addition 
of H2O (5 mL) at –78 C and slowly warmed to room temperature. The mixture was extracted 
with EtOAc, washed with brine, dried (MgSO4), and concentrated under reduced pressure to 
provide a colorless residue. The residue was adsorbed onto SiO2 and purified by chromatography 
on SiO2 (100% hexanes, 10:90 EtOAc:hexanes, 15:85 EtOAc:hexanes) to provide rac-5-50 
(0.749 g, 97%) as a clear, yellow oil: 1H NMR (CDCl3, 400 MHz)  7.38 (d, 2 H, J = 7.2 Hz), 
7.32 (t, 2 H, J = 7.2 Hz), 7.24 (t, 1 H, J = 7.2 Hz), 6.66 (d, 1 H, J = 15.9 Hz), 6.22 (dd, 1 H, J = 
15.9, 6.2 Hz), 4.68–4.60 (m, 1 H), 3.73 (s, 3 H), 2.73–2.60 (m, 2 H); retention time of 
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enantiomers determined by chiral HPLC analysis on a CHIRALCEL® OD column; 90:10, 
hexanes:i-PrOH; 1.0 mL/min; R: 13.36 min, S: 17.62 min. 
 
 
rac-5-45 
(E)-Methyl 3-(tert-butyldimethylsilyloxy)-5-phenylpent-4-enoate (rac-5-45).128 To a 
solution of rac-5-50 (0.546 g, 2.65 mmol), DMAP (0.0160 g, 0.132 mmol), and imidazole  
(0.727 g, 10.6 mmol) in CH2Cl2 (13 mL) at room temperature under an atmosphere of N2 was 
added TBSCl (0.598 g, 3.97 mmol). Upon addition of the TBSCl, a precipitate formed. The 
solution was stirred at room temperature for 13 h. The reaction mixture was quenched by 
addition of H2O and was extracted with Et2O. The organic layers were washed with brine, dried 
(MgSO4), and concentrated under reduced pressure to provide a clear, colorless oil.  The oil was 
purified by chromatography on SiO2 (100% hexanes, 5% Et2O/hexanes) to afford rac-5-45 
(0.772 g, 91%) as a clear, light yellow oil: IR (ATR, neat) 2951, 2926, 2885, 2854, 1735, 1435, 
1361, 1249, 1163, 1109, 1072, 1048, 966 cm-1; 1H NMR (CDCl3, 400 MHz)  7.39–7.28 (m,  
4 H), 7.27–7.21 (m, 1 H), 6.57 (d, 1 H, J = 15.9 Hz), 6.18 (dd, 1 H, J = 15.9, 6.7 Hz), 4.80–4.73 
(m, 1 H), 3.68 (s, 3 H), 2.63 (dd, 1 H, J = 14.5, 8.2 Hz), 2.53 (dd, 1 H, J 14.5, 5.1 Hz), 0.89 (s, 9 
H), 0.08 (s, 3 H), 0.06 (s, 3 H); 13C NMR (CDCl3, 125 MHz)  171.6, 136.8, 131.8, 130.1, 128.7, 
127.8, 126.6, 70.9, 51.7, 44.0, 25.9, 18.3, –4.1, –4.9; HRMS (ESI) m/z calcd for C18H28O3SiNa 
([M+Na]+) 343.1705, found 343.1736. 
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rac-5-44 
(E)-3-(tert-butyldimethylsilyloxy)-5-phenylpent-4-en-1-ol (rac-5-44). To a solution of 
DIBAL-H (0.501 g, 3.52 mmol) in toluene (2.4 mL, 1.5 M solution) cooled to –78 C under an 
atmosphere of N2 was added rac-5-45 (0.751 g, 2.34 mmol) in toluene (23 mL) dropwise over  
10 min. The reaction mixture was stirred at –78 C for 1 h. The reaction mixture was quenched 
with sat. aq. NH4Cl (2 mL) at –78 C and allowed to warm to room temperature. Sat. aq. 
Rochelle's salt was added, and the solution was poured into a separatory funnel containing brine. 
The mixture was extracted with EtOAc. The combined organic layers were washed with sat. aq. 
Rochelle's salt and brine, dried (MgSO4), and concentrated under reduced pressure to provide a 
clear residue. The residue was taken up in MeOH (11.5 mL) and cooled to 0 C under an 
atmosphere of N2. NaBH4 (0.136 g, 3.52 mmol) was added in one portion and the solution was 
stirred for 1 h.  The reaction was quenched with sat. aq. NH4Cl, warmed to room temperature, 
and extracted with EtOAc. The combined organic layers were washed with brine, dried 
(MgSO4), and concentrated under reduced pressure to provide a clear, yellow oil. The oil was 
adsorbed onto SiO2 and purified by chromatography on SiO2 (100% hexanes, 10:90 to 20:80 
Et2O:hexanes) to provide rac-5-44 (0.606 g, 88%, 96% BRSM) as a clear, yellow oil:  IR (ATR, 
neat) 3405, 2951, 2926, 2883, 2854, 1471, 1359, 1251, 1117, 1051, 964, 833, 774, 746, 692  
cm-1; 1H NMR (CDCl3, 500 MHz)  7.40–7.30 (m, 4 H), 7.27–7.23 (m, 1 H), 6.55 (d, 1 H, J = 
16.0 Hz), 6.21 (dd, 1 H, J = 15.9, 6.4 Hz) 4.60 (ddt, 1 H, J = 6.4, 4.6, 1.2 Hz), 3.91–3.83 (m,  
1 H), 3.80–3.72 (m, 1 H), 2.51 (bs, 1 H), 1.92 (dddd, 1 H, J = 12.9, 10.4, 6.4, 3.9 Hz), 1.82 
(dddd, 1 H, J = 12.4, 8.7, 8.1, 4.4 Hz), 0.93 (s, 9 H), 0.13 (s, 3 H), 0.08 (s, 3 H); 13C NMR 
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(CDCl3, 125 MHz)  136.9, 132.3, 129.8, 128.7, 127.7, 126.6, 73.3, 60.4, 39.8, 26.0, 18.3, –4.1, 
–4.8. 
 
 
5-51 
(E)-1-(3-((tert-Butyldimethylsilyl)oxy)-5-phenylpent-4-en-1-yl)-5-hydroxypyrrolidin-
2-one (5-51).  To a solution of rac-5-44 (0.0500 g, 0.171 mmol), succinimide (5-43) (0.0190 g, 
0.188 mmol), and PPh3 (0.0500 g, 0.188 mmol) in THF (1.0 mL) cooled to 0 C under an 
atmosphere of Ar was added DBAD (0.0440 g, 0.188 mmol) in THF (0.2 mL) dropwise. The 
solution was warmed to room temperature and stirred for 22.5 h. After 18 h, the reaction was not 
complete by TLC; therefore, an additional 0.5 equiv of succinimide (5-43), PPh3, and DBAD 
was added. The reaction was quenched with sat. aq. NH4Cl and extracted with EtOAc. The 
combined organic layers were washed with brine, dried (MgSO4), and concentrated under 
reduced pressure. The crude residue was adsorbed onto SiO2 and purified by chromatography on 
SiO2 (100% hexanes, 5:95 to 20:80 EtOAc:hexanes) to provide ((E)-1-(3-(tert-
butyldimethylsilyloxy)-5-phenylpent-4-enyl)pyrrolidine-2,5-dione, 0.0621 g, 78%, 80% pure) as 
a yellow oil. The product was contaminated with di-tert-butyl hydrazodiformate and was taken 
onto the next step without further purification.  Diagnostic peaks for the desired product: IR 
(ATR, neat) 2949, 2926, 2854, 1696, 1493, 1446, 1400, 1366, 1338, 1249, 1068, 1081, 1003, 
967, 910, 835, 775, 731, 693 cm-1; 1H NMR (CDCl3, 400 MHz)  7.36 (d, 2 H, J = 7.4 Hz), 7.31 
(t, 2 H, J = 7.3 Hz), 7.22 (t, 1 H, J = 7.1 Hz), 6.52 (d, 1 H, J = 15.9 Hz), 6.15 (dd, 1 H, J = 15.9, 
6.4 Hz), 4.37 (q, 1 H, J = 5.8 Hz), 3.713.62 (m, 1 H), 3.623.52 (m, 1 H), 2.61 (s, 4 H),  
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1.931.80 (m, 2 H), 0.92 (s, 9 H), 0.09 (s, 3 H), 0.05 (s, 3 H); 13C NMR (CDCl3, 125 MHz)  
 177.3, 136.9, 132.1, 129.9, 128.7, 127.7, 126.5, 71.7, 35.6, 28.3, 28.2, 26.0, 18.3, –4.1, –4.8; 
HRMS (ESI) m/z calcd for C21H30NO3Si ([M]+) 372.1995, found 372.1993. 
To a solution of ((E)-1-(3-(tert-butyldimethylsilyloxy)-5-phenylpent-4-enyl)pyrrolidine-
2,5-dione (0.060 g, 0.16 mmol) in MeOH (1.6 mL) at 0 C under an atmosphere of N2 was added 
NaBH4 (0.018 g, 0.48 mmol). The reaction mixture was stirred at 0 C for 1 h.  An additional 
amount of NaBH4 (0.018 g, 0.48 mmol) was added every hour until the reaction was complete.  
The reaction was monitored by the disappearance of starting material by TLC. The reaction was 
complete after 4.5 h. The reaction was diluted with CH2Cl2, quenched with sat. aq. NaHCO3, and 
extracted with EtOAc. The combined organic layers were washed with H2O, dried (MgSO4), and 
concentrated under reduced pressure to provide a crude residue. The residue was adsorbed onto 
SiO2 and purified by chromatography on SiO2 (100% hexanes, 10:90 to 40:60 EtOAc:hexanes) 
to provide 5-51 (0.042 g, 65% from rac-5-44, 1:1 dr) as a clear, light yellow oil: IR (ATR, neat) 
3300, 2949, 2926, 2854, 1735, 1663, 1461, 1448, 1420, 1247, 1163, 1068, 1046, 966, 910, 833, 
775, 731, 667, 692cm-1; 1H NMR (CDCl3, 400 MHz)  7.39  7.27 (m, 4 H), 7.25  7.20 (m,  
1 H), 6.51 (d, 1 H, J = 15.9 Hz), 6.17 (dd, 0.5 H, J = 15.9, 2.8 Hz), 6.16 (dd, 0.5 H, J = 15.9,  
2.6 Hz), 5.285.16 (m, 1 H), 4.454.33 (m, 1 H), 3.573.46 (m, 1 H), 3.433.30 (m, 2 H), 2.59 
2.45 (m, 1 H), 2.332.16 (m, 2 H), 1.931.75 (m, 4 H), 0.92 (s, 9 H), 0.09 (s, 3 H), 0.07 (s, 3 H); 
13C NMR (CDCl3, 125 MHz)  174.8, 174.7, 136.91, 136.90, 132.33, 132.30, 130.0, 129.8, 
128.74, 128.72, 127.71, 121.69, 126.6, 126.5, 84.0, 83.8, 72.3, 72.2, 37.2, 36.4, 35.9, 29.0, 28.52, 
28.46, 26.1, 18.4, –4.00, –4.03, –4.56, –4.58; HRMS (ESI) m/z calcd for C21H33NO3SiNa 
([M+Na]+) 398.2127, found 398.2156. 
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5-52 
(E)-1-(3-(tert-Butyldimethylsilyloxy)-5-phenylpent-4-enyl)-5-oxopyrrolidin-2-yl 2,2-
dimethylpropanoate (5-52).  To a solution of 5-51 (0.050 g, 0.13 mmol) in THF (1.0 mL) at  
0 C under an atmosphere of N2 was added NaH (0.0030 g, 0.14 mmol). The solution was stirred 
at 0 C for 20 min and then at room temperature for 10 min. Upon warming to room temperature, 
vigorous gas evolution was observed. After 10 min the gas evolution ceased and the reaction 
mixture was cooled to 0 C. Trimethylacetyl chloride (0.018 mL, 0.15 mmol) in THF (0.3 mL) 
was added dropwise and the solution was slowly warmed to room temperature and stirred for  
7.5 h. The reaction mixture was quenched with sat. aq. NH4Cl and extracted with EtOAc. The 
combined organic layers were washed with brine, dried (MgSO4), and concentrated under 
reduced pressure to provide 5-52 (0.059 g, 96%, 1:1 dr) as a light yellow viscous oil: 1H NMR 
(CDCl3, 400 MHz)  7.387.18 (m, 4 H), 6.50 (dd, 1 H, J = 15.9, 4.0 Hz), 6.20 (t, 1 H, J = 5.1), 
6.13 (dd, 1 H, J = 15.8, 6.4 Hz), 4.394.28 (m,  1 H), 3.663.53 (m, 1 H), 3.173.05 (m,  
1 H), 2.592.44 (m, 1 H), 2.372.20 (m, 2 H), 1.981.86 (m, 2 H), 1.841.70 (m, 1 H), 2.96 (d, 9 
H, J = 3.0 Hz), 0.90 (s, 9 H), 0.07 (s, 3 H), 0.04 (s, 3 H); 13C NMR (CDCl3, 100 MHz)  
 178.2, 175.8, 175.7, 136.92, 136.91, 132.5, 132.2, 129.9, 129.6, 128.68, 128.65, 127.61, 
127.60, 126.55, 126.5, 85.4, 85.0, 71.83, 71.77, 39.03, 39.01, 37.9, 37.7, 36.3, 35.9, 28.6, 28.5, 
27.2, 27.1, 26.2, 26.1, 26.0, 18.3, –4.1, –4.7, –4.8. 
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5-53 
1-((E)-3-((tert-Butyldimethylsilyl)oxy)-5-phenylpent-4-en-1-yl)-5-((E)-hex-1-en-1-
yl)pyrrolidin-2-one (5-53).  To a solution of 1-hexyne (0.030 mL, 0.25 mmol) in CH2Cl2  
(2.5 mL) at room temperature under an atmosphere of N2 was added zirconocene hydrogen 
chloride (0.065 g, 0.25 mmol) and the resulting suspension was stirred at room temperature for 
10 min. The resulting yellow solution was cooled to 0 °C and Me3Al (1.0 M in CH2Cl2, 0.23 mL, 
0.25 mmol) was added and the solution was stirred at 0 °C for 10 min. 5-52 (0.580 g,  
0.126 mmol) was added and the mixture was warmed to room temperature and stirred for 6 h. 
The reaction mixture was quenched with sat. aq. NH4Cl and extracted with CH2Cl2. The 
combined organic layers were dried (MgSO4) and concentrated under reduced pressure to 
provide a yellow residue. The residue was purified by chromatography on SiO2 (100% hexanes, 
10:90 to 25:75 EtOAc:hexanes) to provide 5-53 (0.0060 g, 11%) as a clear, colorless oil:  1H 
NMR (CDCl3, 300 MHz)  7.34–7.18 (m, 5 H), 6.50 (dd, 1 H, J = 16.1, 4.9 Hz), 6.14 (dd, 1 H, J 
= 16.0, 6.4 Hz), 5.72–5.59 (m, 1 H), 5.28–5.17 (m, 1 H), 4.40–4.26 (m, 1 H), 4.03–3.93 (m, 1 H), 
3.67–3.46 (m, 1 H), 3.10–2.93 (m, 1 H), 2.44–2.24 (m, 2 H), 2.19–1.96 (m, 2 H), 1.80–1.65 (m, 
4 H), 1.38–1.25 (m, 4 H), 1.25–1.20 (m, 3 H), 0.91 (s, 9 H), 0.07 (s, 3 H), 0.04 (s, 3 H). 
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5-54a 
(S)-1-(3-((tert-Butyldimethylsilyl)oxy)pent-4-en-1-yl)pyrrolidine-2,5-dione (5-54a).  
To a solution of 5-21109g (0.214 mL, 0.989 mmol), succinimide (5-43) (0.100 g, 0.989 mmol), 
and PPh3 (0.262 g, 0.989 mmol) in THF (5.7 mL) cooled to 0 °C under an atmosphere of N2 was 
added DBAD (0.232 g, 0.989 mmol) in THF (1.0 mL) dropwise. The reaction mixture was 
stirred at 0 °C for 30 min and was then warmed to room temperature and stirred for 11.5 h. The 
reaction was quenched with sat. aq. NH4Cl and extracted with EtOAc. The combined organic 
layers were washed with brine, dried (MgSO4), and concentrated under reduced pressure to 
provide a yellow residue. The residue was adsorbed onto SiO2 and purified by chromatography 
on SiO2 (5:95 to 20:80 EtOAc:hexanes) to provide 5-54a (0.138 g, 45%) as a yellow oil:  IR 
(ATR, neat) 2951, 2928, 2883, 2853, 1773, 1696, 1461, 1443, 1402, 1361, 1338, 1249, 1171, 
1087, 1029, 923, 833, 774, 660 cm-1; 1H NMR (CDCl3, 500 MHz)  5.81 (ddd, 1 H, J = 17.1, 
10.4, 5.9 Hz), 5.20 (dt, 1 H, J = 17.2, 1.5 Hz), 5.07 (dt, 1 H, J = 10.4, 1.4 Hz), 4.20 (app q, 1 H,  
J = 5.9 Hz), 3.64–3.49 (m, 2 H), 2.67 (s, 4 H), 1.80–1.73 (m, 2 H), 0.91 (s, 9 H), 0.07 (s, 3 H), 
0.03 (s, 3 H); 13C NMR (CDCl3, 125 MHz)  177.2, 140.6, 114.7, 71.9, 35.5, 35.4, 28.3, 26.0, 
18.4, –4.3, –4.8; HRMS (ESI) m/z calcd for C15H28NO3Si ([M+H]+) 298.1838, found 298.1833. 
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5-54 
1-((S)-3-((tert-butyldimethylsilyl)oxy)pent-4-en-1-yl)-5-hydroxypyrrolidin-2-one (5-
54).  To a solution of 5-54a (0.121 g, 0.406 mmol) in MeOH (2.0 mL) at 0 °C under an 
atmosphere of N2 was added NaBH4 (0.0157 g, 0.406 mmol). The reaction mixture was stirred at 
0 °C for 24 h. An additional amount of NaBH4 (6 equiv) was added until the reaction was 
complete.  The reaction was monitored by the disappearance of starting material by TLC. The 
reaction was quenched with sat. aq. NH4Cl and extracted with EtOAc. The combined organic 
layers were washed with brine, dried (MgSO4), and concentrated under reduced pressure to 
provide 5-54 (0.103 g, 85%, 40% from 5-43) as a pale, yellow oil.  The oil was taken on to the 
next step without further purification:  1H NMR (CDCl3, 400 MHz)  5.82 (ddd, 1 H, J = 16.5, 
10.4, 5.9 Hz), 5.28–5.13 (m, 2 H), 5.08 (d, 1 H, J = 10.4 Hz), 4.29–4.17 (m, 1 H), 3.50–3.40 (m, 
1 H), 3.38–3.28 (m, 1 H), 3.03–2.90 (m, 1 H), 2.61–2.47 (m, 1 H), 2.35–2.25 (m, 2 H), 1.90–1.76 
(m, 3 H), 0.90 (s, 9 H), 0.07 (s, 3 H), 0.05 (s, 3 H). 
 
 
5-55 
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1-((S)-3-((tert-Butyldimethylsilyl)oxy)pent-4-en-1-yl)-5-oxopyrrolidin-2-yl pivalate 
(5-55).  To a solution of 5-54 (0.030 g, 0.10 mmol) in THF (0.8 mL) at 0 °C under an 
atmosphere of N2 was added NaH (0.021 g, 0.88 mmol). The solution was stirred at 0 °C for  
10 min and then at room temperature for 30 min. The reaction was cooled to 0 °C and 
trimethylacetyl chloride (14 L, 0.11 mmol) in THF (0.2 mL) was added dropwise.   The 
solution was slowly warmed to room temperature and stirred for 6 h. The reaction mixture was 
quenched with sat. aq. NH4Cl and extracted with EtOAc.  The combined organic layers were 
washed with brine, dried (MgSO4), and concentrated under reduced pressure to provide 5-55 
(0.0349 g, 91%) as a yellow oil:  1H NMR (CDCl3, 300 MHz)  6.18 (dd, 1 H, J = 5.3, 1.9 Hz), 
5.77 (dddd, 1 H, J = 17.1, 10.4, 5.9, 0.8 Hz), 5.16 (dt, 1 H, J = 17.1, 3.8, 1.5 Hz), 5.04 (dt, 1 H,  
J = 10.4, 5.6, 1.3 Hz), 4.20–4.10 (m, 1 H), 3.59–3.43 (m, 1 H), 3.17–3.03 (m, 1 H), 2.60–2.45 
(m, 1 H), 2.39–2.22 (m, 2 H), 1.93 (td, 1 H, J = 10.2, 1.3 Hz), 1.86–1.76 (m, 1 H), 1.74–1.60 (m, 
1 H), 1.18 (s, 9 H), 0.04 (s, 3 H), 0.02 (s, 3 H). 
 
 
5-13 
1-((S)-3-((tert-Butyldimethylsilyl)oxy)pent-4-en-1-yl)-5-vinylpyrrolidin-2-one (5-
13).109g  To a flask containing AlCl3 (0.0466 g, 0.350 mmol) in CH2Cl2 (0.2 mL) cooled to 0 °C 
under an atmosphere of Ar was added vinylmagnesiumbromide (1.0 M in THF, 1.0 mL,  
1.0 mmol) dropwise. Upon addition of the vinylmagnesiumbromide, the white slurry turned clear 
yellow and then cloudy yellow. The cloudy orange-yellow mixture was stirred at 0 °C for 4 h.  
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5-55 (0.0349 g, 0.117 mmol) in CH2Cl2 (0.11 mL) was added in one portion and the reaction was 
stirred at 0 °C for 1 h. The reaction mixture was carefully quenched with 1.0 M HCl at 0 °C. The 
solution was extracted with CH2Cl2 and 1.0 M HCl was added to the extraction until the organic 
layer became clear. The combined organic extracts were washed with brine, dried (MgSO4), and 
concentrated under reduced pressure to provide a yellow oil. The oil was adsorbed onto SiO2 and 
purified by chromatography on SiO2 (100% hexanes, 10:90 to 30:70 EtOAc:hexanes) to provide 
5-13 (0.0155 g, 55%, 1:1 dr) as a pale yellow oil: IR (ATR, neat) 2951, 2928, 2855, 1737, 1685, 
1417, 1249, 1174, 1158, 1081, 1027, 923, 833, 775, 731 cm-1; 1H NMR (CDCl3, 400 MHz)  
 5.78 (ddd, 1 H, J = 16.8, 10.4, 5.8 Hz), 5.65 (dddd, 1 H, J = 17.1, 10.0, 8.6, 3.3 Hz), 5.27–5.12 
(m, 3 H), 5.04 (tt, 1 H, J = 10.3, 1.3 Hz), 4.19–4.10 (m, 1 H), 4.06–3.98 (m, 1 H), 3.59–3.47 (m, 
1 H), 3.05–2.90 (m, 1 H), 2.45–2.26 (m, 2 H), 2.26–2.16 (m, 1 H), 1.79–1.63 (m,  
3 H), 0.88 (d, 9 H, J = 2.2 Hz), 0.04 (d, 3 H, J = 1.2 Hz), 0.02 (d, 3 H, J = 2.5 Hz); 13C NMR 
(CDCl3, 100 MHz)  174.94, 179.90, 141.2, 140.7, 138.1, 137.9, 118.1, 118.0, 114.6, 114.2, 
72.1, 72.0, 61.8, 61.5, 37.7, 37.4, 35.4, 35.3, 30.3, 26.0, 25.7, 25.6, 18.33, 18.29, –4.2, –4.3, –4.7, 
–4.8; HRMS (ESI) m/z calcd for C17H32NO2Si ([M+H]+) 310.2202, found 310.2191; retention 
time of diastereomers determined by chiral SFC analysis on a CHIRALPAK® IA column; 3% 
MeOH/CO2; 2.5 mL/min; 220 nm; 6.46 min and 7.92 min. 
6.6.2 Third Generation Approach 
 
5-60 
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1-Benzylpyrrolidine-2,5-dione (5-60).129a To a flask containing succinimide (5-43)  
(1.06 g, 10.5 mmol) and K2CO3 (1.45 g, 10.5 mmol) under an atmosphere of Ar was added BnBr 
(1.51 mL, 12.9 mmol). The reaction mixture was heated at 80 C for 5 h. The reaction mixture 
was diluted with EtOAc and filtered to remove solids. The filtrate was concentrated under 
reduced pressure to provide a white crystalline solid. The material was adsorbed onto SiO2 and 
purified by chromatography on SiO2 (100% hexanes, 20:80 to 40:60 EtOAc:hexanes) to afford 5-
60 (1.42 g, 72%) as a white crystalline solid: Mp 102.5–103.7 C (EtOAc); IR (ATR, neat) 3072, 
3034, 2971, 1765, 1689, 1586, 1495, 1456, 1426, 1398, 1342, 1308, 1297, 1163, 1148  
cm-1; 1H NMR (CDCl3, 500 MHz)  7.41–7.37 (m, 2 H), 7.31–7.27 (m, 3 H), 4.66 (s, 2 H), 2.71 
(s, 4 H); 13C NMR (CDCl3, 125 MHz)  177.0, 135.9, 129.1, 128.8, 128.1, 42.6, 28.3; HRMS 
(ESI) m/z calcd for C11H12NO2 ([M+H]
+) 190.0868, found 190.0840. 
 
 
5-61 
1-Benzyl-5-hydroxypyrrolidin-2-one (5-61).129b To a solution of 5-60 (2.00 g,  
10.6 mmol) in MeOH (35 mL) and CH2Cl2 (13 mL) at 0 C under an atmosphere of Ar was 
added NaBH4 (0.480 g, 12.7 mmol). The reaction mixture was stirred at 0 C for 13 h. An 
additional amount of NaBH4 (0.480 g, 12.7 mmol) was added at 0 C and stirring was continued 
for 12 h. After the first 24 h, an additional amount of NaBH4 (0.480 g, 12.7 mmol) was added 
every 12 h until the starting material was consumed as indicated by a 1H NMR of an aliquot of 
the reaction mixture.  The reaction mixture was concentrated under reduced pressure to provide a 
white solid. The solid was diluted with CH2Cl2 and quenched with sat. aq. NH4Cl and extracted 
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with CH2Cl2. The combined organic layers were dried (MgSO4) and concentrated under reduced 
pressure to provide a white solid. The solid was adsorbed onto SiO2 and purified by 
chromatography on SiO2 (100% CH2Cl2, 2:98 to 6:94 CH2Cl2:MeOH) to afford 5-61 (1.58 g, 
78%) as a white solid: Mp 109.9–111.6 C (CH2Cl2); IR (ATR, neat) 3156, 2928, 1635, 1480, 
1441, 1426, 1331, 1282, 1260, 1176, 1157, 1074, 997, 947, 753, 697 cm-1; 1H NMR (CDCl3,  
400 MHz)  7.38–7.23 (m, 5 H), 5.12–5.05 (m, 1 H), 4.83 (d, 1 H, J = 14.8 Hz), 4.22 (d, 1 H, J = 
14.8 Hz), 2.70–2.58 (m, 2 H), 2.43–2.23 (m, 2 H), 1.95–1.84 (m, 1 H); 13C NMR (CDCl3, 125 
MHz)  174.9, 136.6, 128.9, 128.5, 127.8, 82.7, 43.6, 29.0, 28.3; HRMS (ESI) m/z calcd for 
C11H14NO2 ([M+H]
+) 192.1025, found 192.1043. 
 
 
5-62 
1-Benzyl-5-oxopyrrolidin-2-yl 2,2-dimethylpropanoate (5-62). To a solution of 5-61 
(0.30 g, 1.6 mmol) in CH2Cl2 (15 mL) at room temperature under an atmosphere of N2 was 
added Et3N (0.67 mL, 4.7 mmol), DMAP (0.039 g, 0.31 mmol), and pivaloyl chloride (0.39 mL, 
3.14 mmol). The mixture was stirred at room temperature for 4 h. The reaction was quenched 
with sat. aq. NH4Cl and extracted with CH2Cl2. The combined organic layers were washed with 
sat. aq. NaHCO3 and H2O, dried (MgSO4), and concentrated under reduced pressure to provide a 
yellow residue. The residue was adsorbed onto SiO2 and purified by chromatography on SiO2 
(100% hexanes, 10:90 to 15:85 EtOAc:hexanes) to afford 5-62 (0.318 g, 74%, 98% BRSM): Mp 
58.6–60.3 C (EtOAc); IR (ATR, neat) 2973, 2958, 2934, 2872, 1689, 1497, 1480, 1443, 1417, 
1366, 1277, 1251, 1131, 1027, 951, 887, 744, 701 cm-1; 1H NMR (CDCl3, 400 MHz)  7.35–
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7.23 (m, 5 H), 5.07 (d, 1 H, J = 5.5 Hz), 4.80 (d, 1 H, J = 14.8 Hz), 4.10 (d, 1 H, J = 14.8 Hz), 
2.64 (ddd, 1 H, J = 17.8, 9.2, 9.2 Hz), 2.42 (ddd, 1 H, J = 17.2, 9.8, 2.3 Hz), 2.36–2.24 (m,  
1 H), 1.95 (ddd, 1 H, J = 14.1, 9.2, 1.3 Hz), 1.12 (s, 9 H); 13C NMR (CDCl3, 125 MHz)  178.1, 
175.8, 136.4, 128.8, 128.4, 127.9, 84.5, 44.7, 39.0, 28.5, 27.0, 26.2; HRMS (ESI) m/z calcd for 
C16H21NO3 ([M+Na]
+) 298.1419, found 298.1424. 
 
 
5-63 
1-Benzyl-5-vinylpyrrolidin-2-one (5-63).  To a flask containing AlCl3 (0.291 g,  
2.18 mmol) in CH2Cl2 (1.3 mL) cooled to 0 °C under an atmosphere of Ar was added 
vinylmagnesiumbromide (1.0 M in THF, 6.5 mL, 6.5 mmol) dropwise. Upon addition of the 
vinylmagnesiumbromide, the white slurry became a clear yellow solution and then a cloudy 
orange-yellow solution. The cloudy orange-yellow mixture was stirred at 0 °C for 4 h. 5-62 
(0.200 g, 0.726 mmol) in CH2Cl2 (0.65 mL) was added in one portion and the reaction was 
allowed to stir at 0 °C for 1 h. Upon addition of 5-62, the mixture became a clear yellow 
solution. The reaction mixture was carefully quenched with 1 M HCl at 0 °C. The solution was 
extracted with CH2Cl2 and 1.0 M HCl was added to the extraction until the organic layer became 
clear.  The combined organic layers were washed with brine, dried (MgSO4), and concentrated 
under reduced pressure to provide an orange oil.  The oil was taken up in Et2O and washed with 
sat. aq. NaHCO3 to remove the remaining pivalic acid. The combined aqueous layers were then 
extracted with Et2O.  The combined organic layers were dried (MgSO4) and concentrated under 
reduced pressure to provide 5-63 (0.519 mmol, 71%) as an orange oil:  1H NMR (CDCl3,  
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400 MHz)  7.36–7.17 (m, 5 H), 5.64 (app dt, 1 H, J = 18.1, 9.7 Hz), 5.22 (d, 1 H, J = 10.0 Hz), 
5.14 (d, 1 H, J = 17.0 Hz), 4.99 (d, 1 H, J = 14.7 Hz), 3.92–3.80 (m, 2 H), 2.54–2.34 (m, 2 H), 
2.23–2.11 (m, 1 H), 1.81–1.74 (m, 1 H). 
 
 
5-68 
5-Hydroxy-1-((S)-1-phenylethyl)pyrrolidin-2-one (5-68).130a To a solution of succinic 
anhydride (1.00 g, 8.17 mmol) in THF (8.2 mL) at room temperature was added (S)-(-)-1-
phenylethylamine (5-65) (1.05 mL, 8.17 mmol) dropwise. The mixture was heated at reflux for 2 
h. The solution was cooled to room temperature and the solvent removed under reduced pressure. 
Acetic anhydride (5-64) (8.2 mL) was added and the mixture was heated at reflux for 2 h. The 
reaction mixture turned from a clear yellow solution to a clear orange solution after 15 min. The 
mixture was cooled to room temperature and poured onto ice. The mixture was extracted with 
CH2Cl2. The combined organic extracts were washed with sat. aq. NaHCO3 and brine, dried 
(MgSO4), and concentrated under reduced pressure to provide (S)-1-(1-phenylethyl)pyrrolidine-
2,5-dione (5-67) as an orange residue. The product was taken on to the next step without 
purification. 
To a solution of 5-67 (0.399 g, 1.96 mmol) in THF (65 mL) at -78 °C under an 
atmosphere of N2 was added LiEt3BH (2.9 mL, 2.9 mmol, 1.0 M in THF) dropwise. The solution 
was stirred at –78 °C for 2.5 h. The reaction was quenched with sat. aq. NaHCO3, warmed to  
0 °C, and H2O2 (10 drops) was added. The solution was kept at 0 °C for 20 min. The reaction 
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mixture was concentrated under reduced pressure and the aqueous residue was extracted with 
CH2Cl2. The combined organic layers were washed with brine, dried (MgSO4), and concentrated 
under reduced pressure to provide a white solid.  The material was purified by chromatography 
on SiO2 (100% CH2Cl2, 1:99 to 5:95 MeOH:CH2Cl2) to provide 5-68 (0.240 g, 60%, >10:1 dr) 
as a white crystalline solid.  The minor diastereomer could not be detected by 1H NMR but was 
observed in the 13C NMR.  Mp 101.2–102.5 °C (EtOAc); IR (ATR, neat) 3193, 3033, 2984, 
2939, 1638, 1603, 1493, 1450, 1443, 1417, 1383, 1359, 1323, 1281, 1247, 1208, 1176, 1158, 
1074, 1059, 984, 913, 788, 699, 669 cm-1; 1H NMR (CDCl3, 500 MHz) major diastereomer:  
 7.38–7.34 (m, 4 H), 7.33–7.27 (m, 1 H), 5.39 (q, 1 H, J = 7.2 Hz), 4.93 (app td, 1 H, J = 7.2, 
1.6 Hz), 2.66 (app dt, 1 H, J = 17.6, 9.0 Hz), 2.34 (dddd, 1 H, J = 17.3, 9.9, 3.0, 1.0 Hz), 2.19–
2.08 (m, 1 H), 1.83 (dddd, 1 H, J = 13.9, 9.3, 3.1, 1.7 Hz), 1.63 (d, 3 H, J = 7.2 Hz); 13C NMR 
(CDCl3, 125 MHz) major diastereomer:   174.7, 140.0, 128.8, 127.9, 127.7, 82.4, 50.4, 29.1, 
29.0, 18.9; minor diastereomer:   175.0, 129.1, 128.1, 127.5, 81.7, 49.8, 29.2, 28.6, 17.2; HRMS 
(ESI) m/z calcd for C12H16NO2 ([M+H]
+) 206.1181, found 206.1193. 
 
 
5-69 
5-Oxo-1-((S)-1-phenylethyl)pyrrolidin-2-yl-4-methylbenzenesulfinate (5-69).130b  To 
a solution of 5-68 (0.0500 g, 0.243 mmol) in CH2Cl2 (2.4 mL) was added toluenesulfinic acid
144 
(0.0761 g, 0.487 mmol). The solution was stirred at room temperature for 4.5 h. The solution was 
quenched with 5% aq. Na2CO3 and extracted with CH2Cl2. The combined organic layers were 
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washed with brine, dried (MgSO4), and concentrated under reduced pressure to provide 5-69 
(0.0797 g, 95% crude, 1:1 dr) as a white solid. The material was taken on without further 
purification.  Characteristic signals for the diastereomeric mixture (reported as observed):  1H 
NMR (CDCl3, 400 MHz)  7.68 (d, 2 H, J = 8.3 Hz), 7.58 (d, 2 H, J = 8.3 Hz), 7.38–7.20 (m, 14 
H), 5.32 (q, 1 H, J = 7.1 Hz), 4.87 (q, 1 H, J = 7.2 Hz), 4.55 (dd, 1 H, J = 8.5, 1.0 Hz), 4.12 (d, 1 
H, J = 8.1 Hz), 2.38 (s, 3 H), 2.35 (s, 3 H), 2.35–1.90 (d, 3 H, J = 7.2 Hz), 1.90 (d, 3 H, J = 7.2 
Hz), 1.80 (d, 3 H, J = 7.2 Hz).  
 
 
5-70 
1-((S)-1-Phenylethyl)-5-vinylpyrrolidin-2-one (5-70).  Vinyl alane generation:  To a 
flask containing AlCl3 (0.260 g, 1.95 mmol) in CH2Cl2 (0.7 mL) cooled to 0 °C under an 
atmosphere of Ar was added vinylmagnesium bromide (1.0 M in THF, 5.8 mL, 3.4 mmol) 
dropwise. The solution was stirred at 0 °C for 4 h.  To a separate flame-dried flask under an 
atmosphere of N2 was added the vinyl alane solution (0.3 M in CH2Cl2, 3.1 mL, 0.928 mmol). 
The flask was cooled to 0 °C and 5-69 (0.0797 g, 0.232 mmol) was added in one portion. The 
reaction mixture was kept at 0 °C for 2 h. The reaction mixture was quenched with sat. aq. 
NH4Cl, warmed to room temperature, and extracted with CH2Cl2.  1 M aq. HCl was added to 
separate the emulsion. The combined organic layers were washed with brine, dried (MgSO4), and 
concentrated under reduced pressure to provide a viscous, yellow oil. The oil was purified by 
chromatography on SiO2 (100% CH2Cl2, 1:99 MeOH:CH2Cl2) to provide 5-70 (0.0316 g, 63%, 
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0.7:1 dr) as a yellow oil: IR (ATR, neat) 3079, 3062, 3057, 3047, 2975, 2926, 2919, 2870, 2854, 
2848, 1678, 1493, 1450, 1402, 1254, 992, 919, 699 cm-1; 1H NMR (CDCl3, 300 MHz) major 
diastereomer:  7.36–7.20 (m, 5 H), 5.80 (ddd, 1 H, J = 17.0, 10.0, 8.0 Hz), 5.45 (q, 1 H, J =  
7.3 Hz), 5.09–4.95 (m, 1 H), 4.95 (d, 1 H, J = 17.1 Hz), 3.71 (td, 1 H, J = 8.4, 4.2 Hz), 2.56–2.25 
(m, 4 H), 1.55 (d, 3 H, J = 7.3 Hz); minor diastereomer:  7.36–7.20 (m, 3.5 H), 5.29 (ddd, 0.7 H, 
J = 17.0, 9.8, 8.7 Hz), 5.18 (q, 0.7 H, J = 7.2 Hz), 5.09–4.95 (m, 0.7 H), 4.86 (dd, 0.7 H, J = 
10.0, 1.0 Hz), 4.13 (td, 0.7 H, J = 8.0, 6.3 Hz), 2.22–2.18 (m, 2.8 H), 1.66 (d, 2.1 H, J =  
7.3 Hz); 13C NMR (CDCl3, 100 MHz) major diastereomer:   175.1, 140.2, 140.0, 128.5, 127.8, 
127.5, 116.3, 60.0, 50.7, 30.2, 26.6, 18.1; minor diastereomer:  175.3, 142.0, 139.1, 128.2, 
127.6, 127.2, 116.4, 61.2, 50.6, 30.7, 26.5, 16.7.  HRMS (ESI) m/z calcd for C14H18NO ([M+H]
+) 
216.1388, found 216.1367. 
 
 
5-72 
(S)-1-(1-(Naphthalen-1-yl)ethyl)pyrrolidine-2,5-dione (5-72).145  To a solution of 
succinic anhydride (5-51) (0.145 g, 1.45 mmol) in THF (1.5 mL) at room temperature was added 
(S)-(-)-1-(1-naphthyl)ethylamine (5-71) (0.234 mL, 1.45 mmol) dropwise. The mixture was 
heated at reflux for 2 h. The solution was cooled to room temperature and concentrated under 
reduced pressure. Acetic anhydride (5-64) (1.45 mL) was added and the mixture was heated at 
reflux for 2 h. The mixture was cooled to room temperature and poured onto ice. The mixture 
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was extracted with CH2Cl2. The combined organic extracts were washed with sat. aq. NaHCO3 
and brine, dried (MgSO4), and concentrated under reduced pressure to provide a brown solid.  
The brown solid was purified by chromatography on SiO2 (100% hexanes, 10:90 to 80:20 
EtOAc:hexanes) to provide 5-72 (0.280 g, 76%) as a brown crystalline solid:  1H NMR (CDCl3, 
300 MHz)  8.08 (d, 1 H, J = 8.3 Hz), 7.94 (d, 1 H, J = 7.8 Hz), 7.90–7.79 (m, 2 H), 7.57–7.44 
(m, 3 H), 6.17 (q, 1 H, J = 7.1 Hz), 2.60 (s, 4 H), 1.92 (d, 3 H, J = 7.2 Hz). 
 
 
5-73 
5-Hydroxy-1-((S)-1-(naphthalen-1-yl)ethyl)pyrrolidin-2-one (5-73).  To a solution of 
5-72 (0.228 g, 0.899 mmol) in THF (30 mL) at –78 °C under an atmosphere of N2 was added 
LiEt3BH (1.3 mL, 1.3 mmol, 1.0 M in THF) dropwise. The solution was stirred at –78 °C for  
40 min. The reaction was quenched with sat. aq. NaHCO3, warmed to 0 °C, and H2O2 (10 drops) 
was added. The solution was kept at 0 °C for 20 min. The reaction mixture was concentrated 
under reduced pressure and the aqueous residue was extracted with CH2Cl2. The combined 
organic layers were washed with brine, dried (MgSO4), and concentrated under reduced pressure 
to provide a white solid.  The material was purified by chromatography on SiO2 (100% CH2Cl2, 
1:99 to 5:95 MeOH:CH2Cl2) to provide 5-73 in two batches. The first batch was isolated as a 1:1 
mixture of diastereomers (0.041 g, 18%), and the second batch, was isolated as a single 
diastereomer (0.167 g, 73%). In total, 0.208 g (0.816 mmol, 91%, 10:1 dr) of the desired product 
was obtained.  Major diastereomer: Mp 196.8–198.6 °C (EtOAc); IR (ATR, neat) 3228, 2978, 
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2967, 2947, 2934, 1646, 1596, 1508, 1443, 1415, 1398, 1322, 1249, 1238, 1185, 1165, 1107, 
1072, 1053, 913, 803, 779, 721, 684 cm-1; 1H NMR (CDCl3, 500 MHz)  7.90–7.81 (m, 3 H), 
7.71 (d, 1 H, J = 7.1 Hz), 7.54–7.48 (m, 3 H), 6.06 (q, 1 H, J = 7.0 Hz), 4.45 (td, 1 H, J = 6.6, 2.2 
Hz), 2.67 (ddd, 1 H, J = 17.3, 9.4, 7.9 Hz), 2.34 (ddd, 1 H, J = 17.3, 10.0, 4.0 Hz), 1.95 (dddd, 1 
H, J = 14.0, 9.9, 7.8, 6.3 Hz), 1.80 (d, 3 H, J = 7.0 Hz), 1.71 (dddd, 1 H, J = 13.6, 9.5, 4.0, 2.2 
Hz); 13C NMR (CDCl3, 125 MHz)  174.2, 134.5, 134.0, 131.8, 129.1, 129.0, 127.2, 126.2, 
125.2, 124.8, 123.2, 82.5, 46.6, 29.1, 28.6, 19.2; HRMS (ESI) m/z calcd for C16H18NO2 
([M+H]+) 256.1338, found 256.1356.  Characteristic signals for the minor diastereomer:   
1H NMR (CDCl3, 500 MHz)   8.19 (d, 1 H, J = 8.5 Hz), 7.89–7.83 (m, 2 H), 7.69 (d, 1 H, J = 
7.2 Hz), 7.60–7.56 (m, 1 H), 7.53–7.47 (m, 2 H), 6.18 (q, 1 H, J = 6.9 Hz), 5.37 (d, 1 H, J = 5.9 
Hz), 2.70–2.60 (m, 1 H), 2.35–2.28 (m, 1 H), 2.14–2.05 (m, 1 H), 1.97–1.88 (m, 1 H), 1.82–1.76 
(m, 1 H), 1.71 (d, 3 H, J = 7.0 Hz). 
 
 
5-74 
1-((S)-1-(Naphthalen-1-yl)ethyl)-5-oxopyrrolidin-2-yl 4-methylbenzenesulfinate (5-
74).  To a solution of 5-73 (0.0500 g, 0.196 mmol) in CH2Cl2 (2.0 mL) was added toluenesulfinic 
acid144 (0.0612 g, 0.392 mmol). The solution was stirred at room temperature for 4.5 h. The 
solution was quenched with 5% aq. Na2CO3 and extracted with CH2Cl2. The combined organic 
layers were washed with brine, dried (MgSO4), and concentrated under reduced pressure to 
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provide 5-74 (0.0698 g, 91%, 10:1 dr) as a white solid. The material was taken on without 
further purification. Major diastereomer:  1H NMR (CDCl3, 400 MHz)  7.93–7.87 (m, 3 H), 
7.62 (d, 2 H, J = 8.3 Hz), 7.60–7.54 (m, 2 H), 7.50–7.41 (m, 2 H), 7.32 (d, 2 H, J = 8.0 Hz), 6.07 
(q, 1 H, J = 7.0 Hz), 3.71 (d, 1 H, J = 8.5 Hz), 2.42 (s, 3 H), 2.17–2.11 (m, 1 H), 2.09 (d,  
3 H, J = 7.0 Hz), 2.06–1.88 (m, 2 H), 1.80–1.68 (m, 1 H). Characteristic signals for the minor 
diastereomer: 1H NMR (CDCl3, 400 MHz)  5.85 (q, 0.1 H, J = 7.3 Hz), 4.53 (d, 0.1 H, J = 8.4 
Hz), 2.50 (s, 0.3 H). 
 
 
5-75 
1-((S)-1-(Naphthalen-1-yl)ethyl)-5-vinylpyrrolidin-2-one (5-75).  Vinyl alane 
generation:  To an oven-dried 2-5 mL microwave vial containing AlCl3 (0.0428 g, 0.321 mmol) 
in CH2Cl2 (0.20 mL) at 0 °C under an atmosphere of N2 was added vinylmagnesium bromide 
(1.0 mL, 1.0 M in THF, 1.0 mmol). The solution was stirred at 0 °C for 4 h and then cooled to  
–30 °C.  To the vial containing the vinyl alane solution at –30 °C was added 5-74 (0.0316 g, 
0.0803 mmol). The reaction mixture was stirred at –30 °C for 2.5 h. The reaction mixture was 
warmed to –20 °C and stirred overnight. The reaction mixture was quenched with 1 M aq. HCl 
and extracted with CH2Cl2. The combined organic layers were washed with brine, dried 
(MgSO4), and concentrated under reduced pressure to provide a viscous, yellow oil. The oil was 
purified by chromatography on SiO2 (100% CH2Cl2, 1:99 MeOH:CH2Cl2) to provide 5-75  
(0.012 g, 57%, dr 0.3:1) as a yellow oil:  IR (ATR, neat) 3074, 3049, 2973, 2887, 1670, 1597, 
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1508, 1396, 1238, 1193, 990, 921, 803, 772, 729. Major diastereomer:  1H NMR (CDCl3,  
300 MHz)  7.93–7.79 (m, 3 H), 7.58–7.42 (m, 4 H), 6.09 (q, 1 H, J = 6.9 Hz), 5.79 (dt, 1 H,  
J = 17.1, 9.4 Hz), 4.99 (d, 1 H, J = 9.9 Hz), 4.71 (d, 1 H, J = 17.1 Hz), 3.20 (td, 1 H, J = 8.6,  
3.7 Hz), 2.60–2.24 (m, 2 H), 1.93–1.77 (m, 1 H), 1.71 (d, 3 H, J = 7.2 Hz), 1.63–1.50 (m,  
1 H); 13C NMR (CDCl3, 100 MHz)  174.6, 139.9, 134.5, 133.8, 132.0, 128.9, 128.8, 127.0, 
126.0, 125.6, 124.8, 123.4, 116.4, 60.1, 47.2, 30.1, 26.2, 18.6.  HRMS (ESI) m/z calcd for 
C18H20NO ([M+H]
+) 266.1545, found 166.1537.  Characteristic signals for the minor 
diastereomer:  1H NMR (CDCl3, 300 MHz)  4.55 (d, 0.3 H, J = 17.0 Hz), 4.28 (d, 0.3 H, J =  
9.9 Hz), 4.06 (td, 0.3 H, J = 8.1, 4.7 Hz); 13C NMR (CDCl3, 100 MHz)  174.9, 138.2, 136.2, 
133.6, 132.4, 128.7, 128.6, 126.6, 125.7, 125.3, 124.8, 123.9, 114.5, 59.8, 46.6, 30.3, 27.2, 17.0.   
 
 
5-77 
(S)-1-(1-Hydroxy-3-phenylpropan-2-yl)pyrrolidine-2,5-dione (5-77).146 To a flask 
containing 3,4-dihydrofuran-2,5-dione (5-64) (1.30 g, 13.0 mmol) and L-phenylalaninol (5-76) 
(2.00 g, 13.0 mmol) in freshly distilled toluene (125 mL) at room temperature under an 
atmosphere of N2 was added Et3N (3.6 mL, 26 mmol). The solution was heated at reflux for 20 h. 
The reaction mixture was concentrated under reduced pressure to give a yellow solid. The solid 
was purified by chromatography on SiO2 (5:95 to 10:90 MeOH:CH2Cl2) to provide 5-77 (1.94 g, 
64%) as a pale yellow solid: Mp 113.0–116.2 °C (CH2Cl2); IR (ATR, neat) 3409, 3061, 3029, 
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2971, 2880, 1761, 1733, 1679, 1416, 1402, 1372, 1301, 1187, 1165, 1048, 1020, 951, 822, 762, 
703 cm-1; 1H NMR (CDCl3, 400 MHz)  7.30–7.15 (m, 5 H), 4.51 (td, 1 H, J = 7.2, 3.2 Hz), 4.00 
(dd, 1 H, J = 12.0, 7.2 Hz), 3.83 (dd, 1 H, J = 12.0, 3.2 Hz), 3.15–3.07 (m, 2 H), 2.62–2.51 (m, 4 
H); 13C NMR (CDCl3, 100 MHz)  178.2, 137.3, 129.1, 128.6, 126.9, 62.3, 55.8, 33.8, 28.0; 
HRMS (ESI) m/z calcd for C13H16NO3 ([M+H]
+) 234.1130, found 234.1113. 
 
 
5-78 
(3S)-3-Benzyltetrahydropyrrolo[2,1-b]oxazol-5(6H)-one (5-78).146  To a flask 
containing 5-77 (0.200 g, 0.857 mmol) in EtOH (8.5 mL) at 0 °C under an atmosphere of N2 was 
added NaBH4 (0.331 g, 8.57 mmol). The reaction mixture was stirred at 0 °C for 2 h. The 
reaction mixture was diluted with EtOAc and quenched with sat. aq. NH4Cl at 0 °C.  The 
mixture was warmed to room temperature and extracted with EtOAc. The combined organic 
layers were washed with brine, dried (MgSO4), and concentrated under reduced pressure to give 
a colorless residue.  Compound 5-78 was the major product by LC/HRMS and attempts to purify 
this compound by chromatography on SiO2 (100% CH2Cl2, 5:95 to 10:90 MeOH:CH2Cl2) were 
unsuccessful. The mixture was taken on to the next step without further purification. LC-HRMS 
(ESI) m/z calcd for peak at 2.14 min C13H16NO2 ([M+H]
+) 218.1176, found 218.1169. 
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5-79 
1-((S)-1-Hydroxy-3-phenylpropan-2-yl)-5-vinylpyrrolidin-2-one (5-79).  Vinyl alane 
generation: To a flask containing AlCl3 (0.265 g, 1.99 mmol) in CH2Cl2 (0.20 mL) at 0 °C under 
an atmosphere of N2 was added vinylmagnesium bromide (6.2 mL, 1.0 M in THF, 1.0 mmol). 
The solution was stirred at 0 °C for 4 h.  To the vial containing the vinyl alane solution at 0 °C 
was added 5-78 (0.108 g, 0.497 mmol) in CH2Cl2 (0.5 mL). The reaction mixture was stirred at  
0 °C for 3.5 h. The reaction was quenched with sat. aq. NH4Cl and 1 M aq. HCl was added.  The 
aqueous layer was extracted with CH2Cl2. The combined organic layers were washed with brine, 
dried (MgSO4), and concentrated under reduced pressure to provide a yellow residue.  The 
material was purified by chromatography on SiO2 (100% CH2Cl2, 1:99 MeOH:CH2Cl2) to give 
5-79 (0.0378 g, 31% crude, 2:1 dr) as a crude yellow oil.  Characteristic signals for the major 
diastereomer: 1H NMR (CDCl3, 400 MHz)  7.34–7.15 (m, 5 H), 5.02 (dd, 1 H, J = 6.1,  
2.4 Hz), 4.42–4.32 (m, 1 H), 4.06 (t, 1 H, J = 8.6 Hz), 3.68–3.60 (m, 1 H), 3.03 (dd, 1 H, J = 
13.9, 5.8 Hz), 2.77 (dd, 1 H, J = 13.8, 8.3 Hz), 2.62 (dd, 1 H, J = 10.4, 7.2 Hz), 2.51 (dd, 1 H, J = 
10.5, 4.5 Hz), 2.43–3.28 (m, 1 H), 2.17 (dd, 1 H, J = 17.2, 9.1 Hz), 2.07–1.91 (m, 1 H), 1.86 (dd, 
1 H, J = 13.5, 8.8 Hz).  Characteristic signals for the minor diastereomer:  1H NMR (CDCl3, 400 
MHz)  7.34–7.15 (m, 2.5 H), 5.10 (d, 0.5 H, J = 6.0 Hz), 4.56–4.47 (m, 0.5 H), 3.68–3.60 (m, 
0.5 H), 3.38 (t, 0.5 H, J = 8.5 Hz), 2.88 (dd, 0.5 H, J = 13.2, 9.0 Hz), 2.70 (dd, 0.5 H,  
J = 13.3, 6.1 Hz), 2.67 (dd, 0.5 H, J = 3.1 Hz), 2.46 (dd, 0.5 H, J = 10.7, 4.7 Hz), 2.43–2.28 (m, 
0.5 H), 2.07–1.91 (m, 1.5 H). 
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6.6.3 Fourth Generation Approach 
 
5-85 
2-(Pent-4-yn-1-yloxy)tetrahydro-2H-pyran (5-85). To a solution of 4-pentyn-1-ol (5-
84) (15.0 mL, 158 mmol), 3,4-dihydro-2H-pyran (17.5 mL, 190 mmol) in CH2Cl2 (200 mL) was 
added p-toluenesulfonic acid monohydrate (0.0601 g, 0.316 mmol). The mixture was stirred at 
room temperature for 1 h. During the course of the reaction, the solution turned a deep blue 
color. The reaction mixture was quenched with sat. aq. NaHCO3 (at which time the teal color 
dissipated to give a yellow-orange colored solution) and extracted with CH2Cl2. The combined 
organic layers were washed with brine, dried (MgSO4), and concentrated under reduced pressure 
to give an orange oil. The material was purified by chromatography on SiO2 (100% hexanes, 
5:95 to 15:85 Et2O:hexanes) to provide 5-85 (27.4 g, quant.) as a light yellow oil:  IR (ATR, 
neat) 3290, 2937, 2869, 1465, 1439, 1351, 1322, 1199, 1180, 1156, 1135, 1118, 1074, 1061, 
1033, 1020, 992, 969, 867, 815 cm-1; 1H NMR (CDCl3, 400 MHz)  4.62–4.57 (m, 1 H), 3.90–
3.79 (m, 2 H), 3.54–3.44 (m, 2 H), 2.34–2.28 (m, 2 H), 1.94 (t, 1 H, J = 2.6 Hz), 1.87–1.77 (m, 3 
H), 1.75–1.67 (m, 1 H), 1.60–1.47 (m, 4 H); 13C NMR (CDCl3, 100 MHz)  99.0, 84.1, 68.6, 
65.9, 62.4, 30.8, 28.8, 25.6, 19.7, 15.5; HRMS (ESI) m/z calcd for C10H17O2 ([M+H]
+) 169.1229, 
found 169.1232.  
 
 
5-86 
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2-((9-Bromonon-4-yn-1-yl)oxy)tetrahydro-2H-pyran (5-86).  To a solution of 5-85 
(26.6 g, 158 mmol) in THF (390 mL) and HMPA (2.8 mL, 15.8 mmol) cooled to -78 °C under 
an atmosphere of Ar was added n-BuLi (1.6 M in THF, 118 mL, 190 mmol) dropwise. The 
reaction mixture was warmed to -40 °C, stirred for 30 min, and 1,4-dibromobutane (95.3 mL, 
790 mmol) was added dropwise. The solution was warmed to room temperature over 1 h and 
then heated to reflux. The mixture was stirred at reflux for 29 h.  The reaction mixture was 
diluted with Et2O and brine was added. The aqueous layer was extracted with Et2O. The 
combined organic layers were washed with brine, dried (MgSO4), and concentrated under 
reduced pressure to provide a crude yellow oil. The oil was purified in two separate batches by 
chromatography on SiO2 (100% hexanes, 2:98 to 10:90 EtOAc:hexanes) to afford the 5-86 (41.9 
g, 88%) as a pale yellow oil:  1H NMR (CDCl3, 400 MHz)  4.62–4.57 (m, 1 H), 3.91–3.77 (m, 2 
H), 3.54–3.45 (m, 2 H), 3.43 (t, 2 H, J = 6.8 Hz), 2.29–2.23 (m, 2 H), 2.22–2.16 (m,  
2 H), 2.01–1.92 (m, 2 H), 1.85–1.70 (m, 4 H), 1.65–1.47 (m, 6 H).  
 
 
5-87 
9-Azidonon-4-ynoic acid (5-87). To a solution of 5-86 (18.15 g, 59.9 mmol) in DMF 
(300 mL) at room temperature under an atmosphere of N2 was added NaN3 (4.67 g, 71.8 mmol). 
The solution was heated to 80 °C and stirred for 25 h. The reaction mixture was cooled to room 
temperature, poured into H2O, and extracted with Et2O. The combined organic layers were 
washed with H2O (5x) and brine, dried (MgSO4), and concentrated under reduced pressure to 
provide crude 2-((9-azidonon-4-yn-1-yl)oxy)tetrahydro-2H-pyran as a yellow oil.  The crude 
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material was taken on without further purification due to the potentially explosive nature of the 
azide.  
To a solution of crude 2-((9-azidonon-4-yn-1-yl)oxy)tetrahydro-2H-pyran (15.9 g,  
59.9 mmol) in acetone (120 mL) at 0 °C was added freshly prepared Jones reagent (2.5 M,  
71.8 mL, 180 mmol). The reaction mixture was stirred at 0 °C for 7 h. After 3 h, the reaction was 
not complete by TLC and an additional amount of Jones reagent (2.5 M, 10 mL) was added.  
After complete consumption of starting material, the reaction mixture was quenched with i-PrOH 
and concentrated under reduced pressure to give a crude residue. The residue was extracted with 
Et2O. The combined organic layers were washed with brine, dried (MgSO4), and concentrated 
under reduced pressure to give a yellow oil. The material was adsorbed onto SiO2 and purified 
by chromatography on SiO2 (100% hexanes, 5:95 to 1:1 EtOAc:hexanes) to provide 5-87  
(8.51 g, 73%) as a pale yellow solid: IR 3072, 2923, 2093, 1702, 1627, 1603, 1502, 1416 cm-1; 
1H NMR (CDCl3, 400 MHz)  11.46 (bs, 1 H), 3.30 (t, 2 H, J = 6.6 Hz), 2.60–2.54 (m, 2 H), 2.51 
–2.45 (m, 2 H), 2.25–2.16 (m, 2 H), 1.71 (quint, 2 H, J = 7.0 Hz), 1.56 (quint, 2 H, J =  
7.2 Hz); 13C NMR (CDCl3, 400 MHz) 178.7, 80.5, 78.6, 51.1, 33.9, 27.9, 26.0, 18.3, 14.5. 
 
 
5-83 
9-Aminonon-4-ynoic acid hydrochloride (5-83).  To a flask containing 5-87 (0.100 g, 
0.495 mmol) in THF (2.5 mL) and H2O (3 drops) was added PPh2(CH2)2PPh2 (0.122 g,  
0.307 mmol). The reaction was stirred at room temperature for 21 h. The reaction was monitored 
by IR, and the disappearance of the azide stretch at 2091 cm-1 was used to indicate completion of 
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the reaction. The reaction mixture was concentrated under reduced pressure to give a yellow 
solid. The solid was suspended in 10% aq. HCl and stirred for 5 min. The suspension was filtered 
and the filtrate was concentrated under reduced pressure to provide 5-83 as the HCl salt (0.084 g, 
80%):  IR 3072, 2902, 2613, 1696, 1623, 1609, 1502 cm-1; 1H NMR (D2O, 400 MHz)  3.03 (t,  
2 H, J = 7.5 Hz), 2.61–2.56 (m, 2 H), 2.50–2.45 (m, 2 H), 2.24 (tt, 2 H, J = 6.8, 2.3 Hz), 1.81– 
1.72 (m, 2 H), 1.61–1.52 (m, 2 H); 13C NMR (CDCl3, 100 MHz)  177.7, 81.8, 80.4, 39.7, 34.0, 
26.5, 25.5, 18.0, 14.6; HRMS (ESI) m/z calcd for C9H16NO2 ([M+H]
+) 170.1181, found 
170.1187. 
 
 
5-82 
3,4,7,8,9,10-Hexahydro-azecin-2-one (5-82).  To a flask containing 5-83 (1.23 g, 5.98 
mmol) in CH2Cl2 (1250 mL) was added Et3N (1.68 mL, 12.0 mmol) and 1-hydroxybenzotriazole 
(10.2 g, 1.37 mmol). The solution was stirred for 15 min and 1-(3-dimethylaminopropyl)-3-
ethylcarbodiimide hydrochloride (1.49 g, 7.77 mmol) was added. The solution was stirred at 
room temperature for 65.5 h. The starting material did not completely dissolve and remained a 
fine suspension throughout the reaction. The reaction mixture was quenched with H2O and 
extracted with CH2Cl2. The combined organic layers were dried (MgSO4) and concentrated 
under reduced pressure to provide a yellow residue. The residue was adsorbed onto SiO2 and 
purified by chromatography on SiO2 (100% CH2Cl2, 1:99 to 5:95 MeOH:CH2Cl2) to provide 5-
82 (0.401 g, 2.65 mmol, 44%) as a light yellow residue that crystallized upon standing:  IR 
(ATR, neat) 3312, 3081, 2933, 2858, 1645, 1541, 1435, 1310, 1277 cm-1; 1H NMR (CDCl3,  
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500 MHz)  5.96 (bs, 1 H), 3.30–3.20 (m, 2 H), 2.50–2.42 (m, 2 H), 2.30–2.24 (m, 2 H),  
2.16–2.06 (m, 2 H), 1.74 (m, 4 H); 13C NMR (CDCl3, 125 MHz)  173.6, 87.3, 80.5, 40.8, 37.3, 
26.4, 26.2, 20.2, 17.2; HRMS (ESI) m/z calcd for C9H14NO ([M+H]
+) 152.1070, found 152.1067.  
This structure was confirmed by X-ray analysis (Appendix A.3). 
 
 
5-95 
1-Iodo-2,3,6,7,8,9-hexahydro-4H-quinolizin-4-one (5-95).  To a solution of 5-82 
(0.0300 g, 0.198 mmol) in THF (6 mL) was added I2 (0.0757 g, 0.298 mmol), Na2CO3 (0.0637 g, 
0.595 mmol), and AgNO3 (0.0340 g, 0.198 mmol). The reaction mixture was stirred at room 
temperature for 20 h. The solvent was removed under reduced pressure and the residue was 
dissolved in EtOAc, washed with sat. aq. Na2S2O3, brine, and dried (MgSO4). The solution was 
concentrated under reduced pressure to give a dark yellow residue. The material was purified by 
chromatography on SiO2 (100% hexanes, 10:90 to 25:75 EtOAc:hexanes) to provide 5-95 as a 
sticky yellow residue (0.0297 g, 54%):  1H NMR (CDCl3, 400 MHz)  3.67–3.58 (m, 2 H),  
2.76–2.69 (m, 2 H), 2.58–2.48 (m, 4 H), 1.72–1.60 (m 4 H); 13C NMR (CDCl3, 125 MHz)  
 169.8, 138.5, 72.7, 41.4, 34.5, 33.4, 33.0, 23.1, 21.5.; HRMS (ESI) m/z calcd for C9H14NOI 
([M+H]+) 278.0036, found 278.0033.   
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1.5:1.0 mixture (5-101:5-98) 
2,3,6,7,8,9-Hexahydro-4H-quinolizin-4-one (5-101) and 1,2,5,6,7,8-Hexahydro-3H-
pyrrolo[1,2-a]azepin-3-one (5-98).  To a solution of 5-82 (0.0200 g, 0.132 mmol) in THF  
(4.0 mL) at room temperature under an atmosphere of N2 was added KHMDS (0.0132 g,  
0.0661 mmol) and 18-crown-6 (0.0141 g, 0.0529 mmol). The solution was stirred at room 
temperature for 1 h 15 min. The solution was poured slowly into an ice/water mixture and 
extracted with EtOAc. The combined organic layers were washed with brine, dried (MgSO4), 
and concentrated under reduced pressure to give a crude residue.  The residue is an inseparable 
mixture of the desired product 5-101 and the undesired product 5-98 (0.0181, 91%):  
Characteristic peaks for 5-101:  1H NMR (CDCl3, 400 MHz)  4.95 (t, 0.7 H, J = 4.4 Hz), 3.68–
3.58 (m, 1.4 H), 2.48–2.41 (m, 1.4 H), 2.29 (t, 1.4 H, J = 5.7 Hz), 2.22–2.14 (m, 1.4 H), 1.72–
1.65 (m, 1.4 H), 1.63–1.56 (m, 1.4 H); 13C NMR (CDCl3, 125 MHz)  170.7, 138.0, 103.8, 40.6, 
32.0, 29.6, 23.8, 22.0, 19.4.  Characteristic peaks for 5-98:  1H NMR (CDCl3, 400 MHz)  
 4.68 (t, 1 H, J = 5.0 Hz), 3.68–3.58 (m, 2 H), 2.60–2.53 (m, 2 H), 2.48–2.41 (m, 2 H), 2.22–
2.14 (m, 2 H), 1.77–1.72 (m, 4 H); 13C NMR (CDCl3, 125 MHz)  176.6, 139.8, 102.3, 44.1, 
30.0, 28.2, 27.34, 27.29, 25.9. 
 
 184 
APPENDIX A 
X-RAY DATA 
A.1 X-RAY STRUCTURE AND DATA FOR 1-24B 
 
Figure 19.  X-Ray crystal structure of 1-24b. 
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Table 15.  Crystal data and structure refinement for 1-24b. 
Identification code  kg927s 
Empirical formula  C30H23F3N2O 
Formula weight  484.50 
Temperature  203(2) K 
Wavelength  0.71073 Å 
Crystal system  Monoclinic 
Space group  C2/c 
Unit cell dimensions a = 52.85(3) Å α = 90° 
 
b = 4.431(3) Å β = 99.786(12)° 
 
c = 20.755(12) Å γ = 90° 
Volume 856.96(6) Å3 
 
Z 4 
Density (calculated) 1.172 g/cm3 
Absorption coefficient 0.604 mm-1 
F(000) 328 
Crystal size 0.03 x 0.05 x 0.21 mm3 
Theta range for data collection 2.26 to 25.09°. 
Index ranges -63<=h<=62, -5<=k<=5, -24<=l<=24 
Reflections collected 17398 
Independent reflections 4253 [R(int) = 0.2705] 
Completeness to theta = 25.09° 99.4 %  
Absorption correction multi-scan (Sadabs) 
Refinement method Full-matrix least-squares on F2 
Data / restraints / parameters 4253 / 6 / 301 
Goodness-of-fit on F2 1.667 
Final R indices [I>2sigma(I)] R1 = 0.1804, wR2 = 0.3834 
R indices (all data) R1 = 0.3980, wR2 = 0.4424 
Largest diff. peak and hole 1.611 and -0.674 e.Å-3 
 
Table 16.  Atomic coordinates (x 104) and equivalent isotropic displacement parameters (Å2 x 103) for 1-24b.   
 x y z U(eq) 
O 906(2) 2750(30) 2458(5) 113(4) 
N(1) 1474(2) 7440(20) 363(6) 70(3) 
C(1) 1000(2) 9430(30) -202(7) 54(4) 
F(1) -45(3) 14670(30) -1766(8) 249(7) 
N(2) 1019(2) 7680(30) 311(5) 69(3) 
C(2) 1217(3) 10530(30) -469(7) 62(4) 
F(2) -151(3) 10920(40) -1712(8) 251(7) 
C(3) 1210(3) 12480(30) -980(7) 71(4) 
F(3) -147(3) 13810(30) -971(7) 233(6) 
C(4) 1438(3) 13450(30) -1169(7) 63(4) 
C(5) 1674(3) 12470(30) -860(6) 57(4) 
C(6) 1689(3) 10260(30) -360(7) 77(5) 
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C(7) 1460(3) 9390(30) -173(7) 62(4) 
C(8) 1265(3) 6800(30) 592(8) 67(4) 
C(9) 736(3) 10170(30) -487(8) 76(4) 
C(10) 580(3) 11430(40) -132(8) 106(6) 
C(11) 328(3) 12190(40) -391(9) 112(6) 
C(12) 243(3) 11770(30) -1019(8) 75(4) 
C(13) 393(3) 10510(30) -1433(8) 93(5) 
C(14) 643(3) 9890(30) -1152(6) 76(5) 
C(15) -60(6) 12660(50) -1353(11) 330(20) 
C(16) 1917(3) 13580(30) -1036(8) 71(4) 
C(17) 1916(3) 14500(40) -1691(8) 85(5) 
C(18) 2134(4) 15680(40) -1836(9) 103(6) 
C(19) 2361(3) 16010(40) -1409(10) 93(5) 
C(20) 2357(3) 15040(40) -772(10) 109(6) 
C(21) 2136(3) 13870(40) -600(9) 100(6) 
C(22) 2596(3) 17530(40) -1579(10) 152(9) 
C(23) 2832(3) 16460(50) -1318(9) 156(9) 
C(24) 1280(3) 4780(30) 1188(6) 50(3) 
C(25) 1082(3) 4660(30) 1519(8) 89(5) 
C(26) 1099(3) 2970(30) 2082(8) 68(4) 
C(27) 1311(3) 1490(30) 2298(7) 81(5) 
C(28) 1518(3) 1460(40) 1990(8) 85(5) 
C(29) 1506(3) 3250(30) 1404(8) 77(5) 
C(30) 673(3) 4560(40) 2260(8) 139(7) 
U(eq) is defined as one third of the trace of the orthogonalized Uij tensor. 
 
Table 17.  Bond lengths (Å) and angles (°) for 1-24b. 
O-C(26)  1.390(15) 
O-C(30)  1.468(16) 
N(1)-C(7)  1.400(15) 
N(1)-C(8)  1.307(15) 
C(1)-N(2)  1.309(15) 
C(1)-C(9)  1.456(16) 
C(1)-C(2)  1.440(16) 
F(1)-C(15)  1.25(2) 
F(1)-F(2)  1.76(2) 
F(1)-F(3)  1.86(2) 
N(2)-C(8)  1.385(15) 
C(2)-C(7)  1.422(16) 
C(2)-C(3)  1.365(16) 
F(2)-C(15)  1.12(2) 
C(3)-C(4)  1.398(15) 
C(3)-H(3A)  0.9400 
F(3)-C(15)  1.11(2) 
C(4)-C(5)  1.372(14) 
C(4)-H(4A)  0.9400 
C(5)-C(6)  1.418(16) 
C(5)-C(16)  1.476(17) 
C(6)-C(7)  1.388(16) 
C(6)-H(6A)  0.9400 
 187 
C(8)-C(24)  1.517(17) 
C(9)-C(10)  1.320(18) 
C(9)-C(14)  1.389(16) 
C(10)-C(11)  1.391(19) 
C(10)-H(10A)  0.9400 
C(11)-C(12)  1.319(18) 
C(11)-H(11A)  0.9400 
C(12)-C(13)  1.380(17) 
C(12)-C(15)  1.68(3) 
C(13)-C(14)  1.378(15) 
C(13)-H(13A)  0.9400 
C(14)-H(14A)  0.9400 
C(16)-C(21)  1.349(17) 
C(16)-C(17)  1.419(17) 
C(17)-C(18)  1.347(18) 
C(17)-H(17A)  0.9400 
C(18)-C(19)  1.37(2) 
C(18)-H(18A)  0.9400 
C(19)-C(20)  1.39(2) 
C(19)-C(22)  1.509(19) 
C(20)-C(21)  1.377(19) 
C(20)-H(20A)  0.9400 
C(21)-H(21A)  0.9400 
C(22)-C(23)  1.355(18) 
C(22)-H(22A)  0.9800 
C(22)-H(22B)  0.9800 
C(23)-H(23A)  0.9700 
C(23)-H(23B)  0.9700 
C(23)-H(23C)  0.9700 
C(24)-C(29)  1.379(15) 
C(24)-C(25)  1.352(16) 
C(25)-C(26)  1.378(17) 
C(25)-H(25A)  0.9400 
C(26)-C(27)  1.308(16) 
C(27)-C(28)  1.358(17) 
C(27)-H(27A)  0.9400 
C(28)-C(29)  1.444(18) 
C(28)-H(28A)  0.9400 
C(29)-H(29A)  0.9400 
C(30)-H(30A)  0.9700 
C(30)-H(30B)  0.9700 
C(30)-H(30C)  0.9700 
C(26)-O-C(30) 117.7(12) 
C(7)-N(1)-C(8) 119.4(13) 
N(2)-C(1)-C(9) 113.6(13) 
N(2)-C(1)-C(2) 123.9(12) 
C(9)-C(1)-C(2) 122.5(14) 
C(15)-F(1)-F(2) 39.3(10) 
C(15)-F(1)-F(3) 35.3(11) 
F(2)-F(1)-F(3) 67.0(7) 
C(8)-N(2)-C(1) 116.6(13) 
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C(1)-C(2)-C(7) 115.8(13) 
C(1)-C(2)-C(3) 126.5(14) 
C(7)-C(2)-C(3) 117.7(15) 
C(15)-F(2)-F(1) 44.7(12) 
C(4)-C(3)-C(2) 120.0(14) 
C(4)-C(3)-H(3A) 119.9 
C(2)-C(3)-H(3A) 120.1 
C(15)-F(3)-F(1) 40.5(13) 
C(5)-C(4)-C(3) 122.2(13) 
C(5)-C(4)-H(4A) 118.9 
C(3)-C(4)-H(4A) 118.9 
C(4)-C(5)-C(6) 119.6(13) 
C(4)-C(5)-C(16) 122.6(14) 
C(6)-C(5)-C(16) 117.8(13) 
C(7)-C(6)-C(5) 117.0(13) 
C(7)-C(6)-H(6A) 121.7 
C(5)-C(6)-H(6A) 121.3 
C(6)-C(7)-N(1) 117.7(14) 
C(6)-C(7)-C(2) 123.2(14) 
N(1)-C(7)-C(2) 118.9(14) 
N(2)-C(8)-N(1) 125.2(15) 
N(2)-C(8)-C(24) 115.2(13) 
N(1)-C(8)-C(24) 119.5(14) 
C(1)-C(9)-C(10) 120.9(15) 
C(1)-C(9)-C(14) 122.4(14) 
C(10)-C(9)-C(14) 116.4(14) 
C(9)-C(10)-C(11) 122.3(16) 
C(9)-C(10)-H(10A) 118.4 
C(11)-C(10)-H(10A) 119.3 
C(12)-C(11)-C(10) 119.4(17) 
C(12)-C(11)-H(11A) 120.7 
C(10)-C(11)-H(11A) 119.9 
C(11)-C(12)-C(13) 122.5(16) 
C(11)-C(12)-C(15) 121.0(17) 
C(13)-C(12)-C(15) 116.5(15) 
C(12)-C(13)-C(14) 115.4(14) 
C(12)-C(13)-H(13A) 122.3 
C(14)-C(13)-H(13A) 122.3 
C(9)-C(14)-C(13) 123.6(14) 
C(9)-C(14)-H(14A) 118.1 
C(13)-C(14)-H(14A) 118.3 
F(2)-C(15)-F(3) 127(3) 
F(2)-C(15)-F(1) 96.0(18) 
F(3)-C(15)-F(1) 104(2) 
F(2)-C(15)-C(12) 113(2) 
F(3)-C(15)-C(12) 107(2) 
F(1)-C(15)-C(12) 107(2) 
C(21)-C(16)-C(17) 118.4(15) 
C(21)-C(16)-C(5) 123.4(16) 
C(17)-C(16)-C(5) 118.1(15) 
C(18)-C(17)-C(16) 117.6(16) 
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C(18)-C(17)-H(17A) 121.1 
C(16)-C(17)-H(17A) 121.2 
C(17)-C(18)-C(19) 125.6(18) 
C(17)-C(18)-H(18A) 117.1 
C(19)-C(18)-H(18A) 117.3 
C(20)-C(19)-C(18) 115.4(16) 
C(20)-C(19)-C(22) 120.4(19) 
C(18)-C(19)-C(22) 124.1(19) 
C(19)-C(20)-C(21) 120.7(16) 
C(19)-C(20)-H(20A) 119.7 
C(21)-C(20)-H(20A) 119.6 
C(16)-C(21)-C(20) 122.1(17) 
C(16)-C(21)-H(21A) 118.8 
C(20)-C(21)-H(21A) 119.0 
C(19)-C(22)-C(23) 119.3(17) 
C(19)-C(22)-H(22A) 108.3 
C(23)-C(22)-H(22A) 106.9 
C(19)-C(22)-H(22B) 107.3 
C(23)-C(22)-H(22B) 107.5 
H(22A)-C(22)-H(22B) 107.0 
C(22)-C(23)-H(23A) 110.0 
C(22)-C(23)-H(23B) 108.8 
H(23A)-C(23)-H(23B) 109.5 
C(22)-C(23)-H(23C) 109.6 
H(23A)-C(23)-H(23C) 109.5 
H(23B)-C(23)-H(23C) 109.5 
C(29)-C(24)-C(25) 121.4(14) 
C(29)-C(24)-C(8) 118.7(14) 
C(25)-C(24)-C(8) 119.8(14) 
C(24)-C(25)-C(26) 120.4(15) 
C(24)-C(25)-H(25A) 119.7 
C(26)-C(25)-H(25A) 119.8 
C(27)-C(26)-C(25) 119.4(16) 
C(27)-C(26)-O 116.1(15) 
C(25)-C(26)-O 124.4(15) 
C(26)-C(27)-C(28) 123.8(16) 
C(26)-C(27)-H(27A) 118.1 
C(28)-C(27)-H(27A) 118.1 
C(27)-C(28)-C(29) 117.9(15) 
C(27)-C(28)-H(28A) 121.0 
C(29)-C(28)-H(28A) 121.2 
C(24)-C(29)-C(28) 117.0(14) 
C(24)-C(29)-H(29A) 121.5 
C(28)-C(29)-H(29A) 121.5 
O-C(30)-H(30A) 109.4 
O-C(30)-H(30B) 109.5 
H(30A)-C(30)-H(30B) 109.5 
O-C(30)-H(30C) 109.5 
H(30A)-C(30)-H(30C) 109.5 
H(30B)-C(30)-H(30C) 109.5 
Symmetry transformations used to generate equivalent atoms. 
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Table 18.  Anisotropic displacement parameters (Å2 x 103) for 1-24b.   
 U11 U22 U33 U23 U13 U12 
O 107(9)  142(11) 89(9)  45(8) 12(8)  24(8) 
N(1) 70(8)  58(7) 76(9)  12(7) -5(7)  -1(7) 
C(1) 37(8)  77(10) 49(9)  -13(8) 13(7)  1(8) 
N(2) 80(9)  80(9) 41(7)  -5(7) -6(6)  2(7) 
C(2) 84(11)  42(9) 51(10)  -4(8) -12(9)  3(8) 
C(3) 72(11)  84(11) 63(11)  13(9) 31(9)  23(9) 
C(4) 75(10)  45(9) 64(10)  -6(7) -3(9)  -1(8) 
C(5) 60(9)  62(9) 45(9)  -17(8) -1(7)  20(8) 
C(6) 60(10)  90(12) 82(12)  27(10) 13(9)  15(9) 
C(7) 81(11)  38(9) 63(10)  -7(8) 0(9)  0(8) 
C(8) 55(10)  72(11) 74(12)  -15(9) 8(10)  -9(9) 
C(9) 76(11)  66(10) 85(13)  -9(9) 11(10)  -2(8) 
C(10) 73(11)  173(18) 67(12)  -18(12) -4(10)  28(11) 
C(11) 114(15)  127(15) 103(15)  -25(12) 39(12)  -18(13) 
C(13) 75(11)  97(12) 103(13)  -20(11) 1(10)  4(10) 
C(14) 66(10)  113(12) 40(9)  -8(9) -18(7)  5(9) 
C(16) 60(10)  88(11) 66(12)  -17(9) 16(9)  -14(9) 
C(17) 89(13)  105(13) 62(12)  -1(10) 15(10)  17(11) 
C(18) 109(15)  98(13) 101(14)  11(11) 15(14)  -2(13) 
C(19) 78(14)  103(13) 104(15)  24(12) 32(12)  -9(11) 
C(20) 64(11)  133(16) 124(17)  34(13) -4(11)  10(11) 
C(21) 80(13)  98(13) 124(16)  10(12) 17(14)  10(11) 
C(22) 83(14)  160(18) 210(20)  75(17) 30(16)  -1(13) 
C(23) 80(13)  220(20) 170(20)  52(17) 20(14)  -20(15) 
C(24) 50(9)  53(9) 43(9)  -6(7) -4(7)  -12(8) 
C(25) 97(13)  70(11) 102(14)  24(10) 20(11)  -1(9) 
C(26) 61(10)  83(11) 56(10)  18(9) -1(9)  -4(9) 
C(27) 91(12)  96(13) 51(11)  2(9) -2(11)  19(11) 
C(28) 87(13)  113(14) 52(11)  -1(10) 3(9)  12(10) 
C(29) 66(11)  53(10) 112(14)  -8(9) 10(10)  -4(8) 
C(30) 115(15)  200(20) 99(14)  38(14) 16(12)  49(16) 
The anisotropic atomic displacement factor exponent takes the form: -2π2[ h2 a*2 U11 + ... + 2 h k a* b* U12 ]. 
 
Table 19.  Hydrogen coordinates (x 104) and isotropic displacement parameters (Å2 x 103) for 1-24b. 
 x y z U(eq) 
H(3A) 1051 13182 -1206 85 
H(4A) 1430 14812 -1518 75 
H(6A) 1848 9432 -164 93 
H(10A) 642 11824 312 127 
H(11A) 219 13008 -121 135 
H(13A) 329 10105 -1875 112 
H(14A) 757 9253 -1426 91 
H(17A) 1769 14287 -2012 102 
H(18A) 2131 16342 -2268 123 
H(20A) 2506 15187 -455 131 
H(21A) 2138 13260 -166 121 
H(22A) 2590 19656 -1455 182 
H(22B) 2583 17464 -2056 182 
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H(23A) 2962 17581 -1495 235 
H(23B) 2843 14341 -1425 235 
H(23C) 2859 16703 -847 235 
H(25A) 931 5748 1365 107 
H(27A) 1320 391 2688 97 
H(28A) 1664 314 2154 102 
H(29A) 1646 3367 1180 93 
H(30A) 557 4257 2569 208 
H(30B) 589 3940 1827 208 
H(30C) 719 6678 2251 208 
A.2 X-RAY STRUCTURE AND DATA FOR KMG-NB4-23 
 
Figure 20.  X-Ray crystal structure of kmg-NB4-23. 
 
Table 20.  Crystal data and structure refinement for kmg-NB4-23. 
Identification code  kg57a2 
Empirical formula  C10 H9 N3 O2 S2 
Formula weight  267.32 
Temperature  203(2) K 
Wavelength  0.71073 Å 
Crystal system  Triclinic 
Space group  P-1 
Unit cell dimensions a = 5.117(8) Å α = 86.01(3)° 
 b = 9.387(14) Å β = 84.90(3)° 
 c = 11.362(17) Å γ = 89.39(3)° 
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Volume 542.3(14) Å3 
Z 2 
Density (calculated) 1.637 Mg/m3 
Absorption coefficient 0.483 mm-1 
F(000) 276 
Crystal size 0.12 x 0.04 x 0.04 mm3 
Theta range for data collection 1.80 to 25.00°. 
Index ranges -6<=h<=6, -11<=k<=11, -13<=l<=13 
Reflections collected 3927 
Independent reflections 1886 [R(int) = 0.1134] 
Completeness to theta = 25.00° 98.8 %  
Absorption correction Multi-scan (Sadabs) 
Max. and min. transmission 0.9810 and 0.9444 
Refinement method Full-matrix least-squares on F2 
Data / restraints / parameters 1886 / 0 / 155 
Goodness-of-fit on F2 1.625 
Final R indices [I>2sigma(I)] R1 = 0.1430, wR2 = 0.3333 
R indices (all data) R1 = 0.1958, wR2 = 0.3435 
Extinction coefficient 0.002(7) 
Largest diff. peak and hole 1.884 and -0.643 e.Å-3 
Largest diff. peak and hole 1.884 and -0.643 e.Å-3 
 
Table 21.  Atomic coordinates (x 104) and equivalent isotropic displacement parameters (Å2 x 103) for kmg-NB4-
23.   
 x y z U(eq) 
S(1) 3845(6) 9715(4) 6478(3) 37(1) 
S(2) 4548(6) 6602(3) 9408(3) 37(1) 
O(1) 8301(15) 8413(9) 9949(7) 40(2) 
O(2) -2411(15) 5532(9) 5947(7) 42(2) 
N(1) 7763(18) 10403(11) 8781(8) 37(3) 
N(2) -620(20) 4696(12) 7552(9) 44(3) 
N(3) 561(17) 7016(10) 6665(8) 28(2) 
C(1) 6650(20) 10723(14) 6710(11) 40(3) 
C(2) 6620(30) 11326(15) 7905(12) 51(4) 
C(3) 7200(20) 9026(14) 9113(10) 32(3) 
C(4) 5200(20) 8249(13) 8598(10) 29(3) 
C(5) 2360(20) 6112(13) 8448(10) 30(3) 
C(6) 950(20) 4912(14) 8421(11) 39(3) 
C(7) -720(20) 5827(14) 6758(10) 34(3) 
C(8) 2160(20) 7171(13) 7516(10) 32(3) 
C(9) 3810(20) 8392(13) 7597(9) 26(3) 
C(10) -2590(30) 6601(16) 4988(12) 51(4) 
U(eq) is defined as one third of the trace of the orthogonalized Uij tensor. 
 
Table 22.  Bond lengths (Å) and angles (°) for kmg-NB4-23. 
S(1)-C(9)  1.714(11) 
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S(1)-C(1)  1.778(12) 
S(2)-C(5)  1.718(12) 
S(2)-C(4)  1.762(11) 
O(1)-C(3)  1.252(12) 
O(2)-C(7)  1.363(14) 
O(2)-C(10)  1.437(14) 
N(1)-C(3)  1.348(15) 
N(1)-C(2)  1.435(13) 
N(1)-H(1C)  0.8700 
N(2)-C(7)  1.348(14) 
N(2)-C(6)  1.355(15) 
N(3)-C(7)  1.294(15) 
N(3)-C(8)  1.337(14) 
C(1)-C(2)  1.505(19) 
C(1)-H(1A)  0.9800 
C(1)-H(1B)  0.9800 
C(2)-H(2A)  0.9800 
C(2)-H(2B)  0.9800 
C(3)-C(4)  1.449(16) 
C(4)-C(9)  1.391(15) 
C(5)-C(6)  1.348(17) 
C(5)-C(8)  1.411(15) 
C(6)-H(6A)  0.9400 
C(8)-C(9)  1.445(16) 
C(10)-H(10A)  0.9700 
C(10)-H(10B)  0.9700 
C(10)-H(10C)  0.9700 
C(9)-S(1)-C(1) 102.5(5) 
C(5)-S(2)-C(4) 92.5(5) 
C(7)-O(2)-C(10) 115.5(10) 
C(3)-N(1)-C(2) 128.4(11) 
C(3)-N(1)-H(1C) 115.8 
C(2)-N(1)-H(1C) 115.8 
C(7)-N(2)-C(6) 113.0(11) 
C(7)-N(3)-C(8) 114.9(10) 
C(2)-C(1)-S(1) 115.4(9) 
C(2)-C(1)-H(1A) 108.4 
S(1)-C(1)-H(1A) 108.4 
C(2)-C(1)-H(1B) 108.4 
S(1)-C(1)-H(1B) 108.4 
H(1A)-C(1)-H(1B) 107.5 
N(1)-C(2)-C(1) 114.0(12) 
N(1)-C(2)-H(2A) 108.7 
C(1)-C(2)-H(2A) 108.7 
N(1)-C(2)-H(2B) 108.7 
C(1)-C(2)-H(2B) 108.7 
H(2A)-C(2)-H(2B) 107.6 
O(1)-C(3)-N(1) 119.3(11) 
O(1)-C(3)-C(4) 118.0(10) 
N(1)-C(3)-C(4) 122.5(10) 
C(9)-C(4)-C(3) 137.6(10) 
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C(9)-C(4)-S(2) 111.5(9) 
C(3)-C(4)-S(2) 110.6(8) 
C(6)-C(5)-C(8) 117.2(10) 
C(6)-C(5)-S(2) 131.6(9) 
C(8)-C(5)-S(2) 111.1(9) 
C(5)-C(6)-N(2) 123.0(11) 
C(5)-C(6)-H(6A) 118.5 
N(2)-C(6)-H(6A) 118.5 
N(3)-C(7)-N(2) 130.2(11) 
N(3)-C(7)-O(2) 120.9(10) 
N(2)-C(7)-O(2) 108.8(10) 
N(3)-C(8)-C(5) 121.5(11) 
N(3)-C(8)-C(9) 125.3(10) 
C(5)-C(8)-C(9) 113.3(10) 
C(4)-C(9)-C(8) 111.6(10) 
C(4)-C(9)-S(1) 130.9(9) 
C(8)-C(9)-S(1) 117.5(8) 
O(2)-C(10)-H(10A) 109.5 
O(2)-C(10)-H(10B) 109.5 
H(10A)-C(10)-H(10B) 109.5 
O(2)-C(10)-H(10C) 109.5 
H(10A)-C(10)-H(10C) 109.5 
H(10B)-C(10)-H(10C) 109.5 
Symmetry transformations used to generate equivalent atoms. 
 
Table 23.  Anisotropic displacement parameters (Å2 x 103) for kmg-NB4-23.   
 U11 U22 U33 U23 U13 U12 
S(1) 41(2)  38(2) 32(2)  11(2) -16(1)  -12(1) 
S(2) 52(2)  26(2) 35(2)  8(2) -19(2)  -9(1) 
O(1) 46(5)  38(6) 37(5)  11(4) -22(4)  -9(4) 
O(2) 48(5)  36(6) 46(5)  -9(5) -25(4)  -7(4) 
N(1) 43(6)  32(7) 39(6)  8(5) -21(5)  -15(5) 
N(2) 58(7)  38(7) 38(6)  5(6) -17(5)  -12(5) 
N(3) 33(5)  22(6) 31(5)  -3(5) -15(4)  -8(4) 
C(1) 52(8)  38(9) 32(7)  8(6) -18(6)  -13(6) 
C(2) 67(9)  40(9) 48(9)  21(7) -34(7)  -10(7) 
C(3) 34(7)  34(8) 27(7)  0(6) -5(5)  -3(5) 
C(4) 32(6)  24(7) 30(6)  2(6) -7(5)  -2(5) 
C(5) 32(6)  32(8) 26(6)  2(6) -7(5)  -7(5) 
C(6) 47(7)  34(8) 35(7)  8(6) -5(6)  -8(6) 
C(7) 38(7)  35(8) 29(7)  -1(6) -8(5)  -7(6) 
C(8) 32(6)  30(8) 35(7)  0(6) -7(5)  -10(5) 
C(9) 28(6)  30(7) 22(6)  1(5) -8(5)  0(5) 
C(10) 71(10)  43(9) 42(8)  2(7) -24(7)  4(7) 
The anisotropic atomic displacement factor exponent takes the form: -2π2[ h2 a*2 U11 + ... + 2 h k a* b* U12 ]. 
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Table 24.  Hydrogen coordinates (x 104) and isotropic displacement parameters (Å2 x 103) for kmg-NB4-23. 
x y z U(eq) 
H(1C) 8983 10780 9144 45 
H(1A) 8208 10111 6601 48 
H(1B) 6839 11515 6100 48 
H(2A) 7562 12234 7816 61 
H(2B) 4793 11526 8188 61 
H(6A) 1058 4193 9033 46 
H(10A) -3839 6300 4463 77 
H(10B) -881 6728 4552 77 
H(10C) -3168 7497 5303 77 
A.3 X-RAY STRUCTURE AND DATA FOR 5-82 
Figure 21.  X-Ray structure of 5-82. 
Table 25.  Sample and crystal data for 5-82. 
Identification code kgw313 
Chemical formula C9H13NO 
Formula weight 151.21 
Temperature 150(2) K 
Wavelength 1.54178 Å 
Crystal size 0.050 x 0.200 x 0.220 mm 
Crystal habit clear colourless plate 
Crystal system triclinic 
Space group P -1 
 196 
Unit cell dimensions a = 5.0049(2) Å α = 61.976(2)° 
 
b = 13.9446(5) Å β = 86.991(2)° 
 
c = 14.1160(5) Å γ = 80.346(2)° 
 
Table 26.  Data collection and structure refinement for 5-82. 
Diffractometer Bruker Apex II CCD 
Radiation source IMuS micro-focus, Cu 
Theta range for data collection 3.55 to 68.20° 
Index ranges -5<=h<=6, -16<=k<=16, -16<=l<=16 
Reflections collected 6549 
Independent reflections 2944 [R(int) = 0.0116] 
Coverage of independent reflections 94.5% 
Absorption correction multi-scan 
Max. and min. transmission 0.9704 and 0.0518 
Structure solution technique direct methods 
Structure solution program SHELXS-97 (Sheldrick, 2008) 
Refinement method Full-matrix least-squares on F2 
Refinement program SHELXL-97 (Sheldrick, 2008) 
Function minimized Σ w(Fo2 - Fc2)2 
Data / restraints / parameters 2944 / 0 / 303 
Goodness-of-fit on F2 1.687 
Final R indices 2716 data; I>2σ(I) R1 = 0.0368, wR2 = 0.1288 
 
all data R1 = 0.0392, wR2 = 0.1312 
Weighting scheme 
w=1/[σ2(Fo2)+(0.0680P)2+0.0000P] 
where P=(Fo2+2Fc2)/3 
Largest diff. peak and hole 0.258 and -0.153 eÅ-3 
R.M.S. deviation from mean 0.032 eÅ-3 
 
 
Table 27.  Atomic coordinates and equivalent isotropic atomic displacement parameters (Å2) for 5-82.  
 
x/a y/b z/c U(eq) 
O1 0.00406(17) 0.69089(8) 0.16071(8) 0.0420(3) 
N1 0.44114(19) 0.71443(8) 0.13998(8) 0.0282(2) 
C1 0.2445(2) 0.65632(9) 0.18969(9) 0.0295(3) 
C2 0.3299(3) 0.54820(10) 0.28819(12) 0.0420(3) 
C3 0.2251(4) 0.56095(14) 0.38646(13) 0.0624(5) 
C4 0.3092(4) 0.65934(13) 0.38185(11) 0.0599(5) 
C5 0.3783(4) 0.74595(13) 0.35722(11) 0.0602(5) 
C6 0.4603(5) 0.85500(13) 0.31095(12) 0.0616(5) 
C7 0.5388(3) 0.89312(11) 0.19378(11) 0.0383(3) 
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x/a y/b z/c U(eq) 
C8 0.3100(2) 0.90224(9) 0.12018(9) 0.0312(3) 
C9 0.3812(3) 0.83097(10) 0.06401(9) 0.0349(3) 
O2 0.52466(16) 0.88098(8) 0.66978(7) 0.0403(3) 
N2 0.9572(2) 0.87788(7) 0.70979(7) 0.0266(2) 
C10 0.7654(2) 0.87879(8) 0.64672(8) 0.0252(3) 
C11 0.8635(3) 0.87068(9) 0.54739(9) 0.0319(3) 
C12 0.8696(3) 0.75114(11) 0.56838(11) 0.0434(3) 
C13 0.0224(3) 0.67468(10) 0.66891(11) 0.0413(3) 
C14 0.1347(3) 0.62617(10) 0.75519(11) 0.0422(3) 
C15 0.2557(3) 0.57986(12) 0.86342(11) 0.0484(4) 
C16 0.2399(3) 0.66848(11) 0.89891(10) 0.0397(3) 
C17 0.9516(3) 0.72801(11) 0.89685(9) 0.0375(3) 
C18 0.9111(3) 0.85202(11) 0.82130(10) 0.0382(3) 
U(eq) is defined as one third of the trace of the orthogonized Uii tensor. 
 
Table 28.  Bond lengths (Å) for 5-82. 
O1-C1 1.2329(15) N1-C1 1.3334(15) 
N1-C9 1.4539(16) N1-H1N 0.918(17) 
C1-C2 1.5051(17) C2-C3 1.535(2) 
C2-H2A 1.008(18) C2-H2B 0.966(18) 
C3-C4 1.473(3) C3-H3A 1.00(2) 
C3-H3B 1.05(2) C4-C5 1.197(3) 
C5-C6 1.468(3) C6-C7 1.532(2) 
C6-H6A 0.99(2) C6-H6B 1.02(3) 
C7-C8 1.5358(16) C7-H7A 0.993(17) 
C7-H7B 0.994(17) C8-C9 1.5283(18) 
C8-H8A 0.974(15) C8-H8B 0.977(16) 
C9-H9A 0.977(19) C9-H9B 0.986(19) 
O2-C10 1.2308(15) N2-C10 1.3377(14) 
N2-C18 1.4551(15) N2-H2N 0.858(17) 
C10-C11 1.5092(16) C11-C12 1.5451(17) 
C11-H11A 0.973(16) C11-H11B 1.011(16) 
C12-C13 1.4678(18) C12-H12B 1.02(2) 
C12-H12A 0.99(2) C13-C14 1.194(2) 
C14-C15 1.4687(19) C15-C16 1.526(2) 
C15-H15B 1.00(2) C15-H15A 1.00(2) 
C16-C17 1.5333(18) C16-H16B 1.015(17) 
C16-H16A 1.014(19) C17-C18 1.5299(18) 
C17-H17A 0.968(17) C17-H17B 0.974(18) 
C18-H18A 1.022(18) C18-H18B 1.011(18) 
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Table 29.  Bond angles (°) for 5-82. 
C1-N1-C9 121.51(10) C1-N1-H1N 117.8(9) 
C9-N1-H1N 119.4(9) O1-C1-N1 122.45(11) 
O1-C1-C2 121.28(11) N1-C1-C2 116.16(10) 
C1-C2-C3 107.86(11) C1-C2-H2A 111.6(9) 
C3-C2-H2A 108.6(9) C1-C2-H2B 111.0(10) 
C3-C2-H2B 108.1(11) H2A-C2-H2B 109.6(14) 
C4-C3-C2 109.26(12) C4-C3-H3A 109.1(14) 
C2-C3-H3A 110.7(14) C4-C3-H3B 113.8(13) 
C2-C3-H3B 107.4(13) H3A-C3-H3B 106.5(18) 
C5-C4-C3 167.32(15) C4-C5-C6 171.72(15) 
C5-C6-C7 110.63(12) C5-C6-H6A 109.1(13) 
C7-C6-H6A 108.9(12) C5-C6-H6B 112.3(13) 
C7-C6-H6B 110.7(14) H6A-C6-H6B 105.0(18) 
C6-C7-C8 114.13(13) C6-C7-H7A 105.4(9) 
C8-C7-H7A 109.3(10) C6-C7-H7B 109.0(10) 
C8-C7-H7B 108.0(9) H7A-C7-H7B 111.0(13) 
C9-C8-C7 113.97(10) C9-C8-H8A 107.4(9) 
C7-C8-H8A 111.2(8) C9-C8-H8B 107.1(10) 
C7-C8-H8B 110.7(10) H8A-C8-H8B 106.0(12) 
N1-C9-C8 112.13(9) N1-C9-H9A 107.8(10) 
C8-C9-H9A 109.5(10) N1-C9-H9B 107.9(10) 
C8-C9-H9B 109.3(10) H9A-C9-H9B 110.1(14) 
C10-N2-C18 122.12(10) C10-N2-H2N 119.1(10) 
C18-N2-H2N 116.1(10) O2-C10-N2 122.68(11) 
O2-C10-C11 121.35(10) N2-C10-C11 115.89(10) 
C10-C11-C12 108.45(10) C10-C11-H11A 109.6(9) 
C12-C11-H11A 107.7(9) C10-C11-H11B 110.7(9) 
C12-C11-H11B 109.7(9) H11A-C11-H11B 110.6(12) 
C13-C12-C11 109.47(10) C13-C12-H12B 113.8(11) 
C11-C12-H12B 107.6(11) C13-C12-H12A 109.5(10) 
C11-C12-H12A 106.8(11) H12B-C12-H12A 109.3(16) 
C14-C13-C12 169.13(13) C13-C14-C15 171.96(14) 
C14-C15-C16 110.86(10) C14-C15-H15B 107.8(11) 
C16-C15-H15B 111.9(12) C14-C15-H15A 112.1(12) 
C16-C15-H15A 108.5(12) H15B-C15-H15A 105.7(15) 
C15-C16-C17 114.12(12) C15-C16-H16B 106.9(9) 
C17-C16-H16B 109.5(9) C15-C16-H16A 107.6(10) 
C17-C16-H16A 111.0(11) H16B-C16-H16A 107.5(13) 
C18-C17-C16 114.00(11) C18-C17-H17A 109.4(9) 
C16-C17-H17A 109.0(9) C18-C17-H17B 106.6(10) 
C16-C17-H17B 110.6(10) H17A-C17-H17B 107.0(13) 
N2-C18-C17 112.57(10) N2-C18-H18A 107.1(10) 
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C17-C18-H18A 109.9(10) N2-C18-H18B 105.3(10) 
C17-C18-H18B 110.2(9) H18A-C18-H18B 111.6(14) 
 
Table 30.  Torsion angles (°) for 5-82. 
C9-N1-C1-O1 13.74(17) C9-N1-C1-C2 -162.56(10) 
O1-C1-C2-C3 -68.01(16) N1-C1-C2-C3 108.34(14) 
C1-C2-C3-C4 -51.52(18) C2-C3-C4-C5 25.5(10) 
C3-C4-C5-C6 2.(2) C4-C5-C6-C7 -15.2(15) 
C5-C6-C7-C8 59.76(18) C6-C7-C8-C9 -121.75(12) 
C1-N1-C9-C8 77.12(13) C7-C8-C9-N1 61.17(14) 
C18-N2-C10-O2 15.63(16) C18-N2-C10-C11 -161.14(10) 
O2-C10-C11-C12 -75.32(14) N2-C10-C11-C12 101.50(11) 
C10-C11-C12-C13 -51.91(15) C11-C12-C13-C14 25.5(9) 
C12-C13-C14-C15 4.5(19) C13-C14-C15-C16 -15.2(12) 
C14-C15-C16-C17 56.73(17) C15-C16-C17-C18 -119.29(13) 
C10-N2-C18-C17 82.94(13) C16-C17-C18-N2 61.73(14) 
 
Table 31.  Anisotropic atomic displacement parameters (Å2) for 5-82.   
 
U11 U22 U33 U23 U13 U12 
O1 0.0186(4) 0.0511(5) 0.0599(6) -0.0280(5) -0.0005(4) -0.0076(4) 
N1 0.0192(5) 0.0375(5) 0.0335(5) -0.0204(4) 0.0028(4) -0.0074(4) 
C1 0.0205(5) 0.0359(6) 0.0399(6) -0.0238(5) 0.0035(4) -0.0068(4) 
C2 0.0398(8) 0.0307(6) 0.0526(8) -0.0168(6) 0.0037(6) -0.0079(5) 
C3 0.0802(13) 0.0449(8) 0.0426(8) -0.0052(6) 0.0172(8) -0.0130(8) 
C4 0.0936(13) 0.0484(9) 0.0275(6) -0.0139(6) 0.0077(7) 0.0008(8) 
C5 0.1016(14) 0.0479(9) 0.0284(6) -0.0203(6) -0.0018(7) 0.0039(8) 
C6 0.1020(14) 0.0458(8) 0.0433(8) -0.0292(7) -0.0169(8) 0.0037(8) 
C7 0.0354(7) 0.0363(6) 0.0494(7) -0.0254(6) -0.0076(5) -0.0024(5) 
C8 0.0251(6) 0.0310(6) 0.0331(6) -0.0114(5) -0.0008(5) -0.0043(4) 
C9 0.0369(7) 0.0414(7) 0.0269(5) -0.0142(5) 0.0028(5) -0.0133(5) 
O2 0.0194(4) 0.0486(5) 0.0427(5) -0.0129(4) 0.0006(3) -0.0054(3) 
N2 0.0217(5) 0.0283(5) 0.0294(5) -0.0136(4) -0.0001(4) -0.0023(3) 
C10 0.0218(5) 0.0202(5) 0.0274(5) -0.0058(4) -0.0012(4) -0.0031(4) 
C11 0.0356(7) 0.0297(6) 0.0252(5) -0.0087(4) -0.0025(5) -0.0037(5) 
C12 0.0603(9) 0.0359(7) 0.0368(7) -0.0198(5) -0.0112(6) -0.0023(6) 
C13 0.0569(8) 0.0261(6) 0.0419(7) -0.0179(5) -0.0061(6) -0.0007(5) 
C14 0.0522(8) 0.0260(6) 0.0422(7) -0.0139(5) -0.0055(6) 0.0054(5) 
C15 0.0544(9) 0.0358(7) 0.0373(7) -0.0075(5) -0.0065(6) 0.0103(6) 
C16 0.0307(6) 0.0455(7) 0.0317(6) -0.0106(5) -0.0069(5) 0.0016(5) 
C17 0.0319(7) 0.0475(7) 0.0268(6) -0.0137(5) 0.0019(5) -0.0017(5) 
C18 0.0406(7) 0.0436(7) 0.0325(6) -0.0226(5) -0.0032(5) 0.0041(5) 
 200 
 
U11 U22 U33 U23 U13 U12 
The anisotropic atomic displacement factor exponent takes the form: -2π2[ h2 a*2 U11 + ... + 2 h k a* b* U12 ]. 
 
Table 32.  Hydrogen atomic coordinates and isotropic atomic displacement parameters (Å2) for 5-82. 
 
x/a y/b z/c U(eq) 
H1N 0.616(3) 0.6833(12) 0.1653(12) 0.036(4) 
H2A 0.533(4) 0.5270(13) 0.2958(13) 0.044(4) 
H2B 0.251(3) 0.4902(14) 0.2868(14) 0.050(4) 
H3A 0.300(5) 0.4949(19) 0.4543(19) 0.079(6) 
H3B 0.014(5) 0.5638(18) 0.3868(18) 0.081(7) 
H6A 0.306(4) 0.9087(18) 0.3137(17) 0.070(6) 
H6B 0.613(5) 0.8568(19) 0.354(2) 0.085(7) 
H7A 0.692(3) 0.8368(13) 0.1959(13) 0.042(4) 
H7B 0.595(3) 0.9666(14) 0.1646(13) 0.045(4) 
H8A 0.146(3) 0.8817(11) 0.1600(11) 0.032(3) 
H8B 0.260(3) 0.9782(13) 0.0642(13) 0.042(4) 
H9A 0.541(4) 0.8514(14) 0.0211(14) 0.048(4) 
H9B 0.226(4) 0.8419(14) 0.0177(14) 0.052(4) 
H2N 1.124(3) 0.8722(12) 0.6921(12) 0.033(4) 
H11A 1.048(3) 0.8864(12) 0.5337(12) 0.036(4) 
H11B 0.739(3) 0.9229(13) 0.4835(12) 0.037(4) 
H12B 0.949(4) 0.7454(16) 0.5028(16) 0.061(5) 
H12A 0.680(4) 0.7385(14) 0.5755(14) 0.056(5) 
H15B 1.158(4) 0.5184(16) 0.9131(16) 0.062(5) 
H15A 1.450(4) 0.5455(16) 0.8675(16) 0.062(5) 
H16B 1.356(3) 0.7238(13) 0.8486(13) 0.045(4) 
H16A 1.327(4) 0.6325(14) 0.9735(15) 0.053(5) 
H17A 0.825(3) 0.6951(13) 0.8766(12) 0.040(4) 
H17B 0.904(3) 0.7189(14) 0.9681(14) 0.046(4) 
H18A 1.045(4) 0.8874(14) 0.8421(14) 0.048(4) 
H18B 0.717(4) 0.8862(14) 0.8225(13) 0.048(4) 
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